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Since healthcare expenditures are expected to rise in the future due to aging 
and the development of new medical technologies, it is necessary to spend the 
healthcare budget wisely. Cost-effectiveness analyses can feed into making choices 
in allocating limited health care resources. Cardiovascular diseases account for a 
large proportion of the total health care expenditure in the Netherlands. In this 
area many non-pharmaceutical technologies (e.g. stents, prostheses or diagnostic 
tests) are used to diagnose and treat patients with cardiovascular diseases. In the 
previous years, many new or improved non-pharmaceutical technologies came to 
the market and therefore it is important to estimate if these interventions are cost-
effective compared to existing interventions. However, it is often challenging to 
accurately estimate the cost-effectiveness of these interventions due to a number 
of reasons. In this dissertation, the aim was to assess the cost-effectiveness of 
various technologies in cardiovascular diseases and to identify and deal with 
challenges in the cost-effectiveness analysis methods.
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Abbreviations
AAA abdominal aorta aneurysm 
ASA American Society of Anaesthesiology 
bEVAR branched endovascular aneurysm 
repair
BMI body mass index
BMS bare-metal stent 
CABG coronary artery bypass graft
CAD coronary artery disease
CEA cost-effectiveness analysis 
CEAC cost-effectiveness acceptability 
curve 
CT computed tomography 
CTCA computed tomography coronary 
angiography 
CUA cost-utility analysis
CVA cerebrovascular accident
CVD cardiovascular disease
DBP diastolic blood pressure 
DES drug-eluting stent
DESM discrete event simulation
DMP disease management programme
DPM disease progression model
DT decision tree
DVT deep venous thrombosis 
EQ-5D EuroQol 5D 
ESC European Society of Cardiology 
EVAR endovascular aneurysm repair
fEVAR fenestrated endovascular aneurysm 
repair
FN false negative
FP false positive
FRS Framingham risk score 
HPM healthy person model 
HR hazard ratio
HRQoL health-related quality of life 
HTA health technology assessment 
ICA invasive coronary angiography 
ICER incremental cost-effectiveness ratio
ICU intensive care unit 
JRAAA juxta-renal abdominal aortic 
aneurysm
LT life time
MCS mental component scores
MI myocardial infarction 
NA not applicable
NGCCT new generation dual-source 
coronary computed tomography
NIHR National Institute for Health 
Research 
NSTEMI non-ST elevation myocardial 
infarction 
NYHA New York heart association class
OSR open surgical repair
PCI percutaneous coronary intervention
PCS physical component scores
PE pulmonary embolism 
PES paclitaxel-eluting stent
PSA probabilistic sensitivity analysis
PTCA percutaneous transluminal coronary 
angioplasty
PVD peripheral vessel disease
QALY quality adjusted life years
QoL quality of life 
RCT randomized controlled trial
RR relative risk
SBP systolic blood pressure
SCORE systematic coronary risk evaluation
SD standard deviation
SE sensitivity
SES sirolimus-eluting stent 
SF-36 short form
SP specificity
STM state-transition model
TAAA thoraco-abdominal aortic aneurysm
TIA transient ischaemic attack 
TIMI thrombolysis in myocardial 
infarction 
TLR target lesion revascularization 
TN true negative
TP true positive
TVR target vessel revascularization
WTP willingness-to-pay 
YRM York radiation model 
ZES zotarolimus-eluting stent
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Despite improvement in the prognosis of patients with cardiovascular disease (CVD) it still 
remains the second leading cause of death across the Western world1. In the Netherlands in 
2013, approximately 39,000 people died of CVD and it is the second leading cause of death after 
cancer1. However, CVD still is the leading cause of death for females, particularly in the older age 
categories1. Besides mortality, CVD also has a major impact on morbidity; in the Netherlands 
more than 1 million persons have CVD2. Furthermore, in 2010 282,000 patients were admitted to 
the hospital due to CVD3. The total hospital admission frequency in the Netherlands in 2010 was 
1,366 per 10,000 individuals, CVD resulted in a hospital admission frequency of 170 per 10,000 
individuals4. Furthermore, patients with CVD have a reduced quality of life (e.g. angina pectoris 
-0.0412) compared with the general population5,6. 
Cardiovascular disease
Cardiovascular disease is an umbrella term for many different diseases, including coronary 
artery disease (CAD) (e.g. angina pectoris), vascular diseases [e.g. abdominal aorta aneurysm 
(AAA)], arrhythmias (e.g. atrioventricular block), congenital heart diseases (e.g. ventricular 
septal defect) and cerebrovascular diseases (e.g. transient ischaemic attack). Some diseases are 
present at birth whereas others are the result of atherosclerosis which is a slow but progressive 
pathological process that leads to narrowing and hardening of the arteries. The risk of 
experiencing a cardiovascular event (e.g. myocardial infarction or stroke) increases with various 
factors, including age, systolic blood pressure and total cholesterol. Furthermore, men and 
smokers have a higher risk of a cardiovascular event than women and non-smokers7. In addition, 
psychosocial factors seems to contribute to the pathogenesis of CVD8. For primary prevention of 
CVD, the SCORE risk function7 or the Framingham risk equation9 is often used to determine the 
10-year risk of developing a cardiovascular event. Based on the results of the risk functions the 
type of treatment (e.g. statins) is determined.
Most of the treatments for CVD are focused on preventing primary and secondary events due to 
CAD which accounts for the largest proportion (25%) of CVD deaths in the Netherlands1. Many 
treatment options for CAD involves non-pharmaceutical technologies (e.g. coronary stents), 
which are also often used for patients with other CVD disorders such as aortic aneurysms that 
accounts only for 2% of the CVD deaths1. The research area of this thesis is on CVD with a main 
focus on CAD and aortic aneurysms. 
Coronary artery disease
Patients can be diagnosed with CAD if the coronary arteries are affected by atherosclerosis. 
Atherosclerosis reduces blood flow in the coronary arteries in such a way that the oxygen 
demands cannot be fulfilled and this can lead to chest pain (i.e. angina). Angina can be classified 
into stable or unstable angina, depending on the degree of clinical symptoms. Patients with 
stable angina have angina symptoms (e.g. chest pain) only with exertion or stress. In contrast, 
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patients with unstable angina have angina symptoms that occur without exertion and do not 
stop with rest. Besides narrowing, a lesion could also be obstructed due to a ruptured plaque 
leading to an event like myocardial infarction (MI) or a cardiac arrest. 
When patients are suspected of CAD due to clinical symptoms, a computed tomography (CT) 
angiography or an invasive coronary angiography (ICA) is often performed to determine the 
degree of narrowing (stenosis) in the arteries. Patients with ≥70% diameter narrowing of at least 
one major epicardial artery segment or ≥50% diameter stenosis in the left main coronary artery10 
are considered to have significant CAD and are often offered medication in combination with a 
revascularization procedure (i.e., percutaneous coronary intervention (PCI) or a coronary artery 
bypass graft (CABG)) to restore oxygen supply. These treatments, often based on the results of a 
diagnostic test, aim at relieving symptoms, preventing progression and plaque rupture. A PCI is 
an endovascular treatment that restores blood flow by reopening the lesion and consequently 
symptoms are relieved. Originally, angioplasty was performed with an expanding balloon 
to dilate the narrowed segment of the artery but this has been combined with a bare-metal 
stent (BMS) since 1994 to ensure that the segment remains dilated. Compared with balloon 
angioplasty, BMS reduces restenosis (reoccurrence of stenosis) which often requires a repeat 
revascularization11. Since the frequency of restenosis was still substantial after BMS, drug-eluting 
stents (DES) were developed and came to market in 2003 to reduce the frequency of restenosis 
even more. However, some studies suggest that patients treated with DES may have a higher 
chance of developing very late stent thrombosis12. CABG is a more invasive intervention than PCI 
since the chest cavities need to be opened and the heart often needs to be stopped (‘on-pump’ 
bypass). A CABG restores the blood flow by diverting the flow of blood around a section of a 
blocked artery using an artery from another part of the body. 
Aneurysms of the aorta
An aneurysm of the aorta is defined as a widening that is more than 50% of the normal diameter 
of the vessel, partially caused by atherosclerosis. Seventy-five percent of the aneurysms involving 
the aorta are located in the abdomen [abdominal aortic aneurysm (AAA)], below the diaphragm, 
and usually located below the renal arteries. Patients with an AAA are often asymptomatic and 
a sonography or CT scan is required to diagnose patients with AAA. Depending on the age group 
studied and the definition of AAAs, screening studies have shown that 1.3–12.7% of the population 
have an AAA13. Nowadays, patients with an AAA diameter larger than 5.5 cm are treated with 
an open surgical repair (OSR) or endovascular aneurysm repair (EVAR) to prevent rupture. Most 
patients can be treated with EVAR depending on the access of the iliac artery (e.g. diameter or 
tortuosity), and the angulation, diameter and length of the neck. In an OSR, the abdominal cavity 
need to be opened to repair the aneurysm with a graft. EVAR is a less invasive technique where 
a stent graft is inserted through the common femoral artery. When the aneurysm is located close 
to the origin of the renal arteries (juxta-renal abdominal aortic aneurysm) or in both the thoracic 
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and abdomen (thoracoabdominal aortic aneurysms) and patients are not fit for surgery, EVAR 
might not be possible. Fenestrated (fEVAR) and branched EVAR (bEVAR) can be considered for 
these patients, respectively. FEVAR/bEVAR are more complex procedures than EVAR due to the 
branches and fenestrations allowing blood flow to the organs.
Cost-effectiveness of cardiovascular interventions
In 2012, health care expenditure as a percentage of gross domestic product was approximately 
17.9% in the US, 12.4% in the Netherlands and 9.4% in the UK14. In the Netherlands, 9.2% of 
the total health care expenditure (approximately 8.3 billion euro) is spent on CVD2. Health care 
expenditures are rising globally due to aging populations and the development of new medical 
technologies15. Therefore, it is important to make wise choices when allocating the limited 
health care resources. Cost-effectiveness analyses can help in deciding between interventions 
for specific indications but also for interventions across indications. 
Many non-pharmaceutical technologies (e.g. stents, prostheses and diagnostic tests) are used in 
the prevention, diagnosis, prognosis, monitoring, and treatment of CVD. Over the past few years, 
many new or improved non-pharmaceutical technologies for CVD have entered the market and 
it is therefore important to ascertain if these technologies are cost-effective compared with 
existing interventions. 
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Aim AnD oUTLinE of THis THEsis 
The overall aim of the thesis is to assess the cost-effectiveness of various technologies in CVD 
and to identify and deal with challenges in assessing the cost-effectiveness of CVD technologies.
Several studies are presented to demonstrate the assessment of the cost-effectiveness of 
technologies in CVD. First, the cost-effectiveness of a hypothetical test for primary prevention 
of CVD was estimated. Furthermore, various non-pharmaceutical technologies† are used as case 
studies for the assessment of the cost-effectiveness in the diagnosis and treatment of CAD and 
AAA. In addition, to these cost-effectiveness studies, analyses of treatment variation and health 
related quality of life of patients diagnosed with CAD are performed. Finally, we described the 
challenges that arise in modelling the cost-effectiveness of cardiovascular interventions in a 
review paper.
In Chapter 2, we study the potential cost-effectiveness, using modelling techniques, of a biomarker 
test that could be used to decide which individuals with an intermediate CVD risk would benefit 
from statin treatment. The cost-effectiveness of new generation coronary CT scanners versus ICA 
for difficult to image patients suspected of CAD or with CAD was estimated in Chapter 3. For that 
study, a literature based Markov model was developed to estimate the cost-effectiveness from 
an UK NHS perspective. Patients with CAD undergoing a PCI are often treated with BMS or DES 
stents and it is sometimes unclear what determined the choice of stent. We therefore explore in 
Chapter 4 which factors lead to variation in stent choice in Dutch patients with stable or unstable 
CAD undergoing a PCI. Chapter 5 describes which patient characteristics are associated with 
health related quality of life in Dutch patients with stable or unstable CAD undergoing a coronary 
angiography. In Chapter 6, we systematically summarized the available evidence on the cost-
effectiveness of DES compared with BMS. In addition, we explored the added value of meta-
regression analyses compared with conventional review methods to examine the variation in 
incremental costs and incremental effectiveness in terms of quality adjusted life years and repeat 
revascularizations avoided between studies. Patients with an AAA larger than 5.5.cm are often 
offered elective reparative treatment. In Chapter 7, we have estimated the cost-effectiveness of 
an endovascular approach compared with open surgical repair for a Dutch setting. In Chapter 
8, we describe how the cost-effectiveness of fenestrated and branched endovascular aneurysm 
repair for juxta-renal and thoraco-abdominal aneurysms should be modelled when an UK NHS 
perspective is adopted. Chapter 9 provides a thorough overview of challenges that currently 
exist in modelling the cost-effectiveness of various interventions for cardiovascular disease. 
Finally, in Chapter 10, the results of the studies are summarized and discussed; furthermore we 
recommend further research challenges.
†
Throughout the thesis, non-pharmaceuticals we defined as medical devices and tests. With the exception of Chapter 9, we 
did not combine the two types of interventions and defined them as non-drug interventions (devices) and test interventions.

Chapter 2
is it cost-effective to use a test to decide 
which individuals with an intermediate 
cardiovascular disease risk would benefit 
from statin treatment?
Burgers LT
Nauta ST
Deckers JW
Severens JL
Redekop WK
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ABsTrACT
 
Background: The 2012 European guidelines recommend statins for intermediate-risk individuals 
with elevated cholesterol levels. Improved discrimination of intermediate-risk individuals is 
needed to prevent both cardiovascular disease (CVD) and statin side-effects (e.g. myopathy) 
efficiently since only 3–15 in every 100 individuals actually experience a cardiovascular event 
in the next 10 years. We estimated the potential cost-effectiveness of a hypothetical test which 
helps to determine which individuals will benefit from statins. 
methods and results: Prognosis of different age- and gender-specific cohorts with an intermediate 
risk was simulated with a Markov model to estimate the potential costs and quality-adjusted 
life-years for four strategies: treat all with statins, treat none with statins, treat according to the 
European guidelines, or use a test to select individuals for statin treatment. The test-first strategy 
dominated the other strategies if the hypothetical test was 100% accurate and cost no more than 
€237. This strategy and the treat-all strategy were equally effective but the test generated lower 
costs by reducing statin usage and side-effects. The treat-none strategy was the least effective 
strategy. Threshold analyses show that the test must be highly accurate (especially sensitive) and 
inexpensive to be the most cost-effective strategy, since myopathy has a negligible impact on 
cost effectiveness and statin costs are low.
Conclusion: Use of a highly accurate prognostic test could reduce overall CVD risk, frequency 
of drug side-effects and lifetime costs. However, no additional test would add usefully to risk 
prediction over SCORE when it does not satisfy the costs and accuracy requirements.
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inTroDUCTion
Cardiovascular disease (CVD) is the leading cause of death across Europe and one of the major 
causes of disability16. Due to its high prevalence and morbidity rate, the economic burden of 
CVD is also substantial. Means to prevent CVD include lifestyle modification and medicines such 
as statins17,18. Although the annual costs of generic statins per individual are low, the budgetary 
impact of wide-scale statin usage is substantial due to the high prevalence and lifetime utilization. 
Since preventive statin treatment is associated with some risk, e.g. myopathy, the use of statins 
is not cost-effective in individuals at low risk19. In subjects at higher risk, however, the issue may 
be quite different.
Risk scores such as the Framingham risk score (FRS)9 and the Systematic coronary risk evaluation 
(SCORE) method7 are well-accepted tools to estimate the 10-year risk of (non-) fatal CVD and 
decide which individuals qualify for statin treatment. The most recent 2012 European guidelines20 
make use of the SCORE, which categorises individuals into three risk categories (low, intermediate, 
high). Individuals at intermediate risk with an elevated cholesterol level are recommended to 
receive statin therapy. However, only 3–15% of them actually develop a cardiovascular event. In 
theory, tests could potentially be used to reclassify some of these intermediate-risk individuals 
into a lower or higher risk category21, with subsequent implications for their medical treatment. 
This would lead to better discrimination and thus a reduction in costs and an increase in 
effectiveness since cardiovascular events and unnecessary usage of statins would be prevented. 
However, the discriminative ability of biomarkers such as C-reactive protein beyond traditional 
markers (SCORE) is only modest22. The limited prognostic value of the risk scores and traditional 
markers as well as the rapid increase in the prevalence of CVD risk factors necessitates the 
development of other strategies to predict and prevent the development of CVD. 
Therefore, the aim of our study was to use the 10 year SCORE risk to estimate the potential 
10-year cost-effectiveness of a (theoretical) test compared with a treat-none strategy, treat-all 
strategy, and a strategy based on European guidelines. In addition, we examined the conditions 
(accuracy estimates and costs) under which the use of a novel test (e.g. biomarker) would be 
cost-effective. 
 
mETHoDs
The cost-effectiveness of a test was estimated for eight age- and gender-specific cohorts of 
individuals with an intermediate risk (3–15%) of developing a first-time CVD event in the next 
10 years20. The SCORE risk equation was used to identify individuals with an intermediate risk 
based on age, gender, systolic blood pressure, total cholesterol and smoking status. SCORE risk 
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estimates were multiplied by a factor of three to obtain the risks of non-fatal and fatal events, as 
proposed by the European Society of Cardiology (ESC) guidelines20. We subsequently modelled 
the prognosis of eight cohorts, defined by the SCORE, of men and women with an age of 50, 55, 
60, and 65 years. 
strategies
We compared the costs and effectiveness of four strategies: 1) “treat-all” strategy, where all 
individuals receive statin treatment; 2) a “treat-none” strategy, where none of the individuals 
receive statin treatment, 3) a “guidelines” strategy, where individuals receive statin treatment 
according to the ESC guidelines on CVD prevention20 (which recommend that statins should 
only be given to those with total cholesterol level ≥5 mmol/L and/or low-density lipoprotein 
cholesterol level ≥3 mmol/L) and 4) a “test-first” strategy, where statin treatment is recommended 
for individuals having a positive test result. A positive test result suggests that a first-time CVD 
event in the next 10 years will occur if statin treatment is not provided. 
model structure
For each strategy, the prognosis of a cohort of individuals for the next 10 years was modelled 
in a Markov model (Microsoft Excel™ 2010) with eight health states (Figure 2.1). A time horizon 
of 10 years was chosen since the SCORE only provides an accurate estimate of 10-year risks. 
All individuals started in the “intermediate risk” state and annual transition probabilities 
determined the likelihood of moving to other health states (Table 2.1). Individuals experiencing 
a non-fatal CVD event (myocardial infarction (MI), stroke or revascularization) or a statin-
induced non-fatal adverse event (myopathy) moved to the post-event states afterwards the 
event. Individuals experiencing cardiovascular or non-cardiovascular fatal events moved to the 
absorbing health states “cardiovascular death” and “non-cardiovascular death”, respectively. 
In all strategies, individuals experiencing a cardiovascular event received statin treatment 
afterwards. Statin treatment was discontinued permanently if individuals developed myopathy 
and its discontinuation also meant loss of the protective effects of the statins.
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Intermediate 
risk Myopathy 
Post 
Myopathy 
Rhabdomyolysis 
MI Revascularizaon (angina) Stroke 
Post minor 
stroke 
Post major 
stroke 
Post 
Revascula- 
rizaon 
Post MI 
EVENT 
(Non-) Cardiovascular death 
figure 2.1 | Model structure*
*Cardiovascular death and non-cardiovascular death are presented as one state in this Figure. Rectangles are (non) cardio-
vascular events and ovals are disease states. MI, myocardial infarction.
input parameters
A literature search using PubMed was performed to obtain input values. Table 2.1 shows the 
input parameters for the subgroup of men aged 65 years, illustrative for the eight cohorts that 
were modelled. 
a | Risks
The risk of developing (non-) fatal CVD events (MI, stroke, angina-induced revascularization and 
cardiovascular death) was obtained from the SCORE chart by taking the average of all possible 
combinations with an intermediate risk in each gender- and age-specific cohort. Based on the 
randomized controlled trials (RCTs) included in the meta-analysis of Brugts et al.18 we divided 
the individuals treated according to the guidelines into two groups: 1) individuals with elevated 
cholesterol levels, indicated for statin treatment and 2) individuals with normal cholesterol 
levels. We assumed that individuals with normal cholesterol levels had the lowest possible 
intermediate risk of CVD in their respective gender- and age-specific cohort (appendix). In our 
analyses, individuals with elevated cholesterol levels were assigned inherently higher risk than 
the average intermediate risk in the same gender- and age-specific cohort to ensure that the 
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average risk remained unchanged when the two groups were combined. A meta-analysis18, UK 
audit data23, the FRS9 and three RCTs24-26 were used to estimate age- and gender-specific relative 
proportions of the CVD events. The annual probabilities of developing myopathy and (non-) fatal 
rhabdomyolysis caused by statins were based on Law et al.27. Mortality was based on national 
and international mortality statistics23,28-32.
The sensitivity and specificity of the hypothetical test were both assumed to be 100% in the 
base-case scenario and the impact of their values was explored through sensitivity analyses. 
Therefore, in the base-case scenario it is assumed that the test will discriminate absolutely and 
perfectly all individuals who will experience a cardiovascular event over the specified time period 
and those who will not. 
Table 2.1 | Input data used in the Markov model (men 65 year)
Base-case value Distribution reference
Parameters
Probabilities of (non-) cardiovascular events*
10-year risk of event (myocardial infarction, stroke, 
revascularization or cardiovascular death)
0.107 7
Annual risk of event (myocardial infarction, stroke, 
revascularization or cardiovascular death)
0.0113 7
Myocardial Infarction 0.0061 Beta 9
Mortality (first year) 0.1530 Beta 29
Mortality (subsequent years) 0.0343 Beta 29
Stroke 0.0030 Beta 9
Fatal 0.12 Beta 24-26
Minor stroke vs. major stroke 0.80 Beta Assumption
Revascularization 0.0022 Beta 18,23
Fatal 0.0064 Beta 23,31,32
Non-cardiovascular death 0.0125 Beta 28
Treatment effectiveness of statins
RR of non-fatal myocardial infarction, statins vs. placebo 0.56 Lognormal 18
RR of revascularization, statins vs. placebo 0.67 Lognormal 18
RR of stroke, statins vs. placebo 0.81 Lognormal 18
Myopathy 0.00011 Beta 27
Rhabdomyolysis 0.31 Beta 27
Diagnostic accuracy of the biomarker
Sensitivity 100% Beta Assumption
Specificity 100% Beta Assumption
Proportion of patients with elevated cholesterol 0.82 Beta 26,33-36
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Table 2.1 | (Continued)
Base-case value Distribution reference
Costs (€) 
Biomarker test 250 Gamma Assumption
Costs of events, first year
Myocardial infarction 4873 Gamma 37
Myopathy 166 Gamma 27,38,39
Minor stroke 8494 Gamma 40
Major stroke 18,084 Gamma 40
Revascularization 12,426 Gamma 32,41
Costs of events (annual), subsequent years
Myocardial infarction 2708 Gamma 42
Minor stroke 2722 Gamma 40
Major stroke 3924 Gamma 40
Costs of fatal events
Myocardial infarction 1834 Gamma 42
Stroke 11,618 Gamma 40
Revascularization 8293 Gamma 41
Costs of statin therapy
Statin treatment (simvastatin 40mg/d) 17 Gamma 43
Doctor visits (4 visits) 35 Gamma 44
Utilities
Healthy 0.86 Beta 41
Post-myocardial infarction 0.86 Beta 41
Post-major stroke 0.32 Beta 45
Post-minor stroke 0.71 Beta 45
Post-revascularization 0.86 Beta 41
Disutility myopathy -0.1 Beta Assumption
Disutility minor stroke -0.1 Beta Assumption
Disutility major stroke -0.3 Beta Assumption
Disutility revascularization (angina) -0.0825 Beta 41
Disutility myocardial infarction -0.0825 Beta 41
RR: Relative risk; vs: versus; * Annual probabilities
b | Cost, treatment effectiveness and quality of life
The impact of changes in 10-year risks of CVD events was translated into costs and quality-
adjusted life-years (QALY). Costs (€2012) and QALYs were estimated from a health care sector 
perspective and discounted at 4% and 1.5%, respectively, in accordance with Dutch guidelines46. 
Costs were converted to the price year 2012 using consumer price indices and inflation 
corrections if necessary47,48.
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The cost of the hypothetical test was initially set at €250 in the base-case scenario and the cost of 
statin treatment was based on Dutch wholesale prices43,44. Costs of events were based on recent 
cost-effectiveness and cost-of-illness studies37-42,49. Treatment effectiveness of statins was based 
on a recently published meta-analysis18 and, based on this meta-analysis, treatment effectiveness 
was assumed to be independent of age, gender and risk since differences between the groups 
were non-significant. Because costs for yearly doctor visits were included, the adherence rates 
(80–90%) were assumed to be comparable to statin trial results50,51. Quality-of-life values were 
derived from two studies41,45.
We estimated the differences in costs and effectiveness (QALYs) between the four strategies 
and arranged them according to increasing effectiveness. Where possible, we also calculated 
incremental cost-effectiveness ratios (ICER).
Additional analyses
Additional analyses were performed to determine how much the uncertainty about the values of 
input parameters influenced the results. Probabilistic sensitivity analysis (PSA), where the values 
of many input parameters are varied simultaneously, was also performed. The test sensitivity 
and specificity were varied between 90% and 100% (in steps of 5%). Threshold analyses were 
performed to determine the maximum price and minimal diagnostic performance (sensitivity 
and specificity) of a test that were possible while ensuring that the test-first strategy was the 
most cost-effective strategy; i.e., either cost-saving and more effective or cost-effective given a 
willingness-to-pay (WTP) of €50,000. In addition, scenario analyses were performed to assess 
the impact of: 1) reducing the effectiveness of statin treatment; 2) including the inconvenience 
(disutility) of taking statins; 3) higher statin treatment costs; 4) greater health loss (disutility) 
from myopathy; and 5) increasing the time horizon from 10 years to 20 years.
rEsULTs
The base-case results of the four strategies for all cohorts are presented in Table 2.2 and Figure 
2.2. For all strategies, mean costs increased and mean QALYs decreased as age increased (and 
thereby also 10-year CVD risk). In all cases, the treat-none strategy was the least effective strategy, 
followed by the guidelines strategy, treat-all strategy, and the test-first strategy. The test-first 
strategy was also the least expensive strategy for most of the cohorts, making it the dominant 
strategy since it reduced costs and increased effectiveness. The only exception was for the cohort 
of 50-year old women, where the treat-none was the least expensive strategy due to the very low 
risk (about only 4.3%) of developing a cardiovascular event. Furthermore, the guidelines strategy 
was less effective than the treat-all strategy although in almost all cohorts cost-saving. Overall, 
the test-first strategy resulted in a marginal QALY gain of 0.0002 and a cost-savings of €128 per 
individual over a 10-year period versus the treat-all strategy. Figure 2.3 presents the cumulative 
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costs for each strategy (for 65 year old men) and shows that the test-first strategy becomes less 
expensive than the other strategies after approximately 7 years. 
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis revealed that the test-first strategy had the highest probability of 
being the most cost-effective strategy, regardless of the WTP since the incremental effectiveness 
versus the treat-all strategy is very small. 
Threshold analyses
The test-first strategy remained the dominant choice for all cohorts as long as the perfect test 
cost no more than €237. When the price of the test was set at €250, the test had to have a 
sensitivity and specificity of at least 94% to be cost-effective at a willingness-to-pay of €50,000 
euro per QALY gained. Figure 2.2 shows the influence of changes in test accuracy on the costs 
and effectiveness of the test-first strategy. A decrease in specificity leads to an increase in false 
positives, resulting in a higher frequency of unnecessary statin treatment. The solid arrow 
(purple) shows that reduced specificity increases the total costs of the test-first strategy; when 
the specificity is zero, the test-first strategy is more expensive – and therefore less cost-effective 
– than the treat-all strategy. Note that since the side-effects of statin treatment are rare and 
minimal, this solid arrow is almost vertical. The impact of a decrease in sensitivity is shown by the 
dash-dotted arrow (green). Reduced sensitivity is associated with an increase in false negatives, 
meaning that some individuals who have a negative test result will experience a CVD event in 
the next 10 years if they are not treated with statins. Reduced sensitivity makes the test-first 
strategy more costly and less effective since some individuals do not receive beneficial statin 
treatment. The test-first and treat-none strategies are equally effective when the sensitivity is 
0% and specificity is 100%, since the test is negative in all individuals and no complications are 
associated with the test itself. However, the costs of the test-first strategy are higher than the 
treat-none strategy because of the costs of the test. The dashed line (blue) shows how an equal 
decrease in the sensitivity and specificity of the test affects the results and demonstrates that the 
sensitivity has more influence on the cost-effectiveness of the test-first strategy than specificity. 
scenario analyses
Use of a 20-year time horizon increases the relative effectiveness and cost-savings potential of 
a test-first strategy since the benefits of preventing CVD and unnecessary statin treatment were 
extended for a longer period. 
As presented in Table 2.3, the addition of disutility for statin use (reflecting the inconvenience 
of taking statins daily) improved the effectiveness and cost-effectiveness of the test-first strategy 
since this strategy ensures that only individuals who will benefit from statin treatment are 
treated. The use of disutility increased the maximum possible price of the test to €742 at a 
threshold of €50,000 per QALY gained. Besides this effect, the overall findings did not change. 
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Treat-none strategy
Guideline strategy
Se 100%
Sp 0%
Se 0% 
Sp 100%
Se 95%
Sp 95%
Se 90%
Sp 90%
1,200
1,300
1,400
1,500
1,600
1,700
1,800
1,900
7.202 7.204 7.206 7.208 7.210 7.212 7.214 7.216 7.218 7.220 7.222 7.224
Total discounted QALYs  
*  
* 
* Price test 
Lower specificity  
  
To
ta
l d
is
co
un
te
d 
co
st
s (
€)
 increase FP
Treat-all strategy
Test-first strategy
figure 2.2 | Cost-effectiveness plane for 65-year old men†
* Price of the test
† The treat-none strategy is considered as the comparator 
Se: sensitivity; Sp: specificity; QALYs: quality-adjusted life years; FP: false positives; FN: false negatives
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figure 2.3 | Cumulative costs of the strategies for 65-year old men*
* Discounted at 4%
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DisCUssion
The recently introduced European guidelines20 recommend statins for individuals at moderate 
risk of fatal CVD events and elevated cholesterol levels. Consequently, many individuals with 
intermediate risk are treated with statins even though only one in every 7–33 individuals will 
actually develop a CVD event in the next 10 years. 
As could be expected, the results of this cost-effectiveness analysis show that the guidelines 
strategy is a more favourable option than the treat-none strategy. Moreover, after a 4-year 
period the guidelines strategy becomes less expensive and avoids more cardiovascular events 
than the treat-none strategy. Furthermore, the guidelines strategy is less expensive than and 
just as effective as the treat-all strategy in almost all cohorts. However, the guidelines strategy 
and treat-all strategy both lead to unnecessary statin-induced myopathy events and costs. In 
theory, these can be prevented by using a test to identify individuals who would actually benefit 
from statin treatment. A strategy incorporating a prognostic test (e.g. biomarker) can be more 
cost-effective than other strategies, including the current European guidelines. However, the 
test must fulfil certain conditions relating to price and diagnostic accuracy. The test-first strategy 
using a test with 100% accuracy would be more cost-effective than the guidelines strategy as 
long as the price of the test does not exceed €385 given a willingness to pay of €50,000 per QALY 
gained. A test-first strategy is cost-effective only if the diagnostic accuracy of the test is very 
high; the test’s sensitivity is more important than its specificity. It is important to recognize that 
these estimates are reasonably high (90–100%). Currently available tests rarely have these levels 
in any area in cardiology but based on the sensitivity analyses a test with lower sensitivity and 
specificity values were considered not cost-effective. Note that most test results are measured on 
a continuous scale and consequently the positivity criterion (cut-off) determines the sensitivity 
and specificity of the test. Dichotomizing test results on a continuous scale often leads to a trade-
off between maximising sensitivity and specificity. 
Interestingly, in the present study we investigated the cost-effectiveness of a hypothetical test. 
In fact, this could be any test that adds information to the SCORE method such as an imaging 
result (e.g. CT coronary calcium score or a coronary angiogram), a biomarker test (e.g. C-reactive 
protein) or a physiological test (e.g. a treadmill or a stress echo). Our results are important 
because for any test performed to reclassify/discriminate intermediate risk individuals, we 
provide a maximal price or minimal accuracy in order for it to be cost-effective. 
A recent study investigated the cost-effectiveness of statins in primary prevention of CVD for 
individuals at different levels of risk19. This study found that the treat-all strategy was more 
expensive than the treat-none strategy due to higher annual costs of statin therapy (€157). We 
found comparable results in the lower risk cohorts (men of 50 years of age and women 50–60 
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years). However, use of the same annual costs of statins leads to the same result in the higher 
risk cohorts in our study and the incremental effectiveness the authors reported is comparable 
with our result. Another study of individuals at intermediate risk estimated the cost-effectiveness 
of a computed tomography (CT) scanner as an additional reclassification method and compared 
it with American Heart Association guidelines, current practice and treating all individuals with 
statins and aspirin52. In their study, the CT scanner was the most effective strategy. The reported 
incremental QALYs were larger than in our study; one explanation could be that both aspirin-
related and statin adverse events were included. 
strengths and limitations
Our model provides an accurate representation of the clinical pathways for individuals at CVD 
risk. For instance, the model used in our study included the costs and consequences of angina-
related revascularizations, myopathy and rhabdomyolysis. When these costs are also considered, 
the test-first strategy is more cost-effective than alternative strategies even though all patients 
must undergo the test. Our study does not incorporate other adverse events of statin intake 
such as liver damage. However, the incidence of liver damage is extremely low and probably not 
much different than that of individuals not taking statins27. Consequently, its inclusion would only 
marginally reduce the estimated effectiveness of strategies that include statin treatment. 
Unlike other studies, we based CVD event rates on the SCORE method, which is more appropriate 
than estimates derived from studies not focusing on intermediate-risk populations. However, the 
risks found in the SCORE are based on several sources from 12 European countries and therefore 
not specific for the Netherlands. It is also known that the SCORE risk equation overestimates 
the actual risk of fatal CVD events in some populations53. Since we selected individuals from the 
SCORE chart with an intermediate risk (3%–15%), this limitation does not apply to our results. 
Furthermore, we used a multiplier to obtain the risk of fatal and non-fatal cardiovascular events. 
This multiplier, proposed in the European guidelines, may actually be somewhat smaller in older 
individuals. Therefore, our results might not be fully applicable in older patients with a relatively 
low SCORE risk. The health gain from statin intake amongst these patients could therefore 
be overestimated; this would mean that the cost-effectiveness for treat-all, test-first and the 
guidelines vs. treat-none strategy is less favourable than what we estimated. 
In our study, the decision about statin treatment was based only on the estimated CVD risk at 
baseline. However, it is likely that some individuals not treated at baseline will receive statins after 
a few years because of an increase in their estimated CVD risk. This phenomenon would mean a 
gradual increase in statin use in the guidelines strategy, which might improve its effectiveness and 
perhaps also reduce the estimated costs. Lack of detailed data about temporal changes in CVD 
risk made it impossible to incorporate later statin initiation in the analyses. Furthermore, we also 
assumed that the test accurately determines which individuals would benefit from treatment for 
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a time horizon of ten years and therefore assumed that testing once at baseline was sufficient. 
However, it is possible that testing should be repeated every year. Since the threshold analysis 
revealed the maximum possible price for one test in a 10-year time horizon, the strategy of 
regular testing would reduce the maximum acceptable price per test proportionally.
implications
One potential benefit of a CVD prediction test would be to reduce the frequency of myopathy 
by treating only individuals with a high CVD risk. However, the health gain is very small since 
statin use is associated with only a small risk of myopathy. Another value of a test from a patient 
perspective would be that patients would have a better idea of their CVD risk and that patients 
with a negative test result could be reassured that their chances of developing CVD in the next 
10 years will be very small. While this ‘peace of mind’ is not included in the current way of 
quantifying effectiveness, it has been identified as another dimension in the assessment of 
tests54. In addition, it is possible that individuals who become more aware of their high risk 
would improve their lifestyle (e.g. smoking cessation or dietary changes), which would further 
reduce their risk of CVD events and increase the effectiveness of the test-first strategy beyond 
what would be expected based on statin use alone. Furthermore, if statin use is associated with 
disutility its use could be limited to the individuals who would benefit from it. From a clinician’s 
perspective, the foremost goal is to ensure that patients receive the best possible treatment, 
which would mean choosing the most effective strategy available. Based on our results, this 
would be either the treat-all strategy or the test-first strategy in most cases. However, when the 
problem is viewed from a payer perspective, a test-first strategy might provide a way to reduce 
the long-term budget impact of statin use without placing patients at unnecessary risk of CVD 
(Figure 2.3), as long as the test sensitivity and specificity are sufficiently high. However, the payer 
would have to be willing to accept the higher short-term costs of using the test-strategy (mainly 
because of the costs of the test) versus the treat-none strategy. The same trade-off holds true 
for treating all patients with statins or applying the guidelines versus treating no patients with 
statins; both strategies will increase short-term costs because of statin use.
Conclusions
There is a large population of individuals with an intermediate CVD risk who may benefit from 
statin treatment. A test capable of stratifying individuals in this population into lower and higher 
risk groups has the potential to be cost-effective versus alternative strategies as long as it is not 
too expensive and its diagnostic accuracy is high. In particular, a test with a sufficiently high 
sensitivity would have the potential to be more effective and cost-saving than the strategy 
proposed in the European guidelines and the more extreme treat-all strategy. No additional test 
would add usefully to risk prediction over SCORE or similar risk scores when it does not satisfy 
the costs and accuracy requirements given the effectiveness and relatively low costs of currently 
available statins.
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Cost-effectiveness analysis of new 
generation coronary CT scanners for 
difficult to image patients
Burgers LT
Redekop WK 
Al MJ
Lhachimi SK
Armstrong N
Walker S
McKenna C
Westwood ME
Severens JL
Submitted, based on Chapter 4 of 
Westwood ME, Al MJ, Burgers LT, Redekop WK, Lhachimi SK, Armstrong N, et al. A systematic 
review and economic evaluation of new-generation computed tomography scanners for 
imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, 
Aquilion ONE, Brilliance iCT and Discovery CT750 HD. Health Technol Assess 2013;17(9)
34 | Chapter 3
ABsTrACT
Aims: New generation dual-source coronary CT (NGCCT) scanners with more than 64 slices were 
evaluated for patients with (known) or suspected of coronary artery disease (CAD) who are 
difficult to image: obese, coronary calcium score >400, arrhythmias, previous revascularization, 
heart rate >65 beats per minute, and intolerance of beta-blocker. A cost-effectiveness analysis of 
NGCCT compared with invasive coronary angiography (ICA) was performed for these difficult to 
image patients for England and Wales.
methods and results: Five models (diagnostic decision model, 4 Markov models for CAD 
progression, stroke, radiation and healthy person) were integrated to estimate the cost-
effectiveness of NGCCT for both suspected and known CAD populations. The lifetime costs and 
effects from the National Health Service perspective were estimated for three strategies: i) 
patients diagnosed using ICA, ii) using NGCCT, and iii) patients diagnosed using a combination 
of NGCCT and in case positive, followed by ICA. In the suspected population, the strategy 
where patients only undergo a NGCCT is a cost-effective option at accepted cost-effectiveness 
thresholds. The strategy NGCCT in combination with ICA is the most favourable strategy for 
patients with known CAD. The most influential factors behind these results are the percentage of 
patients being misclassified (a function of both diagnostic accuracy and the prior likelihood), the 
complication rates of the procedures, and the cost price of a NGCCT scan.
Conclusion: The use of NGCCT might be considered cost-effective in both populations since it is 
cost-saving compared to ICA and generates similar effects.
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inTroDUCTion
In recent years imaging technologies have been developed rapidly leading to the introduction 
of new generation coronary computed tomography (NGCCT) scanners. The latest generation of 
dual-source instruments may have a significant benefit over the current technologies, especially 
for difficult-to-image patients through improvements in image quality, and reductions in the scan 
duration and radiation exposure. 
Currently, for patients suspected of coronary artery disease (CAD) the diagnosis is usually 
based on tests such as an invasive coronary angiography (ICA), functional imaging, computed 
tomography (CT) coronary angiography (CTCA), or a computed tomography calcium scoring. 
The appropriate diagnostic test depends on the likelihood of having CAD10. Furthermore, these 
diagnostic tests can also be used to decide if a revascularization is necessary. The performance 
of 64-slice CT for diagnosing CAD has been well established. Recent systematic reviews have 
estimated that 64-slice CT, for the detection of ≥50% coronary artery stenosis, is very accurate55-57. 
However, 64-slice CT cannot be (routinely) used for specific groups of patients who are difficult 
to image due to decreased image quality58. These include patients with: i) arrhythmias, ii) heart 
rate >65 beats per minute, iii) obesity, iv) coronary calcium level >400, v) a previous coronary 
revascularisation with a stent, vi) β-blocker intolerance or vii) a previous coronary artery bypass 
graft (CABG). In these difficult-to-image patients, ICA a more invasive diagnostic procedure may 
therefore be indicated. Newer generation CT instruments may provide an alternative to an ICA 
for these patients, which has a lower procedure-related mortality and morbidity. One potential 
disadvantage may be a slightly lower sensitivity and specificity compared to ICA, which means a 
greater frequency of false positive (FP) and false negative (FN) results that may lead to incorrect 
treatment decisions, health loss and increased costs. We performed a cost-effectiveness study of 
the NGCCT compared with ICA for difficult-to-image patients for England and Wales.
mETHoDs
The lifetime cost-effectiveness of NGCCT for difficult-to-image patient groups was estimated 
for two separate populations: patients with suspected CAD and patients with known CAD. The 
suspected CAD population includes patients with chest pain or other symptoms suggestive of CAD. 
Patients with known CAD were defined as patients with a diagnosis of CAD whose symptoms are 
no longer controlled with drug treatment and/or are being considered for revascularization. The 
characteristics (e.g. age, systolic blood pressure) of the difficult-to-image subgroups are based on 
the studies that are included in a systematic review32. The NGCCT has a different purpose in each 
population: diagnose CAD in the suspected population or decide if revascularization is necessary 
in the known CAD population. 
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figure 3.1 | Diagnostic model for suspected CAD population
CAD: coronary artery disease; ICA: invasive coronary angiography; NGCCT: new generation coronary computed tomography; 
TP: true positive; FP: false positive; FN: false negative; TN: true negative; CABG: coronary artery bypass graft; PCI: 
percutaneous coronary intervention; DPM: disease progression model
figure 3.2 | Diagnostic model for known CAD population
CAD: coronary artery disease; ICA: invasive coronary angiography; NGCCT: new generation coronary computed tomography; 
TP: true positive; FP: false positive; FN: false negative; TN: true negative; CABG: coronary artery bypass graft; PCI: 
percutaneous coronary intervention; DPM: disease progression model
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strategies
Three strategies were examined: i) a strategy where patients only undergo an ICA (ICA–only 
strategy), ii) a strategy where patients only undergo the NGCCT (NGCCT–only strategy), and 
iii) a strategy where patients are first assessed with NGCCT and undergo an ICA if the NGCCT 
is positive (NGCCT–ICA strategy). NGCCTs are defined as dual-source cardiac CT scanners with 
>64 slices (Brilliance iCT (Phillips Healthcare), Somatom Definition Flash (Siemens Healthcare), 
Aquilion ONE (Toshiba Medical Systems), and Discovery CT750 HD (GE Healthcare)).
Models
The cost-effectiveness analyses were conducted by combining five models: i) a decision model 
of the diagnostic pathway (diagnostic model)59, ii) a Markov model reflecting the prognosis of 
CAD patients (disease progression model (DPM)60), iii) a Markov model to estimate the impact 
of radiation on cancer mortality and morbidity (adjusted York radiation model (YRM)32,61), iv) a 
Markov model to account for mortality amongst persons without CAD (healthy person model 
(HPM)59), and v) a Markov model to estimate the impact of stroke due to the initial test and 
treatment (stroke model). The diagnostic model (Figure 3.1 and Figure 3.2), where the entire 
cohort of patients starts, splits up the cohort based on diagnostic performance, complication 
rates and prior likelihood. For example, the proportion with a true positive (TP) test was modelled 
with the DPM (Figure 3.3) and the proportion of patients experiencing a stroke due to ICA was 
modelled with the stroke model. At the end we combined all the proportions modelled through 
one of the five models with their outcomes leading to a total cost-effectiveness estimate for 
each specific difficult-to-image subgroup. However, the aim was to compare the overall cost-
effectiveness of the three strategies in each of the two populations (suspected and known CAD). 
Expert opinion was used to gather information on the relative frequencies of patients (Tables 
3.2 and 3.3) in the difficult-to-image subgroups in the known or suspected CAD population. 
Multiplication of the relative proportions with the subgroup-specific costs and effects produced 
an overall ICER for both populations. 
The analyses were based on cohort simulations. Costs and effects were discounted at 3.5%, and 
the study was performed from a National Health Service perspective. 
model variables
Input parameters, based on published literature and expert opinion, are provided as 
supplementary data in Table S3.1. 
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figure 3.3 | Disease progression model*
* Adapted from Briggs et al. 200760
MI: myocardial infarction; CA: cardiac arrest; CV: cardiovascular; Eq: equation
Transition probabilities
Prior likelihood, accuracy estimates of the tests and complication rates of the procedures are 
important parameters in the diagnostic model. The prior likelihood (20%) of having CAD in 
patients with suspected CAD was based on the clinical guideline “Chest pain of recent onset”10. 
Patients with a prior likelihood of 20% are normally diagnosed with a 64-slice CT, the technology 
that the NGCCT will replace for patients who are difficult to image. The prior likelihood of 
performing a revascularisation in patients with known CAD was based on the CE-MARC study59 
(Table S3.1). We used this estimate due to lack of data despite the possibility that the CE-MARC 
population may not perfectly match our population. The sensitivity and specificity of ICA were 
assumed to be 100%, as in Mowatt et al.55. The estimates of the sensitivity and specificity for the 
NGCCT were based on a systematic review which aimed to identify accuracy estimates for all type 
of scanners62. This review found 21 studies evaluating the Somatom definition (flash), one study 
evaluating the Aquilion ONE and one study evaluating the Discovery CT750 HD. In the remainder 
of the paper we will assume that these accuracy estimates are generalizable to other NGCCTs. 
Complication rates of ICA and the procedures were based on West et al.63, Tarakji et al.64, Serruys 
et al.65, Rajani et al.66, and Bridgewater et al.67. 
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The risks of cardiovascular events for patients with CAD in the DPM were based on the results of 
the EUROPA trial60. We used four equations to calculate: i) the probability of any event that will 
occur in one cycle of three months; ii) the probability that the event is fatal; iii) the probability 
of a subsequent event in the first year after a first non-fatal event; and iv) the probability of a 
subsequent event after one year.
Life expectancy for patients without CAD was based on UK life tables68; the life expectancy for 
stroke patients was derived by adjusting the UK life tables for excess mortality risk based on an 
observational study of stroke patients30.
The adjusted version of the YRM models the harmful consequences of radiation exposure. 
Based on age at exposure, gender, and radiation dose (mSv) we have estimated the probability 
of developing cancer. For patients developing radiation-induced cancer, the remaining quality-
adjusted life-years (QALYs) given the average age of cancer incidence and the average treatment 
cost for cancer are calculated61.
Costs
The costs of the three strategies included the cost of the diagnostic tests, non-fatal events 
(myocardial infarction (MI) and cardiac arrest), procedures (e.g., revascularisation), CAD 
management costs (e.g. medication), stroke-related costs and costs due to radiation-induced 
cancer (Table S3.1). Original cost prices were inflated to reflect costs for 2010 using PSSRU Health 
Unit costs of Health and Social Care 201069.
The cost of the NGCCT procedure was calculated using a bottom-up costing since only data for 
CT in general (i.e. not specifically for CTCA) was available32. The costs occurring in the first year 
after a non-fatal cardiovascular event, a fatal cardiovascular event, and a non-cardiovascular 
fatal event were based on the EUROPA trial70. For subsequent years after the non-fatal event, 
the additional cost was estimated at £98660. CAD management costs for each difficult-to-
image patient group were calculated using a previously published regression model, which 
estimates costs using patient characteristics such as age, diabetes mellitus, medication usage, 
and symptomatic disease60. Costs due to radiation-induced cancer are based on a number of 
previous comprehensive assessments of the economic burden of treating several different types 
of cancer61.
Health related quality of life
The overall effectiveness of the three strategies was expressed in QALYs. QALYs represent a 
combination of life expectancy and health-related quality of life (HRQoL). The HRQoL estimates 
of CAD patients were based on three sources: UK population norms for the EQ5D71, EQ5D scores 
per Canadian Cardiovascular Society class of angina pectoris72 and treatment effect on HRQoL 
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based on the RITA2 trial73. These sources were used to calculate HRQoL for each difficult-to-
image group59. It was assumed that a non-fatal event was associated with a disutility of 0.0102 
for the subsequent three months5. Loss in QALYs due to radiation induced cancer were based on 
the UK population61. HRQoL of patients with stroke were estimated to be 0.37 using the results 
of the study of Sandercock et al.30. 
Assumptions
A number of assumptions were made in this study. First, the ICA (“gold standard”) was assumed 
to have a sensitivity and specificity of 100%. Second, we assumed that all diagnostic tests are 
performed immediately after each other without any relevant time delay. Third, we also assumed 
that the sensitivity and specificity of the tests for each difficult-to-image subgroup are the same 
for both populations. Lastly, the complication rates of revascularization and ICA were assumed to 
be the same in all subgroups. The full set of assumptions is provided in Westwood et al.32.
Analyses
Base-case scenarios were based on a probabilistic sensitivity analysis due to the non-linearity 
of the model. Scenario analyses were performed to determine the impact of different values 
for the input parameters on the ICERs. The cost of the NGCCT, the prior likelihood of CAD in the 
suspected population, and the complication rates were varied. The cost of NGCCT was fixed at 
£150 and at £207; this range was based on the bottom-up costing method where we have varied 
the number of procedures performed per year. The prior likelihood of the suspected population 
was increased to 0.3, which was the upper limit of the range when a 64-slice CT should be 
performed to diagnose patients suspected of CAD10. Worst-case and best-case scenarios for the 
NGCCT strategies were performed by varying the complication rates (lower and upper limits 
of 95% confidence interval) of a revascularization and of the test. Moreover, cost-effectiveness 
acceptability curves are created to present the probability of a strategy being cost-effective given 
the willingness-to-pay threshold. Currently, NICE applies a threshold of £20,000 to £30,000 per 
QALY gained74. More information concerning the modelling methods and input parameters can 
be found in Westwood et al.32. All analyses were performed using Microsoft Excel™ 2010.
rEsULTs
The base-case results revealed that NGCCT was initially less expensive than ICA, but that the 
lower sensitivity and specificity of NGCCT leads to more incorrect diagnostic classifications (Table 
3.1). Furthermore, the NGCCT reduces radiation induced cancer, complications (stroke & MI) and 
mortality due to the diagnostic procedure compared with ICA. 
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Table 3.1 | Intermediate outcomes       
Proportion 
correct 
classification
misclassification Test 
mortality
Test 
morbidity
mortality 
revasculariza-
tion
morbidity 
revasculari-
zationa
fPs fns
suspected CAD population
ICA – only 1  –  – 0.00073 0.00064 0.00027 0.00047
NGCCT – ICA 0.9903  – 0.0097 0.00019 0.00018 0.00026 0.00044
NGCCT – only 0.8934 0.0969 0.0097  –  – 0.00039 0.00067
Known CAD population
ICA – only 1  –  – 0.0007 0.0006 0.0030 0.0051
NGCCT – ICA 0.9818  – 0.0182 0.0001 0.0003 0.0028 0.0048
NGCCT – only 0.9042 0.0775 0.0182  –  – 0.0034 0.0058
a Stroke or MI due to the procedure
suspected CAD population
Table 3.2 presents the overall costs and effects for the suspected CAD population and the cost 
and effects per difficult-to-image subgroup. The strategies are arranged according to increasing 
effectiveness and ICERs are estimated for the two most effective strategies by comparing the 
strategies with the strategy that is ranked lower in effectiveness.
The three strategies differed very little in their effectiveness; the ICA-only strategy was only 
slightly more effective than the other strategies (i.e., 10.597 QALYs vs. 10.590 QALYs for NGCCT-
ICA and 10.588 for NGCCT-only). However, the ICA-only strategy was also the most expensive 
strategy (£6,534), followed by NGCCT-ICA (£5,950) and the NGCCT-only strategy (£5,808). The 
NGCCT-only strategy might be considered as a cost-effective strategy, since its effectiveness is 
very similar to that of the ICA-only strategy and its overall costs are lower than that of the other 
strategies. The ICER of NGCCT-ICA versus NGCCT-only is considerably higher (£71,000) than 
the currently used threshold of £20,000 to £30,000 per additional QALY. The ICA-only strategy 
generated the most effects but was also the most expensive strategy leading to an ICER that 
would exceed the threshold (£83,429). The subgroups analyses correspond with the overall 
results; however ICA-only is the most cost-effective strategy for patients with arrhythmias 
(ICER: £24,645) if a threshold of £30,000 per additional QALY is used. Figure 3.4 shows a cost-
effectiveness acceptability curve; the NGCCT-only strategy has the highest probability of being 
cost-effective if the cost-effectiveness threshold is less than £70,000. For thresholds above 
£70,000, the three different strategies are more or less equivalent. However, the probability 
of NGCCT-only being the cost-effective strategy is still less than 50% compared with the other 
strategies.
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Table 3.2 | Cost effectiveness of NGCCT for the suspected CAD population
Suspected CAD 
population
relative 
proportionsa
Costs QALYs   
  Mean (£) se Mean se ΔCosts ΔQALYs iCEr  
(£/QALY)
overall      
NGCCT – only  5,808 573 10.588 0.109   
NGCCT – ICA  5,950 589 10.590 0.109 142 0.002 71,000
 ICA – only  6,534 572 10.597 0.107 584 0.007 83,429
Obese     
NGCCT – ICA
16.25%
6,297 1,237 10.508 0.167   
NGCCT – only 6,106 1,202 10.508 0.167 –191 0.000 Dominates 
NGCCT – ICA
 ICA – only 6,968 1,217 10.519 0.163 862 0.011 81,318
Arrhythmias     
NGCCT – ICA
11.75%
6,227 1,190 9.419 0.171   
NGCCT – only 6,077 1,161 9.42 0.171 –150 0.000 Dominates 
NGCCT – ICA
 ICA – only 6,785 1,205 9.448 0.166 708 0.029 24,645
Heart rate >65 bpm 
NGCCT – only
29.25%
6,595 1,256 10.967 0.156   
NGCCT – ICA 6,758 1,289 10.968 0.157 162 0.001 312,047
 ICA – only 7,342 1,263 10.969 0.155 584 0.001 440,057
Coronary calcium level >400     
NGCCT – only
27.50%
5,962 1,168 10.201 0.169   
NGCCT – ICA 6,142 1,248 10.202 0.169 180 0.001 205,536
 ICA – only 6,801 1,189 10.21 0.167 659 0.008 80,446
intolerance β-Blocker     
NGCCT – ICA
15.25%
6,430 1,320 11.54 0.151   
ICA – only 7,016 1,242 11.541 0.148 586 0.001 972,803
NGCCT – only 6,279 1,240 11.542 0.151 –736 0.001 Dominant
a Expert opinion
Known CAD population
Table 3.3 shows the cost-effectiveness results for the known CAD population. The NGCCT 
strategies were more effective than ICA-only in all subgroups. Overall NGCCT-only was the most 
effective strategy (9.538 QALYs) compared to NGCCT-ICA (9.537 QALYs) and ICA-only (9.516 
QALYs). However, NGCCT-only was also more expensive (£28,228) compared with NGCCT-ICA 
(£27,785) leading to an ICER of £726,230 per QALY gained. Consequently, NGCCT-ICA seems 
to be cost-effective for the known CAD population since the ICER of NGGCT-only (£726,230) is 
considerably higher than the threshold of £30,000 per QALY gained. When uncertainty is taken 
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into account, the above results still hold. The acceptability curve graph (Figure 3.4) shows that 
the NGCCT-ICA strategy has the highest probability of being cost-effective independent of the 
willingness to pay thresholds, while the ICA-only strategy has the smallest probability of being 
cost-effective. 
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figure 3.4 | Acceptability curves for suspected and known CAD populations
CAD: coronary artery disease; QALY: quality adjusted life years; ICA: invasive coronary angiography; NGCCT: new generation 
coronary computed tomography
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Table 3.3 | Cost effectiveness of NGCCT for the known CAD population
Known CAD 
population
 
relative 
proportionsa
Costs QALYs  
Mean (£) se Mean se ΔCosts ΔQALYs iCEr (£/QALY)
overall     
ICA – only  28,234 502 9.516 0.288  
NGCCT – ICA  27,785 531 9.537 0.283 -449 0.022 Dominates  
ICA – only
 NGCCT – only  28,228 498 9.538 0.286 443 0.001 726,230
Obese    
ICA – only
10%
29,694 928 8.857 0.464  
NGCCT – only 29,254 924 8.869 0.477 -439 0.012 Dominates ICA 
– only
 NGCCT – ICA 29,177 920 8.872 0.46 -77 0.003 Dominant
Arrhythmias    
ICA – only
7.33%
27,428 908 6.545 0.504  
NGCCT – ICA 27,084 916 6.588 0.503 -344 0.043 Dominates  
ICA – only
 NGCCT – only 27,726 971 6.595 0.499 642 0.007 90,683
Heart rate >65 bpm 
ICA – only
27.33%
30,434 1,169 11.223 0.381  
NGCCT – only 30,477 1,190 11.233 0.377 43 0.011 4,021
 NGCCT – ICA 30,080 1,184 11.242 0.378 -397 0.009 Dominant
Coronary calcium level >400  
ICA – only
25.67%
31,145 1,079 9.271 0.538  
NGCCT – only 30,839 1,103 9.301 0.533 -306 0.03
Dominates ICA 
– only
 NGCCT – ICA 30,661 1,075 9.306 0.539 -178 0.005 Dominant
intolerance β-blockers 
ICA – only
9.33%
29,339 986 10.016 0.392  
NGCCT – only 29,354 1,004 10.039 0.392 14 0.024 610
 NGCCT – ICA 28,972 988 10.042 0.394 -381 0.003 Dominant
Previous stent    
ICA – only
11%
28,450 842 8.724 0.364  
NGCCT – ICA 28,056 855 8.737 0.358 -394 0.013 Dominates  
ICA – only
 NGCCT – only 28,672 888 8.744 0.354 617 0.007 93,526
Previous CABG    
ICA – only
9.33%
28,466 844 8.719 0.363  
NGCCT – ICA 28,088 859 8.725 0.36 -378 0.006 Dominates  
ICA – only
NGCCT – only 28,554 1,028 8.725 0.359 466 0 2,943,850
a Expert opinion
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scenario analyses
The scenario analysis with a cost price of £150 for the NGCCT did not affect the overall results; 
the NGCCT-ICA strategy was still the most favourable strategy. However, when the price of the 
NGCCT was increased to £207, the ICA-only strategy became less expensive than the NGCCT-only 
strategy for the known CAD population. Varying the complication rates and the prior likelihood 
of having CAD for the suspected population did not change the overall results.
DisCUssion
64-slice CT has proven accuracy for the diagnosis of CAD in most patients55-57. However, these 
scanners are less useful for difficult-to-image patient groups, e.g. those with irregular or fast 
heartbeats, those who are obese, or in whom artefacts produced by high levels of coronary 
calcium or existing stents might reduce image quality. Newer generation CT scanners have the 
advantage of being capable of producing diagnostic quality images in these patient groups. This 
study has estimated the cost-effectiveness of new generation CT scanners in these difficult-to-
image patients. 
For patients with suspected CAD, the NGCCT-only strategy might be considered as cost-effective, 
since its effectiveness is very similar to that of the most effective strategy (difference: -0.009 
QALYs) and since its overall costs are much lower than those of the other strategies. For patients 
with known CAD, a cost-effective strategy is probably NGCCT followed by ICA if the NGCCT is 
positive (NGCCT-ICA), since it yields the highest cost-saving, and dominates the ICA-only strategy. 
implications
The NICE recommendations about the use of these scanners in the UK were based in part on the 
results of this study. They recommended the use of new generation cardiac CT scanners as an 
option for first line imaging of the coronary arteries in patients with suspected CAD and for first-
line evaluation of disease progression to establish the need for revascularization in patients with 
known CAD in whom imaging with earlier generation CT scanners is difficult75.
strengths and limitations
The strength of this cost-effectiveness analysis is that we were able to capture as well as possible 
the whole range of patient experience from diagnostics to clinical pathway to complications and 
radiation by combining economic model components. Of course, combining evidence with the 
use of economic models could be viewed as a limitation because it introduces uncertainty and it 
was necessary to make several assumptions. However, assumptions and evidence sources have 
been explicitly reported and uncertainty accounted for by probabilistic sensitivity analyses and 
scenario analyses.
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The estimated accuracy of the NGCCT is based on the accuracy of ICA, which was assumed to be 
100%. However, the use of ICA as the gold standard is very common in this field55 but this may have 
influenced our results since the estimated accuracy of the NGCCT is also based on the accuracy of 
the ICA. In addition, ICA in combination with fractional flow reserve is currently a frequently used 
procedure and can be considered as a better alternative than ICA-only76. Moreover, accuracy 
estimates for NGCCT were only based on studies evaluating Somatom definition Flash, Discovery 
CT750 HD and Aquilion ONE since none of the studies evaluating the Brilliance iCT were eligible 
for inclusion. Extrapolation of the cost-effectiveness results to the other NGCCTs is therefore 
debatable. Furthermore, the accuracy estimates of the NGCCT are assumed to be the same for 
the known and suspected population and do not differ between the different types of NGCCT 
scanners. It is uncertain whether these assumptions may have led to an overestimate or an 
underestimate of the cost-effectiveness of NGCCT-only and NGCCT-ICA strategies.
The prior likelihood of CAD in the suspected CAD population was based on the clinical guideline 
for chest pain of recent onset10 and for the known population it was based on the prior 
likelihood estimated by the CE-MARC study59. For the suspected CAD group, we had to rely on 
the recommendations of the clinical guideline “Chest pain of recent onset”10 to quantify the 
prior likelihood. According to the clinical guideline, CT scans are recommended for use in the 
diagnostic path of patients with a prior likelihood of CAD of 10–29% and a non-zero calcium score 
10. This likelihood is based on presence of certain clinical symptoms (suggestive of angina), age, 
gender, diabetes, smoking and hyperlipidaemia. However, scenario analyses showed that the 
overall results did not change when the prior probability of patients suspected of CAD increased. 
For the prior likelihood estimate in the known CAD population, it is not entirely certain that the 
CE-MARC study59 and our study consider exactly the same patient population. It is therefore 
possible that the actual prior likelihood in our populations differs from that currently assumed 
in our model. 
Complication rates for the initial procedures are a compilation of various sources and are assumed 
to be the same for all subgroups. This assumption may have led to an inaccurate estimation of 
the MI and stroke rates for CABG, PCI and ICA. Potential differences in any of these factors could 
lead to different conclusions for the various NGCCTs. However, we have performed scenario 
analyses changing the parameters, which did not alter our conclusions. 
Generalizability
The results of this analysis may differ by setting due to differences in costs, incidence and severity 
of the CAD, the availability of health care resources and clinical practice patterns77. However, the 
modelling methods and input parameters are presented in a transparent and reproducible way 
and therefore the developed model can be adapted to other jurisdictions.
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Conclusions
The use of NGCCT in difficult-to-image CAD patients might be considered cost-effective based 
on the cost-effectiveness thresholds used in England and Wales. NGCCT is equal in effectiveness 
to ICA but is cost-saving in both the suspected CAD and the known CAD populations. NGCCT is 
therefore recommended in the assessment of patients who are difficult to image with earlier CT 
scanners.
48 | Chapter 3
Table s3.1 | Input parameters and costs   
Value source
Prevalence
Suspected CAD population 0.200 (0.1 – 0.29) 10
Known CAD population 0.395 59
Accuracy estimates
Sensitivity
ICA: ‘gold’ standard 1 Assumption 55
NGCCT 0.904 – 0.977a 78
Specificity
ICA: ‘gold’ standard 1 Assumption 55
NGCCT 0.816 – 0.921a 78
Complications iCA
Mortality rate 0.0007 63
Cerebrovascular accident rate 0.0006 63
Myocardial infarction rate 0.00003 63
Complications PCi
Mortality rate 0.0029 66
Cerebrovascular accident rate 0.0005 66
Myocardial infarction rate 0.0005 66
Complications CABG
Mortality rate 0.018 67
Cerebrovascular accident rate 0.016 64
Myocardial infarction rate 0.024 64,65
Costs per procedure
ICA 1,003 79
NGCCT 169 78
Coronary artery bypass graft 8,280 79
Percutaneous coronary intervention 3,633 79
Coronary artery bypass graft + ICA 9,242 79
Percutaneous coronary intervention + ICA 4,196 79
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Table s3.1 | (Continued)   
Value source
Cost per event
Non-fatal event (MI or cardiac arrest) 11,805 60
Cardiovascular fatal event 3,641 60
Non-cardiovascular fatal event 1,241 60
Non-fatal event history 986b 60
Background costs regressionc 60
Stroke first year 9,429b 80
Stroke subsequent years 4,894b 80
Radiation induced cancer 12,389 – 22,712d 61
a Range for all subgroups; b Per cycle; c Depending on age, the existence of cardiovascular diseases, diabetes mellitus, 
medication usage, clearance and symptomatic disease; d Depending on type of cancer
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ABsTrACT
 
Aim: Variations in treatment are the result of differences in demographic and clinical factors 
(e.g. anatomy) but physician and hospital factors may also contribute to treatment variation. 
The choice of treatment is considered important since it could lead to differences in long-term 
outcomes. This study explores the associations with stent choice; i.e. drug-eluting stent (DES) 
versus bare metal stents (BMS) for Dutch patients diagnosed with stable or unstable coronary 
artery disease (CAD). 
methods and results: Associations with treatment decisions were based on a prospective cohort 
of 692 patients with unstable or stable CAD. Of those patients 442 patients were treated with 
BMS or DES. Multiple logistic regression analyses were performed to identify variables associated 
with stent choice. Bivariate analyses showed that NYHA class, number of diseased vessels, 
previous PCI, smoking, diabetes, and the treating hospital were associated with stent type. After 
correcting for other associations the treating hospital remained significantly associated with 
stent type in the stable CAD population. 
Conclusions: This study showed that several factors were associated with stent choice. While, 
patients generally appear to receive the most optimal stent given their clinical characteristics, 
stent choice seems partially determined by the treating hospital, which may lead to differences 
in long-term outcomes. 
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inTroDUCTion
Despite improvement in the prognosis of patients with cardiovascular disease (CVD) it still 
remains the second leading cause of death across the Western world and one of the major causes 
of disability1. For many years patients with coronary artery disease (CAD), the most frequent type 
of CVD, have been treated mainly with a percutaneous coronary intervention (PCI), coronary 
artery bypass graft (CABG) or with medication only. Both revascularizations reduce the incidence 
of death and myocardial infarction (MI) in CAD patients compared with no treatment, but most 
patients are now treated with a PCI. In 2012 approximately 39,000 PCIs were performed in the 
Netherlands81. Originally, a PCI was performed with an expanding balloon to dilate the narrowed 
segment of the artery but in 1994 the bare-metal stent (BMS) was developed to prevent 
restenosis11. However, the restenosis rate leading to repeat revascularizations of the target lesion 
was still substantially high after the introduction of BMS. In 2003, the drug-eluting stent (DES) 
was approved to the market to reduce restenosis compared with BMS (8.4% versus 20.9%)12. 
However, patients treated with DES, especially the early-generation, might have a higher chance 
of developing very late stent thrombosis (0.7% versus 0.1%)12. Both types of stents have pros and 
cons; decisions should be based on what is considered appropriate for a patient since the choice 
of stent type may have impact on long-term outcomes. Variations in treatment are the result 
of differences in patient characteristics and clinical factors (e.g. anatomy) but previous studies 
have shown that the physician and hospital factors may contribute to treatment variation. In the 
UK, stent choice was associated with the operator and the treating hospital82. Tu et al.83 have 
shown that the physician performing the diagnostic catheterization and the treating hospital 
were strong independent predictors of the type of revascularization (CABG versus PCI) in Canada. 
Furthermore, the type of stent was also determined by the type of payer (e.g. Medicaid, private 
insurance)84. Of course these results may be expected to be health care system specific and do 
not apply for Dutch patients, since the Netherlands have a centrally publicly funded healthcare 
system.
This study will explore the associations with stent choice (DES or BMS) for Dutch patients 
diagnosed with stable CAD or unstable CAD focusing on variation due to clinical factors and 
treating hospital.
mETHoDs
study design
Treatment variation of patients with stable or unstable CAD was explored through analysing data 
from the Circulating Cells prospective cohort study, which has the aim of discovering markers 
that identify patients who are at an increased risk of developing a cardiovascular event. In 
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this multicentre study, patients undergoing a coronary angiography were included if they had 
known or suspected stable or unstable CAD; specific diagnoses included unstable angina and 
non-ST elevation MI (NSTEMI). Patients with relevant concomitant disease, relevant recent 
infectious disease (in the last 6 weeks) or suspected elevated state of the immune system were 
excluded. More details about the Circulating Cells cohort study design can be found in a previous 
publication85. 
Treatment 
Patients undergoing a coronary angiography were asked to participate in the study. Data were 
collected regarding patient characteristics, test results and treatment decisions. Patients who 
were treated with a PCI could have received a BMS, DES, drug-eluting balloon angioplasty or 
standard balloon angioplasty. The aim of this study is to examine the factors that are associated 
with stent choice (DES vs. BMS), meaning that patients treated solely with drug-eluting balloon 
angioplasty or standard balloon angioplasty are excluded from the analyses. Stent choice DES 
was defined as a PCI with at least one DES, including patients treated with only DES but also 
patients treated with DES in combination with BMS, drug-eluting balloon angioplasty or standard 
balloon angioplasty. Stent choice BMS was defined as a PCI with only BMS such that patients 
treated with BMS in combination with balloon angioplasty or DES are excluded. 
Data and statistical analyses
Choice of stent type (DES or BMS) was compared between patient subgroups (determined by 
diagnosis). The following baseline characteristics were also collected during the study: age, 
gender, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), 
thrombolysis in myocardial infarction (TIMI) score for unstable CAD patients, New York Heart 
Association (NYHA) class, number of diseased vessels (50–99% stenosis), cardiac history (previous 
heart failure, previous MI, previous PCI, and previous CABG), non-cardiac history (cerebrovascular 
accident (CVA) or transient ischaemic attack (TIA), pulmonary disease, peripheral vessel disease 
(PVD), and renal failure), and CVD risk factors (diabetes mellitus, hypertension, hyperlipidaemia, 
smoking, and pack-years (tobacco)). 
Multiple imputation was used to prevent patients from being excluded from the analyses due 
to missing values. Baseline characteristics (SBP, DBP, BMI, NYHA class, previous heart failure, 
previous MI, CVA or TIA, pulmonary disease, PVD, renal failure, diabetes mellitus, hypertension, 
hyperlipidaemia, current smoker and pack years) were missing for less than 2% of all cases 
except pack years, which was missing for 14% of all cases. These characteristics were imputed 
using predictive mean matching for scale variables. Five imputation sets were created with ten 
iterations each using fully conditional specification in SPSS 22 (IBM Corp. Released 2013. IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). Age, gender, previous PCI, 
previous CABG, and diagnosis were only used as predictors and not imputed since there were no 
missing values for these variables.
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Differences between groups were tested using Chi-squared analysis for categorical variables. 
Bivariate analyses using logistic regression were performed to identify variables that were 
associated with choice for stent type; stable and unstable CAD patients were analysed separately. 
Backwards selection was used to create the final multivariate model(s). P values lower than 0.05 
were considered statistically significant, although a higher threshold of 0.1 was used to select 
variables for the multivariate analysis. Associations were discussed with clinical experts in order 
to see if the results make sense (face validity).
Table 4.1 | Baseline characteristics
 All patients after 
imputation
Patients with stable 
CAD
Patients with unstable 
CAD
   mean sd nb mean sd nb mean sd nb p valuea
Baseline characteristics   
Age 62.72 10 442 62.96 10 358 61.71 11 84 0.319
Male (%) 72% 442 73% 358 68% 84 0.354
SBP (mmHg) 135 19 442 135 19 358 134 21 84 0.748
DBP (mmHg) 77 11 442 77 11 358 79 11 84 0.273
BMI (kg/m2) 28 4 442 28 4 358 27 4 84 0.266
TIMI scorec     
1 8% 83 8% 83
2 18% 83 18% 83
3 30% 83 30% 83
4 28% 83 28% 83
5 12% 83 12% 83
6+7 4% 83 4% 83
Number of diseased vessels (50–99%)   0.077
1 44% 442 46% 358 36% 84
>1 56% 442 54% 358 64% 84
NYHA    p<0.001
NYHA I 73% 442 73% 358 76% 84
NYHA II 18% 442 20% 358 7% 84
NYHA III 6% 442 7% 358 4% 84
NYHA IV 2% 442 0% 358 13% 84
Cardiac history (%)      
Previous heart failure 2% 442 2% 358 1% 84 0.542
Previous MI 31% 442 33% 358 23% 84 0.066
Previous PTCA 33% 442 35% 358 26% 84 0.116
Previous CABG 7% 442 8% 358 5% 84 0.369
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Table 4.1 | (Continued)
 All patients after 
imputation
Patients with stable 
CAD
Patients with unstable 
CAD
   mean sd nb mean sd nb mean sd nb p valuea
non-cardiac history (%)      
CVA/TIA 8% 442 6% 358 14% 84 0.017
Pulmonary disease 11% 442 10% 358 14% 84 0.242
Peripheral vessel disease 13% 442 13% 358 14% 84 0.684
Renal failure 3% 442 4% 358 1% 84 0.25
risk factors (%)      
Diabetes mellitus 21% 442 22% 358 20% 84 0.764
Hypertension 66% 442 67% 358 60% 84 0.189
Hyperlipidemia 68% 442 70% 358 60% 84 0.057
Current smokers (%) 19% 442 16% 358 32% 84 0.001
Pack yearsd 19.7 18 442 19.2 18.1 358 21.9 22 84 0.302
Diagnosis (%)     
Stable angina 81% 442    
Unstable angina 10% 442    
NSTEMI 9% 442    
Treatment / stent choice    0.736
DES 66% 442 66% 358 68% 84
BMS 34% 442 34% 358 32% 84
Hospital    
I 29% 442 28% 358 37% 84
II 22% 442 24% 358 13% 84
III 18% 442 14% 358 37% 84
IV 30% 442 34% 358 13% 84
a Stable versus unstable; b Number of patients on which the analyses were based; c only reported for unstable angina and 
NSTEMI; d Number of packs per day multiplied with years of smoking
BMI: body mass index; CABG: coronary artery bypass graft; CVA: cerebrovascular accident; DBP: diastolic blood pressure; 
MI: myocardial infarction; NA: not applicable; NSTEMI: non ST elevation myocardial infarction; NYHA: New York heart 
association; PTCA: percutaneous transluminal coronary angioplasty; SBP: systolic blood pressure; TIA: transient ischaemic 
attack; TIMI: thrombolysis in myocardial infarction
rEsULTs
In total, 714 patients were included in the Circulating Cells cohort, 22 of whom were excluded 
from the analyses since they did not have significant coronary atherosclerosis. The remaining 
692 patients were included in three teaching hospitals and one general hospital and 477 patients 
were treated with a PCI. Of those patients, 442 patients were treated with BMS or DES. Others 
were treated with a combination of a BMS and balloon angioplasty (N=4), drug-eluting balloon 
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angioplasty or standard balloon angioplasty (N=18) or missing (N=13) and are excluded from the 
analysis. The number of patients treated per hospital (I-IV) was 130, 98, 81, and 133, respectively. 
Table 4.1 presents the baseline demographic and angiographic characteristics of the included 
patients. The mean age of the cohort was 63 years and 72% were male. The majority (81%) 
of the patients were diagnosed with stable CAD (including silent ischemia) after the coronary 
angiography. There were three significant differences in characteristics of stable CAD (N=358) 
and unstable CAD patients (N=84). Stable CAD patients more often had a lower NYHA class, were 
less often current smokers and had less often experienced a CVA/TIA compared to unstable CAD 
patients. 
In total 771 stents were used to treat 442 patients with 612 target lesions. On average 1.385 
target lesions were stented per patient (range 1–3), where 1.260 stents were used per lesion 
and 1.744 stents (range 1–6) per patient were used. Of the 442 patients, 66% was treated with 
one or more drug-eluting stents. Bivariate analyses (Table 4.2) showed that NYHA class, number 
of diseased vessels, previous PCI, smoking, diabetes and the treating hospital were significantly 
associated with stent choice for a patient. The frequency of DES use varied widely (50–99%) 
between the four hospitals, considering the total population. The variation in stent choice was 
larger in the unstable patient group (45–100%). 
Table 4.2 | Associations with therapeutic decision (DES vs BMS)
 All patients Patients with stable CAD Patients with unstable CAD
   DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value
overall 66% 442  66% 358  68% 84  
Diagnosis 0.558   
Stable CAD 66% 358    
Unstable angina 63% 46    
NSTEMI 74% 38    
Hospital p<0.001 p<0.001 p<0.001
1 50% 130  52% 99  45% 31  
2 64% 98  66% 87  55% 11  
3 99% 81  98% 50  100% 31  
  4 64% 133  65% 122  55% 11  
Baseline characteristics
Age (years) 1.008 442 0.387 1.005 358 0.682 1.023 84 0.272
Gender 0.474 0.46 0.872
Male 67% 318  67% 261  68% 57  
Female 64% 124  63% 97  67% 27  
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Table 4.2 | (Continued)
 All patients Patients with stable CAD Patients with unstable CAD
   DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value
SBP (mmHg) 1.007 442 0.188 1.003 358 0.598 1.022 84 0.074
DBP (mmHg) 0.998 442 0.815 0.997 358 0.767 1.001 84 0.968
BMI (kg/m2) 1.038 442 0.128 1.049 358 0.08 0.994 84 0.912
TIMI scorea 0.085  0.085
1 71% 7   71% 7  
2 80% 15   80% 15  
3 48% 25   48% 25  
4 83% 23   83% 23  
5 60% 10   60% 10  
6+7 100% 3   100% 3  
NYHA p<0.01 0.036 0.011
NYHA I 62% 324  63% 260  59% 64  
NYHA II 71% 79  69% 73  100% 6  
NYHA III & IV 90% 39  88% 25  93% 14  
Number of diseased vessels p<0.01 p<0.01 0.102
1 58% 196  58% 166  57% 30  
>1 73% 246  72% 192  74% 54  
Cardiac history    
Previous heart failure 0.981 0.836 0.489
yes 67% 9  63% 8  100% 1  
no 66% 433  66% 350  67% 83  
Previous MI 0.077 0.090 0.536
yes 72% 137  72% 118  74% 19  
no 64% 305  63% 240  66% 65  
Previous PTCA p<0.01 p<0.01 0.271
yes 76% 148  76% 126  77% 22  
no 61% 294  60% 232  65% 62  
Previous CABG 0.541 0.736 0.433
yes 61% 31  63% 27  50% 4  
  no 67% 411  66% 331  69% 80  
non-cardiac history    
CVA/TIA 0.748 0.682 0.924
yes 69% 35  70% 23  67% 12  
no 66% 407  66% 335  68% 72  
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Table 4.2  | (Continued)
 All patients Patients with stable CAD Patients with unstable CAD
   DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value DEs (%) / 
OR
n p value
Pulmonary disease 0.103 0.142 0.445
yes 56% 47  55% 35  58% 12  
no 68% 395  36% 323  69% 72  
PVD 0.086 0.124 0.445
yes 56% 57  56% 45  58% 12  
no 68% 385  67% 313  69% 72  
Renal failure 0.059 0.126 0.144
yes 43% 14  46% 13  0% 1  
  no 67% 428  67% 345  69% 83  
risk factors    
Diabetes mellitus p<0.001 p<0.001 0.009
yes 93% 95  92% 78  94% 17  
no 59% 347  59% 280  61% 67  
Hypertension 0.306 0.498 0.324
yes 68% 290  67% 240  72% 50  
no 63% 152  63% 118  62% 34  
Hyperlipidaemia 0.943 0.427 0.144
yes 66% 302  65% 252  74% 50  
no 67% 140  69% 106  59% 34  
Current smokers 0.037 0.066 0.246
yes 57% 85  55% 58  59% 27  
no 69% 357  68% 300  72% 57  
Pack yearsb 1.001 442 0.898 1.000 358 0.974 1.002 84 0.877
a only for unstable angina and NSTEMI; b Number of packs per day multiplied with years of smoking
BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; CVA: cerebrovascular accident; 
DBP: diastolic blood pressure; MI: myocardial infarction; NA: not applicable; NSTEMI: non ST elevation myocardial infarction; 
NYHA: New York heart association; PTCA: percutaneous transluminal coronary angioplasty; PVD: peripheral vessel disease; 
SBP: systolic blood pressure; TIA: transient ischaemic attack; TIM: thrombolysis in myocardial infarction
All multivariate analyses (Table 4.3) showed that patients with diabetes had a significantly higher 
chance of receiving DES. The use of DES versus BMS in the stable CAD population was not only 
associated with diabetes but also with the treating hospital, smoking status, and previous PCI. 
Patients treated in hospital II or III, patients having diabetes, and patients with a previous PCI had 
a higher chance of being treated with DES. Patients treated in hospital I and patients who were 
current smokers had a lower chance of being treated with DES. 
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Table 4.3 | Multivariate analyses therapeutic decision (BMS versus DES)
Total population (N=442) Bivariate analyses (or) multivariate analyses (or) p value*
number of diseased vessels  
1 0.520 0.560 0.006
>1 ref  
nYHA class  
NYHA class I ref  
NYHA class II 1.478  
NYHA class III + IV 5.311  
Hospital  
1 0.565  
2 1.016  
3 45.176  
4 ref  
Diabetes (yes vs no) 8.680 8.318 p<0.001
renal artery disease (yes vs no) 0.368  
Current smoker (yes vs no) 0.599  
Previous mi (yes vs no) 1.486  
PVD (yes vs no) 1.017  
Previous PTCA (yes vs no) 2.045  
Timi scorea  
1 ref  
2 1.20  
3 0.37  
4 2.000  
5 0.600  
6+7 646189937  
Constant 1.911 p<0.001
Nagelkerke R2 16%
Stable CAD (N=358)
Bmi (kg/m2) 1.049  
Hospital  
1 0.578 0.466 0.013
2 1.034 1.047 0.884
3 26.671 29.381 0.001
4 ref ref
Previous mi (yes vs no) 1.513  
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Table 4.3 | (Continued)
Bivariate analyses (or) multivariate analyses (or) p value*
nYHA class  
NYHA class I ref  
NYHA class II 1.280  
NYHA class III + IV 4.319  
number of diseased vessels  
1 0.536  
>1 ref  
Current smoker (yes vs no) 0.588 0.404 0.014
Diabetes (yes vs no) 8.454 12.001 p<0.001
Previous PTCA (yes vs no) 2.103 2.284 0.003
Constant 1.207 0.397
Nagelkerke R2 33%
Unstable CAD (N=84)
Hospital  
1 0.686  
2 1.000  
3 1346229036  
4 ref  
nYHA class  
NYHA class I ref  
NYHA class II 1105324892  
NYHA class III + IV 8.895  
Diabetes (yes vs no) 10.146 10.146 0.029
Timi scorea  
1 ref  
2 1.600  
3 0.369  
4 1.900  
5 0.600  
6+7 646189937  
sBP (mmHg) 1.007  
Constant 1.577 0.069
Nagelkerke R2 13%
a P value of multivariate analyses
SBP: systolic blood pressure; BMI: body mass index; NYHA: New York heart association; PTCA: percutaneous transluminal 
coronary angioplasty; TIMI: Thrombolysis In Myocardial Infarction
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DisCUssion
This study explored the factors associated with stent choice for Dutch patients diagnosed with 
stable CAD or unstable CAD. Various factors are associated with the frequency of DES use, 
including diabetes, previous PCI, number of diseased vessels, NYHA class, smoking and the 
hospital where patients were treated. 
Patients requiring a PCI were in most cases treated with at least one DES (66%), which is in line 
with the guidelines that suggest that patients with stable CAD should receive a DES if there is 
no contraindication of prolonged dual antiplatelet therapy86. Furthermore, DES is recommended 
over BMS in NSTEMI or unstable angina patients with diabetes87. Since patients with diabetes 
have a higher restenosis risk than patients without diabetes, DES is considered the most optimal 
treatment for these patients since DES reduces restenosis compared with BMS. Consequently, 
diabetes was significantly associated with stent choice in this study. Patients who have been 
treated before with a PCI were also more likely to receive DES (76%); these patients have a higher 
risk of developing restenosis and thus DES was preferred. Patients with multi-vessel disease 
(73% DES) and patients with a high NYHA class (range I-IV: 62–90% DES) were significantly more 
frequently treated with DES. Studies suggest that patients with multi-vessel disease should be 
treated with a CABG or a PCI using DES since these interventions have shown to be more effective 
than BMS88. Patients currently smoking were less often treated with DES. 
These clinical factors can be considered as legitimate leading to variation in stent choice. 
However, 19% of the variation in stent choice was explained for by these factors in the stable CAD 
population. Beside clinical factors other potential reasons for treatment variation could exist due 
to: 1) the operator, 2) the availability and supply of resources, or 3) the preferences of the patient. 
Considering operator variation, physicians use different methods to decide which stent is most 
suited for a particular patient. It is known that some physicians are believers of DES and some 
do not believe in the added value of DES compared with BMS, while BMS is less expensive. It is 
likely that believers use DES more often than physicians who can be considered as non-believers. 
DES has shown in several randomized clinical trials to be more effective than BMS for several 
indications (e.g. diabetes, long lesions). Some operators strictly follow the results of these trials 
and the guidelines while some operators use DES also for other indications with a high restenosis 
risk since guidelines do not provide recommendations concerning the most optimal stent for 
every type of patient, although it is probably unrealistic to expect this. In our study, one hospital 
treated almost all patients with DES (99%); probably DES was used also for “off-label” indications. 
A Dutch report concluded that world-wide in 47–81% of the patients DES is used off-label leading 
to differences in safety and clinical effectiveness89. The second potential reason, availability and 
supply of resources, focuses on the hospital level. In our analyses, the treating hospital was 
significantly associated with stent choice even after correcting for clinical factors in the stable 
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CAD group. After adding treating hospital to the regression analysis with only clinical factors, 33% 
of the variation in stent choice could be explained instead of 19%. The analyses showed that the 
frequency of DES use ranged from 50–99% of all patients across hospitals. This difference could 
result from a difference in patient case mix, despite the adjustment for many individual patient 
characteristics in the analyses. Furthermore, payment arrangements with stent manufacturers 
and budget constraints may have influenced the stent choice. Another potential reason, patient 
preference, could have influenced the variation in stent choice. However, we expect this to be 
minimal since both interventions can be considered as equally invasive. 
implications
In general, patients receive the most optimal stent given their clinical characteristics. However, 
stent choice is also determined by the treating hospital probably due to operator variation 
and availability and supply of resources. Variation should only occur due to demographic and 
angiographic factors. When variation is due to factors other than demographic or angiographic 
it could lead to less optimal stent choices and subsequently differences in long term outcomes.
Patients receiving DES have a lower risk of target lesion revascularization than patients treated with 
BMS12. However, there is some concern of late stent thrombosis that may occur more frequently 
after DES than BMS12. Besides the implications of treatment variation on the effectiveness, it is 
also important to consider the implications of treatment variation on the costs. While BMS is a 
less expensive stent than DES, BMS leads to more reinterventions than DES. Several economic 
evaluations have estimated the cost-effectiveness of DES versus BMS and many of the studies 
concluded that initial DES treatment was overall more expensive than the BMS-strategy90-101; the 
reduction in reinterventions did not offset the initial higher stent costs. In most of the studies 
DES was slightly more effective90-101 leading often to an incremental cost-effectiveness ratio that 
could not be considered cost-effective91,92,95,96,101. However, some specific subgroups (patients 
with diabetes, patients with complex lesions (i.e. restenotic, angulation <45°, calcified or long), 
patients with complex vessels (i.e. small), patients with multi-vessel disease, and patients with 
a combination of these risk factors), were identified in which DES resulted in a higher health 
gain in terms of quality-adjusted life-years compared to subgroups who were not at high risk 
of restenosis and complications. Consequently, in these subgroups, DES was considered more 
cost-effective. In our study some of these specific subgroups were also associated with a more 
frequent use of DES. 
Limitations
The factors examined in the analyses explained 13–33% of the variation in treatment decisions, 
depending on the specific subpopulation. While the treating hospital was associated with stent 
choice, it is possible that hospital is a proxy for a pre-existing patient case mix. Many clinical 
factors were included in the regression models but it is possible that factors that are of predictive 
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value were not included. Furthermore, the underlying reason why the treating hospital is 
associated with stent choice is not clear. This could be due to the operator (e.g. experience), of 
which data were not available for our analyses, or the availability and supply of resources might 
explain why the treating hospital is associated, even though the Netherlands has a centrally 
publicly funded healthcare system. 
Most of the patients (81%) in this study had stable CAD, so only a relatively small number 
of patients (N=84) had unstable CAD. This may have limited the power to identify existing 
associations between stent choice and patient characteristics and may explain why only a few 
characteristics were significantly associated. 
We were not able to compare patients treated solely with BMS and patients treated solely with 
DES. Stent choice DES was defined as a PCI with at least one DES which includes patients treated 
with only DES but also patients treated with DES in combination with BMS, drug-eluting balloon 
angioplasty or standard balloon angioplasty. Consequently, the associations that we have found 
actually explain why some patients receive DES and why other patients did not receive DES. 
In addition, this study did not take into consideration the differences within stent choice. For 
example, ultra-thin struts BMS lead to less restenosis than thicker struts BMS. In the SOLSTICE 
registry it was shown that ultra-thin strut BMS leads to encouraging 6 months major adverse 
cardiac event rates (5.8%), including target lesion revascularizations102. Furthermore, we did not 
made a distinction between the several types of drugs (e.g. paclitaxel, sirolimus or everolimus) 
that are used for DES which may also have an effect on clinical outcomes.
Lastly, the latest guideline on myocardial revascularization103 concluded that the newer generation 
DES have improved safety outcomes including death, MI and stent thrombosis compared with 
early-generation DES and BMS. During this study, this guideline was not available and thus it is 
possible that stent choice might be somewhat different if the new guidelines were applicable; 
DES could be more frequently used. Furthermore, we did not focus on fully bioresorbable stents 
which has promising clinical outcomes since it provides desirable transient vessel support 
without compromising the restoration of normal vessel biology, vessel imaging or treatment 
options in the long run104. Consequently, the stent evaluated in the Circulating cells cohort may 
not reflect the stent choices that will be made in the near future.
recommendations
This study showed the existence of treatment variation across hospitals that may have an impact 
on long-term outcomes. It would be interesting to investigate if the treatment variation seen 
in this cohort will actually lead to difference in long-term outcomes and costs, which could be 
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achieved by increasing the follow-up period. Van der Sijde et al.105 have also emphasized the role 
of clinical observations to determine the most appropriate indication for specific types of stents.
Conclusions
This study showed that several clinical factors were associated with stent choice (DES or BMS) 
for CAD treatment, including diabetes, smoking, NYHA class, multi-vessel disease and previous 
PCI. In general, it appears that patients receive the most optimal stent given their clinical 
characteristics. After correcting for the clinical factors, stent choice was also associated with the 
treating hospital probably due to operator variation and the availability and supply of specific 
stent types. These differences may lead differences in long term outcomes. 
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introduction: Patients with coronary artery disease (CAD) are known to have a reduced health-
related quality of life (HRQoL) compared with the general population. Poor HRQoL also seems 
to be associated with long-term morbidity and mortality. Therefore, insight into the patient 
characteristics which are associated with poor HRQoL may help to identify ways in which patient 
care can be improved. 
methods: 465 patients had filled in at least one question of the SF-36 questionnaire which was 
used to estimate HRQoL (SF-6D), physical (PCS) and mental (MCS) component scores. Multiple 
imputation of missing values resulted in a population of 441 patients. Multiple linear regression 
analysis was performed to identify variables that were associated with HRQoL and component 
scores. 
results: The average SF-6D index of all patients was 0.671±0.134. Multivariate analyses showed 
significant associations with gender, systolic blood pressure, BMI, previous percutaneous 
coronary intervention, New York Heart Association class, previous cerebrovascular accident or 
transient ischaemic attack, peripheral vascular disease, pack-years (tobacco) and pulmonary 
disease in the stable CAD group. Unstable CAD patients had higher average PCS, MCS and SF-36 
dimension scores than stable CAD patients. The mental health dimension was the least affected 
dimension of the SF-36 but CAD had a negative impact on the physical dimensions.
Conclusions: This study showed that HRQoL of patients with stable or unstable CAD was 
moderate. Various patient characteristics appear to be significantly associated with HRQoL. 
Knowledge of these associations can help to identify ways to improve care (e.g. increase physical 
activity) and thereby improve HRQoL. 
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inTroDUCTion
Despite improvements in the treatment of cardiovascular disease (CVD) it still remains the 
second leading cause of death and disability across the Western world106. Patients with coronary 
artery disease (CAD), accounting for the largest proportion (25%) of deaths within CVD106, are 
known to have a reduced quality of life compared with the general population5,6. Moreover, 
these patients often suffer from other disorders such as diabetes mellitus or obesity, which may 
lead to further loss in quality of life. 
Quality of life is a subjective measure of overall well-being and reflects how a disease and its 
symptoms are perceived by a patient. Health-related quality of life (HRQoL) is often measured 
with generic questionnaires such as the EuroQol 5D (EQ-5D) or the Short Form (SF) 36. Various 
studies have already examined the HRQoL of patients with CAD107-109. Most of these studies 
have focused on the SF 36 with its physical (PCS) and mental component scores (MCS) or the 
preference based utility measure EQ-5D. The most common aim of those studies was to evaluate 
the impact of cardiovascular interventions like percutaneous coronary intervention or coronary 
artery bypass graft (CABG) on HRQoL. In contrast, only a handful of studies have evaluated the 
baseline HRQoL of patients before treatment and the relationship between HRQoL and baseline 
characteristics. 
Poor HRQoL also seems to be associated with long-term morbidity and mortality. Therefore, 
insight into the patient characteristics which are associated with poor HRQoL may help to identify 
ways in which patient care can be improved. De Smedt et al. examined the relationship between 
patient characteristics and HRQoL but measured HRQoL at least 6 months after hospitalisation110. 
Furthermore, they used the two component scores of the SF-36 and the EQ-VAS, which are non-
preference based measures while other methods such as the SF-6D are preferred for estimating 
the HRQoL111. Xie et al. compared patient characteristics and HRQoL measured with the SF-36 
component scores, EQ-5D and EQ-VAS between coronary heart disease and non-coronary heart 
disease patients but did not study the associations between patient characteristics and HRQoL112. 
Van Stel et al. estimated the HRQoL of CAD patients using both the SF-6D and the EQ-5D113, 
but the aim of their study was to compare the instruments and not to identify associations 
between HRQoL and patient characteristics. Therefore, the goal of this study is to estimate 
comprehensively HRQoL with both the SF-6D and the two SF-36 component scores for patients 
with CAD. The secondary aim of our study is to describe the associations between the SF-6D and 
routinely collected patient characteristics which could help to optimize care and consequently 
HRQoL.
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study design
The HRQoL of patients with stable or unstable CAD was measured as part of the Circulating Cells 
prospective cohort study, which has the aim of identifying patients who are at an increased 
risk of developing a cardiovascular event by identifying markers that are associated with the 
instability of atherosclerotic plaque. In this study, patients undergoing a coronary angiography 
were included if they had known or suspected stable or unstable CAD; specific diagnoses 
included unstable angina and non-ST elevation MI (NSTEMI). Patients with serious concomitant 
disease, serious recent infectious disease (in the last 6 weeks) or suspected elevated state of 
the immune system were excluded. The study was approved by the medical ethical committees 
of the participating centers and conforms to the Declaration of Helsinki. All patients received 
oral and written information about the objectives of the study and provided written informed 
consent. More details about the Circulating Cells cohort study design can be found in a previous 
publication85. 
Health related quality of life measurement
Baseline HRQoL was measured using the Short Form (SF) 36 questionnaire, which contains 36 
questions and eight dimensions114. The SF-6D is a revised version of the SF-36 and focuses on six 
domains: physical functioning, role participation, social functioning, bodily pain, mental health, 
and vitality each with between two and six levels114. 249 of all possible health states were valued 
by the general public with the standard gamble technique. HRQoL was estimated for each patient 
and associations with baseline patient characteristics were identified.
 
Beside the SF-6D estimates we have also estimated the PCS and MCS. These sex dependent 
scores, developed by Aaronson et al., estimate the means and the standard deviations (SD) for 
the general population for each of the eight domains: general health, physical functioning, role 
physical, role emotional, social functioning, bodily pain, vitality, mental health115. Furthermore, 
the individual scores for each dimension are also estimated. Patients were asked to complete the 
SF-36 questionnaire immediately after the coronary angiography and before treatment decision.
statistical analyses
HRQoL and component scores were compared between patient subgroups determined by 
diagnosis. The following baseline characteristics were also collected during the study: age, 
gender, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), thrombolysis in 
myocardial infarction (TIMI) score for unstable CAD patients, New York Heart Association (NYHA) 
class, cardiac history [heart failure, previous MI, previous percutaneous transluminal coronary 
angioplasty (PTCA), and previous CABG), non-cardiac history (cerebrovascular accident (CVA) or 
transient ischaemic attack (TIA), pulmonary disease, peripheral vessel disease (PVD), and renal 
failure], and CVD risk factors (diabetes mellitus, hypertension, smoking, and pack years). 
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Multiple imputation was used to reduce the number of patients that could not be included in the 
analyses due to missing values. Missing values of patients who had filled in at least 75% of all SF-
36 questions were imputed. Baseline characteristics (SBP, DBP, BMI, NYHA, previous heart failure, 
previous MI, CVA or TIA, pulmonary disease, PVD, renal failure, diabetes mellitus, hypertension, 
hyperlipidaemia, current smoker and pack years) were missing for less than 2% of all cases 
except for pack years which was missing for 6.6% of all cases. These characteristics and missing 
values of the SF-36 questionnaire (missing for less than 8.2%) were imputed using predictive 
mean matching for scale variables. Five imputation sets were created with ten iterations each 
using fully conditional specification in SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows, Version 22.0. Armonk, NY: IBM Corp). Age, gender, previous PTCA, previous CABG, and 
diagnosis were only used as predictors and not imputed since there were no missing values for 
these variables.
T-tests and ANOVA were used to test for differences between groups (e.g. diagnosis) for 
continuous variables. The Chi-square test was used to test for differences between groups for 
categorical variables. 
Bivariate analyses using linear regression were performed to identify variables that were 
associated with HRQoL and component scores; stable and unstable CAD patients were analysed 
separately. Backwards selection was used to create the final multivariate models and stepwise 
selection was used to validate the selection of variables. P values lower than 0.05 were considered 
statistically significant, although a higher threshold of 0.10 was used to select variables for the 
multivariate analysis. 
rEsULTs
In total, 714 patients were included in the Circulating Cells cohort, 22 of whom were excluded 
from the analyses since they did not have significant coronary atherosclerosis. Of the remaining 
692 patients, 465 answered at least one question in the questionnaire. HRQoL could not be 
assessed for 53 patients due to missing values. Baseline characteristics of the patients with a 
complete questionnaire (N=412) and the patients with an incomplete questionnaire (N=53) are 
presented in Table 5.1. The characteristics of the two groups were comparable, except for age, 
which significantly differed (Table 5.1). Multiple imputation was subsequently used to reduce 
the number of patients that were missing, which resulted in a population of 441 patients. Eighty-
one percent of the patients with a completed questionnaire were diagnosed with stable angina 
including patients with silent ischemia. The frequency of current smokers in the unstable CAD 
population (N=85) were significantly (p<0.01) different to the frequency of current smokers in 
the stable CAD population (N=356) (Table 5.1). Furthermore, age and NYHA class significantly 
differed between the groups.
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Tables 5.2 and 5.3 present the SF-6D, PCS, and MCS estimates for the total population, as well 
as the results for the stable and unstable CAD populations separately. The SF-6D index of all 
patients was 0.671 (SD: 0.134). The SF-6D scores were significantly associated with the diagnosis 
(stable/unstable), gender, SBP, BMI, previous PTCA, previous CVA or TIA, pulmonary disease, 
PVD, diabetes, hypertension, and pack years (Table 5.2). Male patients and patients with a high 
SBP reported a higher SF-6D score than female patients and patients with lower SBP; the other 
variables had a negative effect on SF-6D. SF-6D of the stable CAD group (0.663±0.132) was 
associated with almost the same characteristics as for the total population. Diabetes mellitus 
and hypertension were not significantly associated with SF-6D but NYHA class was. Patients with 
unstable CAD had a higher SF-6D score (0.704±0.136) than patients with stable CAD; PVD and 
previous CVA or TIA were negatively associated with the SF-6D. The mean PCS and MCS scores 
of patients with stable CAD were 40.20 and 44.25, respectively (Table 5.3). The unstable CAD 
group had a higher average PCS and MCS than the stable CAD group, which was in line with the 
HRQoL outcomes. Furthermore, unstable CAD patients also had higher average scores on each 
dimension than stable CAD patients. The mental health dimension had in both subgroups the 
highest score and the role physical dimension had the lowest score and was the most affected 
dimension by CVD compared to the general population115. Bivariate analyses performed on the 
total population (Tables S5.1 and S5.2) showed that diagnosis, previous PTCA, pack years, and 
previous CVA/TIA were all associated with both PCS and MCS. Other baseline characteristics, risk 
factors and non-cardiac history were also significantly associated with PCS or MCS.
Multivariate analyses showed that 15% of the variation in SF-6D scores in the stable CAD group 
could be explained by gender, SBP, BMI, previous PTCA, peripheral vessel disease, and pulmonary 
disease (Table 5.4). For unstable CAD patients, multivariate analyses showed that a previous CVA 
or TIA was significantly associated with SF-6D and explained 6% of the variation. Multivariate 
analyses were performed for both PCS and MCS scores and the results are presented in Tables 
S5.3 & S5.4. 
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Table 5.4 | Associations between patient characteristics and SF-6D
Stable CAD (N=356) Bivariate analyses multivariate analyses p valuea
Age (per year) 0.001  
Male 0.060 0.062 p<0.001
sBP (per mmHg) 0.001 0.0003 0.008
Bmi (kg/m2) -0.006 -0.005 0.001
nYHA class
NYHA class I ref
NYHA class II (vs. NYHA class I) -0.032  
NYHA class III (vs. NYHA class I) -0.047  
Previous PTCA -0.039 -0.040 0.003
CVA/TiA -0.085
Pulmonary disease -0.088 -0.071 0.001
Peripheral vessel disease -0.054  -0.044 0.028
Pack yearsb -0.001  
Constant 0.666 p<0.001
Adjusted R2 15%
Unstable CAD (N=81) 
CVA/TiA -0.126 -0.126 0.010
Peripheral vessel disease -0.098  
Diabetes -0.064
Constant 0.716 p<0.001
Adjusted R2 6%
a P value of multivariate analyses; b Number of packs per day multiplied with years of smoking
SBP: systolic blood pressure; BMI: body mass index; NYHA: New York heart association; PTCA: percutaneous transluminal 
coronary angioplasty; CVA: cerebrovascular accident; TIA: transient ischaemic attack
DisCUssion
This study estimated the baseline SF-6D score and both the physical and mental component scores 
for patients with stable or unstable CAD with the SF-6D and SF-36, respectively. Furthermore, 
we showed associations between baseline characteristics (e.g. gender, diagnosis, (non-)cardiac 
history, and risk factors) and SF-6D, PCS, and MCS. As shown in other studies, the mental health 
dimension was the least affected dimension of the SF-36 and, as expected, CAD had a particularly 
negative association with the physical dimensions. 
Bivariate analyses showed a negative association between age and PCS. In contrast, age was 
positively but not significantly associated with MCS but this association was also identified 
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before110,112. Furthermore, similar relationships between the component scores with gender, 
diabetes, history of stroke, smoking, and raised blood pressure were identified as reported in 
De Smedt et al.110 and Emery et al.108. Besides these associations we also found that non-cardiac 
history (e.g. pulmonary disease, PVD and renal failure) and other risk factors (e.g. hypertension 
and hyperlipidaemia) were associated with both PCS and MCS. Covariates were in general more 
strongly associated with PCS than with MCS. For HRQoL, measured with the SF-6D, similar 
associations were present: gender, SBP, BMI, previous PTCA, non-cardiac history (e.g. CVA/TIA, 
PVD or pulmonary disease), diabetes mellitus, hypertension, and pack-years. 
implications
The HRQoL, measured with the SF-6D index, of the included patients was 0.67±0.13 compared 
with 0.85±0.17, measured with the EQ-5D, in the general population within the same age 
category116. Quality of life can be improved by optimizing care for patients with stable or unstable 
CAD using our results. During the workup, it could be useful to measure the HRQoL of these 
patients as a standard part of their care. Dimension specific care can be provided to patients 
with lower scores in those dimensions. The results from this study suggest that CAD patients 
should receive more care that focuses on the ‘role physical’ dimension. For example, patients 
could be encouraged to increase physical activity which is in line with current European Society 
of Cardiology guidelines20. Other characteristics found in this study to be associated with a lower 
HRQoL (BMI, smoking) can be addressed by encouraging patients to adopt healthier lifestyle 
behaviours. 
Furthermore, these results from this study can be used by researchers to estimate the HRQoL in 
their population as part of a cost-effectiveness analysis of CVD interventions. However, patient 
characteristics of the Circulating Cells cohort need to be transferable with the population under 
consideration in the economic analysis. 
Limitations
Multiple imputation was performed for patients who completed 75% or more of the SF-36 
questionnaire since some patients started with the questionnaire but were reluctant to continue. 
Twenty-four patients of the 465 patients were not included in the analyses; on average they had 
filled in the questionnaire for 47% of all questions. These 24 patients were on average older than 
the analysed population (N=441). Brazier et al. have also recognized that the extent of missing 
data of SF-36 specific dimensions was significantly associated with age117. It is possible that a 
selection effect could have occurred by removing those 24 cases from the analyses; since they 
were unable to fill in the questionnaire. Consequently, the estimated HRQoL of the patients could 
be lower in practice but excluding only 5% of the cases from the analyses has probably a minimal 
effect.
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Most of the patients (81%) that were included in this study were diagnosed with stable CAD, 
meaning that a relatively small group of patients had unstable CAD. This reduced power to 
identify existing associations between HRQoL and patient characteristics may explain why only 
a few characteristics were significantly associated with HRQoL and health status. Surprisingly, 
unstable CAD patients had on average a higher HRQoL than patients with stable CAD. This 
association can be the result of a selection effect. However, Hlatky et al.118 have also shown that 
stable angina patients with CCS class 3 or 4 have a lower HRQoL than unstable patients. 
In our study we used the United Kingdom (UK) decrements to calculate the SF-6D index scores 
since there is no set of values available for The Netherlands. However, we do not expect 
substantial differences in the valuation of health states between the Netherlands and the UK. 
PCS and MCS scores are normalized with Dutch gender-specific dimension scores115. 
One possible limitation of the SF-36 is that the answer possibilities are assumed to have the same 
impact on HRQoL. For example, the answer possibilities of questions concerning how limited 
patients are in daily activities are possibly not linear. Other limitations of using the SF-36 in CAD 
patients have been described thoroughly by Brazier et al.117. However, the benefit of using a 
preference-based instrument is the ability to compare the impact that various diseases have on 
HRQoL.
Conclusion
This study showed that HRQoL of patients with stable or unstable CAD was moderate. Various 
patient characteristics appear to be significantly associated with HRQoL, even after adjustment 
for other factors. Knowledge of these associations can help to identify ways to improve care and 
thereby improve HRQoL. At the very least, this knowledge should stimulate more discussion 
about the needs of patients that are currently being inadequately addressed.
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Table s5.3 | Associations between patient characteristics and PCS
Stable CAD (N=360) Bivariate 
analyses
multivariate 
analyses
p valuea
Male  2.504 2.450 0.027
sBP (mmHg) 0.082 0.099 p<0.001
DBP (mmHg) 0.140  
Bmi (kg/m2) -0.524 -0.393 0.001
nYHA class
NYHA class I ref
NYHA class II -2.934  
NYHA class III -4.587 -3.802c 0.029
Heart failure -5.232  
Previous PTCA -3.282 -2.712 0.010
Previous CABG -3.858  
CVA/TiA  -8.066  
Pulmonary disease -9.513 -8.445 p<0.001
PVD -5.390 -3.768 0.017
renal artery disease -10.874 -9.994 0.002
Pack yearsb -0.058  
Constant 39.027 p<0.001
Adjusted R2 20%
Unstable CAD (N=81) 
Bmi (kg/m2) -0.858 -0.872 0.002
CVA/TiA  -8.158 -8.594 0.031
Pulmonary disease -7.474 -7.191 0.040
Diabetes mellitus -8.016  
Hypertension -6.272  
Hyperlipidaemia -4.799
Constant 67.318 P<0.001
Adjusted R2 17%
a P value of multivariate analyses; b Number of packs per day multiplied with years of smoking
BMI: body mass index; CABG: coronary artery bypass graft; CVA: cerebrovascular accident; DBP: diastolic blood pressure; 
NYHA: New York heart association; PTCA: percutaneous transluminal coronary angioplasty; PVD: Peripheral vessel disease; 
SBP: systolic blood pressure; TIA: transient ischaemic attack
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Table s5.4 | Associations between patient characteristics and MCS
Stable CAD (N=360) Bivariate  
analyses
multivariate 
analyses
p valuea
Age  0.259  0.252 p<0.001
DBP (mmHg) -0.098
BMI (kg/m2) -0.292  
Previous PTCA -2.946 -2.593 0.044
CVA/TIA  -4.872
Diabetes mellitus -2.976  -3.155 0.037
Current smoker -5.448
Pack yearsb -0.102  -0.087 0.012
Constant 31.818 p<0.001
Adjusted R2 7%
a P value of multivariate analyses; b Number of packs per day multiplied with years of smoking
BMI: body mass index; DBP: diastolic blood pressure; PTCA: percutaneous transluminal coronary angioplasty; 
CVA: cerebrovascular accident; TIA: transient ischaemic attack
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ABsTrACT
objectives: Systematic reviews of cost-effectiveness analyses summarize results and describe 
study characteristics. Variability in the study results is often explained qualitative or based on 
sensitivity analyses of individual studies. However, variability due to input parameters and study 
characteristics (e.g. funding or quality of the study) is often not statistically explained. As a case 
study, a systematic review on the cost-effectiveness of drug-eluting stents (DES) versus bare-
metal stents (BMS) using meta-regression analyses will be performed to explore the usefulness 
of such methods compared with conventional review methods.
methods: We identified and reviewed all modelling studies published until January 2012 that 
compared costs and consequences of DES versus BMS. We extracted general study information 
(e.g. funding), modelling methods, values of input parameters, and quality of the model (Philips). 
Associations between study characteristics and the incremental costs and effectiveness of 
individual analyses were explored using regression analyses corrected for study ID. 
results: Sixteen eligible studies were identified, with a combined total of 508 analyses. The 
overall quality of the models was moderate (59%±15%). This study showed associations (e.g. 
type of lesion) that were expected (based on individual studies), however the meta-regression 
analyses revealed also unpredicted associations: e.g. model quality was negatively associated 
with repeat revascularizations avoided.
Conclusions: Meta-regressions can be of added value, identifying significant associations that 
could not be identified using conventional review methods or by sensitivity analyses of individual 
studies. Furthermore, we indicated the need to examine input parameters and of performing a 
quality check of studies when interpreting the results. 
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inTroDUCTion
Economic evaluations are increasingly used to assist in decision making of interventions. Often 
for a specific certain decision problem many economic evaluations are conducted, the results of 
these studies often differ substantially between studies: from interventions being dominated to 
being dominant. Therefore, it is necessary that systematic reviews are performed to summarize 
the results of the individual economic evaluations. Besides summarizing the study characteristics 
and results it would be interesting to explain statistically the variability in the incremental costs 
and incremental effects and thus the conclusions. Differences can exist due to differences in 
values used for input parameters, perspective, time horizon and other factors. Some differences 
could easily be explained by the values that were used for the input parameters, since for some 
input parameters a linear relationship with the outcomes exists. For example, an increase in 
one-off intervention costs will lead to an increase in the incremental costs, ceteris paribus. Often 
these variations are explained by sensitivity analyses of individual studies. Other associations 
such as the influence of funding could be identified using meta-regression analyses in addition 
to conventional systematic review methods. Meta-regression analyses are currently used to 
combine the results of clinical trials and to investigate the effect of methodological diversity of 
the studies on the results119. To explain the variability in the incremental costs and incremental 
effects of cost-effectiveness analysis (CEA) it could be useful to apply these meta-regression 
analyses in systematic reviews of economic evaluations.
The aim of this study is to explore the usefulness of meta-regression analyses in systematically 
explaining the variability in the results compared with conventional review methods and 
sensitivity analyses of individual studies. Many economic evaluations have estimated the cost-
effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) for the treatment of 
patients with coronary artery disease. The results between the studies vary considerably, which 
makes this decision problem a good case study to explore if meta-regression analyses are of 
added value. Systematic reviews91,120,121 on the cost-effectiveness of DES versus BMS have been 
performed but did not explore statistically the causes of the variability in incremental costs and 
incremental effects between the studies. Associations with the incremental outcomes (costs, 
quality-adjusted life years and repeat revascularizations avoided) will be identified in this 
study. Besides the ‘known’ factors (e.g. age, type of lesion, price of stents, relative risk repeat 
revascularisations avoided) explaining the cost-effectiveness of DES versus BMS we will identify 
associations that could only be identified at a meta-level such as the quality of the studies and 
funding.
98 | Chapter 6
mETHoDs
inclusion and exclusion criteria
A systematic literature search was performed to identify all English-language publications (at 
any time before January 2012) of CEAs using decision analytic models to compare the costs and 
consequences of DES (sirolimus-eluting stent (SES), paclitaxel-eluting stent (PES), everolimus 
or zotarolimus-eluting stent (ZES)) versus BMS for patients who require a stent implantation 
due to an atherosclerotic lesion of the coronary artery. The effectiveness of the studies had 
to be expressed in quality adjusted life years (QALY) or in disease specific measures such as 
repeat revascularizations avoided, TLR (target lesion revascularization) and TVR (target vessel 
revascularization). Furthermore, studies were only included if they reported results in enough 
detail to enable separation of incremental costs from incremental effects. There was no 
restriction on the perspective used in the economic evaluation. Reviews, editorials and abstracts 
were not included in the review. 
Studies were identified using electronic databases (PubMed, EMbase, NHS EED, Cochrane Library 
and INAHTA) and by scanning reference lists of eligible articles. The full search strategies for 
EMbase and PubMed are presented in appendix 6.1. To ensure that all relevant publications were 
identified in the CRD (NHS EED and HTA) and Cochrane Library databases we limited the search 
terms to “stent” and “stents”. These terms were searched in “any field” for CRD and in “title, 
abstract, keywords” for Cochrane Library. We also included the relevant publications found in the 
reviews by Ligthart et al.121, Hill et al.91, and Neyt et al.120. 
Data extraction
One reviewer (LB) screened the titles and abstracts identified through the searches. The full 
text evaluation was performed by two reviewers (LB & FW) and discrepancies were discussed 
and resolved by consensus or by consulting a third reviewer (WR). Various parameters (Tables 
6.1 and 6.3) were extracted from the relevant publications by one reviewer (LB). Costs were 
converted to Euros47 and corrected for inflation if necessary48 to present the costs as 2012 Euros. 
In addition, two reviewers (LB & FW) independently assessed the quality of the models using 
the Philips et al. checklist122 for the assessment of model-based economic analyses. The Philips 
checklist is a framework based on existing guidelines on the use of decision analytic modelling in 
health technology assessments. The checklist is structured in three themes: a) structure, which 
focusses on the scope and mathematical structure; b) data, which examines data identification 
and uncertainty methods; and c) consistency, which assesses the overall quality of the model 
based on the publication. Both overall study quality and the quality per theme were given a score 
from 0–100%, which was calculated by dividing the sum of the questions answered positively by 
the total number of relevant questions. Since some questions were not relevant for all studies 
(e.g. questions concerning quality-of-life values) the denominator could differ between studies.
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Analysis
The influence of modelling methods, the choice of parameters and the quality of the models on 
the main outcomes (incremental costs, incremental QALYs and absolute risk reduction repeat 
revascularizations) were analysed both quantitatively and qualitatively. Associations between 
parameters and the outcomes were assessed by identifying outliers found on cost-effectiveness 
planes. Furthermore, several bivariate linear regressions were estimated to confirm the 
associations and also to measure the influence of other parameters on the outcomes. Including 
associations that could be predicted beforehand (e.g. type of lesion, price stent) are included in 
the regression analyses since it could be seen as a validation check if the model predicts what it 
should predict. 
We included every subgroup or sensitivity analysis found in a study as long as incremental 
costs or incremental effectiveness were provided or could be calculated. As a result, our meta-
regression analyses were based on many more observations than the number of studies that 
were included. Since Hill et al.91 provided more than 30% of the observations used in our study; 
we incorporated study ID as a random effect in the regression models. Data management and all 
statistical analyses were performed with SPSS 19.0 (SPSS Inc., Chicago, IL, USA).
rEsULTs
Figure 6.1 presents the process of identifying relevant publications. Of the 1957 potentially 
relevant publications, 1872 were excluded based on title, abstract and keywords. Full-text 
evaluation was performed for 85 articles leading to 18 relevant studies. Reasons to exclude 
studies after a full text assessment were: lack of a model (n=24), no original CEA (n=22), language 
other than English (n=8), no relevant outcome (n=6), comparator not BMS (n=4), and results 
were not presented at a disaggregated level (n=3). In one case, we found that a full report123 and 
a paper101 reported results from the same analyses; data was therefore extracted from the full 
report. In another case, we found two papers with the same content and results and considered 
them as one paper124,125.
The 16 eligible studies were divided into five groups based on the type of DES that was evaluated 
and accounted for 508 separate analyses (Table 6.1). Four studies calculated the incremental 
cost-effectiveness ratio (ICER) for both PES and SES91,92,99,126, two studies93,127 focused on PES, three 
studies focused only on SES98,128,129, and one study used ZES as the intervention97. The remaining 
six publications90,94-96,123-125 did not specifically identify the type of eluting drug under evaluation 
and calculated an ICER for a DES in general.
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PES & 
SES
N = 4
ZES
N = 1
PES
N = 2
SES
N = 3
DES
N = 6
Title abstract screening
N = 1957
Records  idenfied through
database  searching
 N = 2688
Records  aer 
duplicates removed 
N = 1957
Full text arcles assessed 
for eligibility 
N = 85
Relevant studies
N = 18
Studies included in qualitave
and quantave synthesis
N = 16
Duplicates 
N =  713
Excluded based on 
tle/abstract 
& keywords
N = 1872
Excluded full
assessment
N = 67
Excluded different
arcles but same
content/results
N = 2
figure 6.1 | Flow of studies through the review process 
PES: paclitaxel eluting stent; SES: sirolimus eluting stent; ZES: zotarolimus eluting stent; DES: drug eluting stent
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Descriptive characteristics
In most analyses, DES was more expensive (88% of analyses) and more effective in both 
QALYs and repeat revascularizations avoided (99% of analyses) than BMS. Most of the 16 
studies91,92,95,96,123-125,127 concluded that DES is not cost-effective for all subgroups since the 
incremental QALYs did not offset the incremental costs. However, many concluded that DES was 
more cost-effective in high-risk patients. The ICER varied considerably between and within studies: 
from DES being dominated by BMS92,95 to DES being dominant in specific analyses90,91,93,123-125,129. 
Figures 6.2 and 6.3 present the variability of the incremental costs and effects of the studies 
using repeat revascularizations avoided or QALYs as an outcome measure, respectively. The mean 
values of input parameters stratified by the type of study outcome are presented in Table 6.2. 
We also assessed the quality of the models of all studies using the Philips et al.122 checklist. 
Studies appeared to score higher on the theme structure (63%±16%) than on the other two 
themes, data (55%±21%) and consistency (59%±21%). The overall quality of the models was 
moderate (mean 59%±15% of a maximum possible score of 100%). 
outcome repeat revascularizations avoided
Based on 124 separate analyses (9 studies), the number of repeat revascularizations avoided (the 
absolute risk reduction in repeat revascularizations) with DES also varied considerably (Figure 
6.2) between and within studies (range: -0.0001, 0.19), which resulted in variation in the ICERs. 
The overall conclusions of most of the studies corresponded with the 124 separate analyses. 
The regression analyses showed that the relative risk reduction of repeat revascularizations and 
the initial probabilities of restenosis were positively associated with repeat revascularizations 
avoided. Furthermore, a more complex vessel or lesion was associated with higher relative risk 
reduction and initial risk of restenosis after a percutaneous coronary intervention with BMS. 
Consequently, this leads to an increase in repeat revascularizations avoided and DES becomes 
more effective. Furthermore, the number of stents was also positively and significantly associated 
with repeat revascularizations avoided, probably because it is a proxy for subgroups who have a 
higher risk of developing restenosis due to diabetes, lesions and vessels characteristics. 
Besides these factors that could be predicted beforehand, with the meta-regression analyses 
we were able to find a negative association between overall quality of a model and repeat 
revascularizations avoided. Furthermore, the theme consistency was also negatively associated 
with this incremental outcome. Consequently, models with a higher quality led to less favourable 
results for DES.
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outcome of incremental QALYs
Figure 6.3 presents the incremental QALYs and incremental costs for 384 separate cost-
effectiveness analyses (11 studies). This Figure shows that Shrive et al.98 and Remak et al.97 clearly 
found a larger incremental QALY gain than the other studies. 
Again the meta-regression analyses found associations with incremental QALYs that were 
expected. Relative risk reduction of repeat revascularizations and the initial probability of 
restenosis after BMS were associated with a greater QALY gain, as seen in individual sensitivity 
analyses90-95. 
Table 6.2 | Averages economic evaluations (univariate analyses)
 Total (CEAs & CUAs) CEAs CUAs
  Average ± sD Average ± sD Average ± sD
input parameters   
Number of stents per procedure 1.503 ± 0.367 1.382 ± 0.355 1.540 ± 0.364
Price of DES stent €1,654 ± €390 €1,912 ± €672 €1,614 ± €307
Price of BMS stent €555 ± €166 €670 ± €307 €534 ± €114
Price difference between stents €1,085 ± €337 €1,189 ± € 336 €1,056 ± €331
Price of DES procedure (incl. stents) €6,328 ± €2,509 €7,811 ± €1,475 €5,998 ± €2,573
Price of BMS procedure (incl. stents) €4,442 ± €2,195 €6,259 ± €1,536 €4,160 ± €2,138
Cost difference between the procedures €1,787 ± €686 €1,551 ± €805 €1,840 ± €647
Probability restenosis BMS 0.142 ± 0.076 0.148 ± 0.055 0.140 ± 0.081
Probability restenosis DES 0.064 ± 0.038 0.056 ± 0.027 0.068 ± 0.041
Relative risk reduction DES vs. BMS 0.484 ± 0.204 0.578 ± 0.214 0.449 ± 0.189
Quality (0–100%)*   
Total 59.5 ± 15.4  
Structure 62.5 ± 16.1  
Data 56.7 ± 21.6  
Consistency 55.1 ± 20.8  
* N=16 studies
CEA: cost-effectiveness analysis; CUA: cost-utility analysis
Furthermore, analyses showed that non-elective patients, patients with a high risk of a repeat 
revascularization, patients with complex vessels or lesions or older patients will benefit more 
from DES, what was also recognised in the individual studies91,94,95,98,99. In addition, we found a 
significant positive association between time horizon (continuous) and incremental QALYs. This 
was also found by Hill et al.90, who varied the time horizon from 12 to 60 months in the sensitivity 
analyses.
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figure 6.2 | Cost-effectiveness plane, repeat revascularizations avoided
Studies91,98 that have explicitly mentioned that they have assumed that the occurrence of repeat 
revascularizations within the time horizon is the result of restenosis and studies assuming 
that repeat revascularization rates are based on angiographic follow-up have estimated 
significantly higher incremental QALYs. Angiographic follow-up leads to inflated estimates of 
clinical effectiveness compared with clinical follow-up since not clinically significant restenosis 
results in “unnecessary” repeat revascularizations when angiographic follow-up is performed. 
Consequently, the difference in repeat revascularizations will be overestimated (oculo-stenotic 
effect)130. Some studies use “real-world”95,123-125 follow-up data and consequently report lower 
estimates (visible in Figures 6.2 and 6.3) than other studies such as, Remak et al.97 that used 
angiographic follow-up93,96,98,99. This phenomenon is described earlier by Eisenberg et al.131, who 
concluded that cost-effectiveness studies using angiographic follow-up overestimate the cost-
effectiveness of DES. 
The meta-regression analyses showed that studies using real-world evidence compared with 
angiographic follow-up leads to a reduction in incremental QALY gain. The added value of 
meta-regression analyses is limited in explaining the variation in incremental QALYs, however it 
identified modelling assumptions that were significantly associated.
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outcome incremental costs
Figures 6.2 and 6.3 show that there was large variation in incremental costs (range: €-4,070 
to €3,506). Regression analyses confirmed associations (cost parameters and population 
characteristics) that were seen in the individual studies91,94,95,97-99,123. The analyses showed that 
probability of restenosis after BMS, the reduction in restenosis risk by DES, the difference in stent 
price, and the number of stents used were important parameters influencing the incremental 
costs. Both input parameters varied considerably between the analyses: the difference in stent 
costs ranged from €0123 to €2,68598 and the number of stents varied between 1 and 2.6 stents per 
procedure depending on the type of patient. 
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figure 6.3 | Cost-effectiveness plane, quality adjusted life years
On a meta-level we were able to conclude that funding and the type of cost-effectiveness 
analysis was associated with incremental costs. Funding was provided by the stent manufacturer 
in five93,97,98,128,129 of the 16 studies and three of them93,97,129 concluded that DES was cost-effective 
compared with BMS. Of the studies that were not funded by a manufacturer only one124,125 of 
them concluded that DES could be cost-saving. Studies that were not funded estimated on average 
higher incremental costs than studies that were (p<0.05). Furthermore, some associations with 
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incremental costs are recognised from scenario analyses performed by studies. The directions 
of the following associations are confirmed by the regression analysis but not significant. 
According to Jahn et al.124,125 it is important to incorporate wait time into the model since it leads 
to a decrease in incremental costs. A time horizon shorter than 12 months was associated with 
higher incremental costs; Hill et al.90 estimated costs and effects for different time horizons and 
showed that a longer time horizon led to lower incremental costs. This is likely because of the 
continuing treatment effect of DES in the subsequent years which would increase in the number 
of repeat revascularizations avoided compared with BMS. This increase in reduction of repeat 
revascularization would further offset the cost of the initially more expensive DES. 
Meta-regression analyses showed also that the number of repeated revascularizations avoided 
explained a large proportion of variation (R2=0.53). As shown in Figure 6.2, there appeared 
to be a linear association between incremental costs and repeat revascularizations avoided. 
Incremental QALYs (Figure 6.3), on the other hand, was not associated with incremental costs 
(R2=0.001), probably since incremental QALYs are determined by several factors including repeat 
revascularizations avoided, life-years gained and quality of life values. 
DisCUssion
This study has explored the usefulness of meta-regression analyses in combination with a 
systematic review of economic evaluations. The variation in incremental costs and effects of 
studies evaluating the cost-effectiveness of DES versus BMS was explained by using this method. 
Besides confirming associations that could be predicted based on individual studies, we were 
able to identify associations on a meta-level such as the quality of the models. Using regression 
analyses to explore the associations between the incremental outcomes and parameters is 
unique for a systematic review of economic evaluations.
The most important factors that were associated with the results were patient characteristics 
(age, vessel, lesion), procedure (type of stent and elective versus non-elective), specific input 
parameters (number of stents per procedure, cost per stent/procedure, restenosis risk with 
BMS and the efficacy of DES) and the quality of the models. Many of these associations had 
already been reported in the studies themselves, which can be seen as evidence that the meta-
regression produced valid results. However, besides these previously reported associations, we 
also found associations between study outcomes and the quality of the model, time horizon, 
efficacy assumptions, and funding which could only be identified at a ‘meta level’. Moreover, 
this review showed that it is possible to predict the incremental costs based on the absolute risk 
reduction in repeat revascularizations on ‘meta-level’ (Figure 6.2). 
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Table 6.3 | Associations between outcomes and covariates (bivariate analyses)a 
Bivariate
outcomes
Covariates ∆ Costs ∆ QALYs ∆ repeat 
revascularization
β β β
Population   
Age   
Age >75 315 0.029* NA
Age 65–75 -31 0.015* -0.018
Age <65 ref ref ref
Complex lesion (yes vs. no) 181* 0.001* 0.029*
Complex vessel (yes vs. no) -22 0.001* 0.042*
Multi vessel disease (yes vs. no) 149 0.001 0.019*
Diabetes (yes vs. no) -216* 0.000 0.02*
Post MI (yes vs. no) -88 0.000 0.007
Elective (yes vs. no) 346* -0.001* NA
High risk (yes vs. no) -291 0.004* NA
Intervention 
Type DES   
Sirolimus eluting stent 551 0.01 0.102*
Paclitaxel eluting stent 379 0.011 0.063*
Zotarolimus eluting stent -324 0.025 NA
Drug eluting stent in general ref ref ref
study characteristics 
Horizon >1 year (yes vs. no) -479 0.002 -0.006
Horizon (months) b -32* 0.000* 0.000
Type of study (CUA vs. CEA)  -194* NA NA
Model   
Markov model 613 0.014 NA
Discrete event simulation model -435 0.001 NA
Decision tree ref ref NA
Perspective   
Health care provider perspective 266 0.006 0.004
Health care sector perspective -1,332 NA 0.04
Non-public perspective -1,057 NA NA
Health care payer perspective ref ref ref
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Table 6.3 | (Continued)a 
Bivariate
outcomes
Covariates ∆ Costs ∆ QALYs ∆ repeat 
revascularization
β β β
Funding   
No 1,350* -0.001 0.03
Yes   
Both Industry and No industry 1,246 0.043* NA
Industry -621 0.012 0.102*
No industry ref ref ref
Discounting (yes vs. no) 929 0.016 -0.063
input parameters 
Number of stents used during the procedure 708* 0.001 0.033*
Price difference between stents 1,215* NA NA
Price of BMS stent 0.503* NA NA
Price of DES stent 1,001* NA NA
Costs of BMS procedure (incl. stents) 0.339* NA NA
Costs of DES procedure (incl. stents) 0.412* NA NA
Difference in procedure costs 0.799* NA NA
Probability of restenosis BMS  -3,072* 0.024* 0.521*
Probability of restenosis DES  -1,907* 0.005 0.436*
Relative risk reduction repeat revascularization  -1,676* 0.007* 0.132*
Disutility of undergoing a CABG NA -0.107 NA
Disutility of undergoing a PCI NA  -0.747* NA
Disutility of experiencing a MI NA -0.021 NA
Disutility for a patient with angina symptoms NA -0.012 NA
Quality of life of a patient with angina symptoms NA  -0.231* NA
Quality of life of a patient after revascularization 
(recovered)
NA  -0.24* NA
Quality of life of a patient suffering from restenosis NA  -0.254* NA
Assumptions
Difference in clopidogrel (medication) usage (yes vs. no) 181 0.00* 0.001
Wait time for revascularization included (yes vs. no) -733  -0.012* -0.051
Repeat revascularization is based on angiographic follow-
up data (yes vs. no)
-593 0.013* -0.082*
DES and BMS are not mixed up during a procedure -541 0.002 -0.061
Repeat interventions that occur during time horizon are 
the result of restenosis
854 0.02* NA
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Table 6.3 – (Continued)a 
Bivariate
outcomes
Covariates ∆ Costs ∆ QALYs ∆ repeat 
revascularization
β β β
The type of repeat revascularization is the same for the 
DES and BMS treatment groups
501 -0.008 -0.071
There does not exist a difference in survival between DES 
and BMS
-238 0.001 0.015
There does not exist a difference in thrombosis between 
DES and BMS
-589 -0.003 0.039
There does not exist a difference in MI between DES and 
BMS
-594 -0.006 0.046
Quality of studies (Philips et al. 2006)122
Structure (%) 2,154 -0.006 -0.145
Data (%) 1,607 0.006 -0.167*
Consistency (%) 718 -0.018 -0.153
Total (%) 2,761 0.000  -0.250*
a Corrected for study; bShrive et al. & Remak et al.97,98 not included (lifetime horizon) 
* p value<0.05
Some of the associations we found are desirable since they involve parameters that influence 
the results and that can be controlled by clinicians and policymakers. For example, factors 
like the costs of a stent are expected to be associated with the results. Other factors such as 
patient characteristics can be changed by means of patient selection. However, the presence 
of other associations such as the quality of the models, assumptions, time horizon or funding 
raises concerns. Moreover, other parameters were not significantly associated but also these 
differences are undesirable and could have influenced the outcomes. It is important for authors 
to follow the recommendations of the ISPOR-SMDM task force for modelling good research132 to 
increase the quality of the study and generalizability of the results.
Limitations
Despite the fact that the quality of models was assessed by two independent reviewers it 
was difficult to judge the quality due to subjectivity of the questions; this problem was been 
recognized in the past133. Furthermore, to provide studies with a score between 0 and 100% we 
needed to assume that all questions of the checklist were equally important. Thus studies could 
obtain a reasonably high score if less informative/important questions were fulfilled. In addition, 
the quality of the models was based on the documentation of the model and therefore it is 
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possible that studies that scored low did not transparently present model details, however the 
actual model could be of high quality. 
Another limitation of our study is that all 508 analyses were analysed as independent 
observations even though in reality these 508 analyses were based on 16 studies. We have used 
study identification number as a random effect in the regression models to address this problem. 
In addition, transparency in documentation is a major issue leading to a high frequency of missing 
values that made it impossible to perform multivariate analyses with all of the parameters 
that were significant in the bivariate analyses. Transparent reporting is crucial in this field 
and would solve the problem of missing values for systematic reviews such as this. A recently 
published review on the challenges of modelling the cost-effectiveness of cardiovascular disease 
interventions has recognized the same problem134.
Lastly, we did not include the studies published after January 2012. However, we expect that 
including newer studies that met inclusion criteria (i.e. estimating the cost-effectiveness of DES 
versus BMS using modelling methods) do not have an impact on the results of our case study 
showing that using meta-regression analyses could be useful method in addition to conventional 
systematic reviews. 
Conclusions
This study has showed that meta-regression analyses can be of added value, identifying significant 
associations that could not be identified using conventional review methods or sensitivity 
analyses of individual studies. The quality of the models was associated with the outcomes of 
the studies and therefore it is important that a quality check is performed before interpreting 
the results of the study.
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Appendix 6.1 – Search terms
Pubmed
#1 cardiovascular disease[MeSH]
#2 stent*
#3 economics 
#4 econom*
#5 cost
#6 costs
#7 costly
#8 costing
#9 price
#10 prices
#11 pricing
#12 pharmacoeconomics
#13 pharmacoecon*
#14 expenditure*
#15 energy
#16 #13 NOT #14
#17 “value for money”
#18 budget*
#19 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #15 OR #16 or #17 OR #18
#20 Humans[Mesh]
#21 “1990”[PDat] : “2012”[PDat]
#22 English[lang]
#23 #1 AND #2 AND #19 AND #20 AND #21 AND #22
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Appendix 6.1 – Search terms
Embase
#1 ‘cardiovascular disease’/exp
#2 ‘stent’/exp
#3 ‘economics’/exp
#4 ‘cost’/exp
#5 costly
#6 costing
#7 price
#8 prices
#9 pricing
#10 pharmacoeconomics
#11 ‘pharmacoeconomics’/exp
#12 ‘value for money’
#13 ‘budget’/exp
#14 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#15 [humans]/lim
#16 [1-1-1990]/sd NOT [31-12-2011]/sd
#17 [english]/lim
#18 #1 AND #2 AND #14 AND #15 AND #16 AND #17
Cochrane (43) CRD (205) and INAHTA (24) are checked for relevant publications
Economic filter:
Centre for Reviews and Dissemination. NHS EED Economics Filter [Internet]. York: Centre for Reviews and Dissemination; 
2010. Available from: http://www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html
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ABsTrACT
Background: Patients diagnosed with a large unruptured abdominal aortic aneurysm (AAA) 
are usually offered elective reparative treatment given the high risk of rupture. Nowadays, 
patients with an AAA diameter larger than 5.5cm are treated with open surgical repair (OSR) 
or endovascular aneurysm repair (EVAR). The aim of this study is to estimate the lifetime cost-
effectiveness of EVAR versus OSR in the Netherlands based on recently published literature.
methods: A model was developed to simulate a cohort of individuals (72 years old, 87% men) 
with a diagnosed AAA diameter of at least 5.5cm and considered fit for both repairs. The model 
consists of two submodels that estimate the lifetime cost-effectiveness of EVAR versus OSR: 1) a 
decision tree for the first 30 days post-operative and 2) a Markov model for the period thereafter 
(beyond 30 days to 30 years). 
results: In the base-case analysis, EVAR was slightly more effective (4.704 versus 4.669 QALYs) 
and less expensive (€24,483 vs. €25,595) than OSR. Improved effectiveness occurs because EVAR 
can reduce 30-day mortality risk as well as the risk of events following the procedure while lower 
costs are primarily due to a reduction in hospital days. The cost-effectiveness of EVAR is highly 
dependent on the price of the EVAR device and the reduction in hospital days, complications and 
30-day mortality.
Conclusion: EVAR and OSR can be considered equally effective, while EVAR can be cost-saving 
compared with OSR. EVAR can therefore be considered a cost-effective solution for AAA patients. 
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inTroDUCTion
Patients diagnosed with a large unruptured abdominal aortic aneurysm (AAA) are usually 
offered elective operative repair given the high risk of rupture. Nowadays, patients with an 
AAA diameter larger than 5.5cm135 are treated electively with open surgical repair (OSR) or 
endovascular aneurysm repair (EVAR). Several randomized controlled trials (RCT) such as the 
DREAM136, EVAR-1137, OVER138 or ACE139 trials have compared the effectiveness of EVAR versus 
OSR and concluded that EVAR leads to a reduction in short term mortality. A systematic review by 
Chambers et al.140 showed that EVAR may significantly decrease 30-day mortality and 6-month all-
cause mortality primarily due to a lower mortality rate during initial hospitalisation141. However, 
EVAR seems to increase the four year chance of AAA-related reinterventions (9%) compared 
with OSR (1.7%)142 and RCTs showed that the gain in all-cause mortality disappears after the first 
2 years143. 
The various observed differences in effectiveness between EVAR and OSR underline the need to 
compare the two procedures in a comprehensive manner. Moreover, costs need to be considered 
as well, since the device used in an EVAR procedure is more expensive than the prosthesis used 
for OSR. These are two important reasons to examine cost-effectiveness of EVAR versus OSR.
Several cost-effectiveness analyses have examined the cost-effectiveness of EVAR versus OSR in 
different settings140,143. A previous study estimated the cost-effectiveness of elective EVAR versus 
OSR for the Netherlands144, however the time horizon of the analysis was one year and the 
data was based on the DREAM trial136 which started patient inclusion in 2000. In the economic 
evaluation144, based on the DREAM trial, they concluded that EVAR was not cost-effective 
compared with OSR. Other studies have also estimated the cost-effectiveness of EVAR compared 
with OSR albeit for another setting and often also used results that were slightly outdated and 
several clinical events were not included. Since endovascular AAA repair is a very dynamic field, 
its cost-effectiveness should be estimated with recent data, including cost data, technological 
improvements of the device and the technical skills of clinicians with EVAR. The aim of this study 
is to estimate the lifetime cost-effectiveness of elective EVAR versus OSR in AAA patients in the 
Netherlands, from a societal perspective. 
mETHoDs
A model was developed to simulate a cohort of individuals (72 years old, 87% men145) with a 
newly diagnosed AAA of at least 5.5cm in diameter and were considered fit for elective OSR and 
EVAR. 
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The model estimates the lifetime cost-effectiveness of elective EVAR versus OSR. The measure 
of health benefit was expressed in expected quality adjusted life years (QALYs) and costs were 
measured in 2013 Euros. A societal perspective, as proposed by the Dutch guidelines146, was 
adopted, however indirect costs and non-medical costs were assumed to be equal between 
the treatment strategies and were left out of the analyses. Costs and health benefits were 
discounted at 4% and 1.5%, respectively, according to the current Dutch guidelines146. The model 
is closely based on a previously published model147 but is adjusted in several aspects: 1) costs 
of procedures are adapted to the Dutch setting, 2) additional events are included (e.g. deep 
venous thrombosis (DVT), pulmonary embolism (PE), major amputation of lower extremities), 
3) transition probabilities (e.g. mortality and events) are derived from other sources presenting 
more detailed data, 4) quality of life (QoL) values are based on the DREAM trial144. 
structure
The model consists of two submodels, namely a short term decision tree model (which captures 
events that take place in the first 30 days post-operative) and a long term Markov model to 
model disease progression thereafter (up to 30 years). Patients who experienced pre-operative 
complications while waiting to undergo the operation were not included in this analysis; we 
assumed no differences in costs and effects between the interventions during waiting time 
(expert opinion). 
Short term model
The short term model (Figure 7.1) includes 30-day mortality, conversion from EVAR to OSR, and 
events (AAA and laparotomy related reintervention, major amputation of lower extremities, 
myocardial infarction (MI), DVT, PE, pneumonia, permanent and temporary renal failure, 
disabling and non-disabling stroke).
figure 7.1 | Short term model (first 30 days)
AAA: abdominal aortic aneurysm; EVAR: endovascular aneurysm repair; OSR: open surgical repair
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Long term model
The costs and health effects (life-years, QALYs) of patients who survive the first 30 days post 
procedure are estimated in the long term model (Figure 7.2) for a lifetime horizon (30 years). 
The cycle length used in the first two years was 1 month and after two years a yearly cycle was 
used. This model consists of four disease states (‘Alive, no event’, ‘Post non-fatal event - first 
year’, ‘Post non-fatal event – subsequent years’ and ‘Death’). Two ‘Post non-fatal event’ states 
were incorporated since the costs and QoL of patients with an event is different for the first year 
compared to subsequent years147. 
Paents survived 
30 days
post-operave,
experienced an event
Alive, no event
Paents survived 
30 days
post-operave,
no event
Post non-fatal event
(first year)†
Non-fatal
event*
Post non-fatal event
(subsequent years)†
Death
figure 7.2 | Long term model (beyond 30 days – 30 years)
* Note that non-fatal event is a predicted event and not a state of the model
† These states are heterogeneous; it represents the weighted average of the different types of events
Depending on the occurrence of an event in the first 30 days, patients can enter the long term 
model in the ‘Alive, no event’ or in the ‘Post non-fatal event - first year’ if they have experienced 
a non-fatal event in the first 30 days. Patients in the ‘Alive, no event’ state have an ongoing 
chance of an event (MI or stroke) and an ongoing chance of dying for any reason. Patients who 
have experienced an event will move to the ‘Post non-fatal event – first year’ state. The costs and 
health outcomes of patients that have survived the first year after the event are modelled in the 
‘Post non-fatal event – subsequent years’ state. Patients in the ‘Post non-fatal event’ states are 
only at risk of death and not at risk of an additional event. The ‘Post non-fatal event’ states include 
patients who have had various types of events, which means that the average costs and QoL 
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represent weighted averages. The costs and health outcomes of patients who have experienced 
an event (e.g. stroke, MI, renal failure) are modelled separately in this heterogeneous state. 
Mortality is not modelled separately, since specific risks after each event were not available. 
Table 7.1 | Transition probabilities 
Base case* Distribution EVAr Distribution osr source
 EVAR osr   
mortality
Mortality – 30 days (cum) 0.008 0.033 142
Mortality – 1 year (cum) 0.063 0.079 142
Mortality – 2 year (cum) 0.119 0.119 142
Mortality – 3 year (cum) 0.167 0.167 142
Mortality – 4 year (cum) 0.216 0.216 142
Mortality – 5 years (cum) 0.267 0.267 142
Mortality > 5y age and gender 
dependent
28
Events (<30 days post-operative) 
Reintervention  
(excl. conversion)
0.0018 0.0033 Beta (42,22788) Beta (75,22751) 148
Conversion to open surgery 0.0024 - Beta (3,1253) - 149
MI 0.07 0.093 Beta (1598,21232) Log-normal (1.340,0.03)† 142
DVT or PE 0.011 0.017 Beta (251,22579) Log-normal (1.210,0.079)† 142
Stroke 0.001 0.001 143
Disabling 0.309 0.309 Beta (62,139) Beta (62,139) 150
Pneumonia 0.093 0.168 Beta (2123,20707) Log-normal (1.890,0.026)† 142
Community management 0.68 0.68 Beta (68,32) Beta (68,32) Assumption147
Acute renal failure 0.055 0.107 Beta (1256,21574) Log-normal (2,0.034)† 142
Renal failure requiring 
dialysis
0.004 0.05 Beta (91,22739) Log-normal (1.33,0.143)† 142
Major amputation 0.0004 0.0012 Beta (9,22821) Log-normal (3.0,0.365)† 142
Proportion above knee 0.317 0.317 Beta (13,28) Beta (13,28) 151
Events (>30 days post-operative)
Annual probability
Reintervention 0.049 0.039 Beta (1126,21700) Beta (888,21938) 148
Cardiovascular event 
(stroke & MI)
0.026 0.031 Beta (16,610) Log-normal (1.205,0.146)† 143
Proportion MI 0.487 0.487 Beta (55,58) Beta (55,58) 143
* Base case: 72 year old, 87% men †RR was used
Cum: cumulative; DVT: deep venous thrombosis; EVAR: endovascular aneurysm repair; MI: myocardial infarction; OSR: open 
surgical repair; PE: pulmonary embolism
121Cost-effectiveness of EVAR vs OSR | 
Chapter
7
input parameters
A literature search using PubMed was performed to obtain values of input parameters and 
experts were consulted whenever needed. An expert panel of four vascular surgeons [AW 
(peripheral teaching hospital), PC and AV (large teaching hospital), HV (academic hospital)] 
provided feedback on structural assumptions, provided cost data and validated the values that 
were used for the input parameters. Table 7.1 presents the values of the input parameters of the 
base-case analysis and their distributions used in the uncertainty analyses. Tables 7.2 and 7.3 
present the costs (unit costs and resource use) and the QoL values used in the analysis.
Probabilities
Survival
In the base-case analysis, the estimated 30-day all-cause mortality rate and the 5-year post-
operative all-cause mortality rate were based on the results of a large cohort study evaluating 
the effectiveness of EVAR and OSR in a US Medicare population (n=45,660 patients)142. Since 
individual patient data were unavailable, mortality rates were directly derived from the Kaplan-
Meier curves published in the article. Mortality rates for OSR and EVAR beyond 5-year follow-
up were derived from Dutch national age-and gender-specific mortality statistics28 by adjusting 
all-cause mortality with a multiplication factor of 1.36 in men and 1.86 in women152. This 
multiplication factor, based on the UK small aneurysm trial152, leads to an increase in mortality 
since patients with AAA have a higher mortality risk than the general population. Mortality rates 
were independent of the disease state.
Events
The risks of events during the first 30-day post-operative, including circulatory system events 
(DVT, PE and MI), neurological events (stroke), renal events (renal failure), pulmonary events 
(pneumonia), were based on Schermerhorn et al.142 and Brown et al.143. In total, patients treated 
with EVAR had a lower 30-day event rate than patients treated with OSR (24% versus 40% 
respectively) in the base-case analysis. The reintervention rate was based on Giles et al.148 (same 
data as in the Schermerhorn paper). The chance of a conversion from EVAR to OSR was based on 
the study by Stokmans et al.149.
The risks of events after 30 days were based on Brown et al.143, who reported the outcomes of 
the EVAR-1 trial, while the probabilities of reintervention were based on Giles et al.148. Patients 
treated with EVAR had a higher reintervention rate than the OSR group, mainly because of the 
higher AAA-related reintervention rate (3.6% versus 0.9%). However, patients treated with OSR 
had a higher chance of laparotomy related reinterventions (e.g. bowel resection or repair of 
abdominal-wall hernia) than EVAR patients (2.99% versus 1.38%). These rates were based on 
six-year follow-up results and were assumed to continue after these six years. Schermerhorn 
et al.142 reported four-year follow-up results and showed that the reintervention risk stays fairly 
constant over the years. 
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Costs and quality of life
Unit costs and resource use were obtained from hospital databases, the Dutch Surgical Aneurysm 
Audit (DSAA)145, literature and expert opinion (Table 7.2). We combined these estimates with 
reference values from the Dutch costing manual153 and Dutch tariffs154. 
The costs of the primary admission for EVAR and OSR were based on a large Dutch AAA registry145 
and data obtained from three general hospital databases. These costs include the device and 
guidewires, theatre time, consumables, blood products, cell saver, diagnostics, laboratory, and 
length of stay on wards and intensive care. The frequency of outpatient visits and follow-up 
tests were based on expert opinion. It was assumed that patients who underwent EVAR have an 
outpatient visit with a diagnostic test (duplex test (80%) or computed tomography (20%)) at one 
month follow-up and then once every year thereafter. Patients treated with OSR were assumed to 
have an outpatient visit at one month and six months follow-up, after which they would have an 
outpatient visit in combination with a computed tomography (50%) or a duplex test (50%) every 
five years. Follow-up schedule was based on primary treatment; i.e. reinterventions did not alter 
the follow-up scheme in the model. Costs of events, reinterventions and conversions were based 
on previously published studies37,150,155-160 and inflated and converted to 2013 Euros47,48.
Total QALYs were estimated by combining QoL values from the DREAM trial144 with UK population 
norms71 and survival. The DREAM trial136 is the only randomised trial that measured QoL, using the 
EQ-5D, in Dutch patients undergoing EVAR or OSR who were considered fit for both procedures. 
EVAR patients had a higher QoL than OSR patients at 1-month follow-up (0.67 versus 0.61) but 
a lower QoL at 3 months (0.75 versus 0.78) and 12 months (0.77 versus 0.81). In line with QoL 
measured in the EVAR-1 trial137, other studies161,162, and expert opinion we assumed that QoL is 
comparable for both groups in the mid-term. In the base-case analysis, we assumed that the QoL 
of the patient groups did not differ after 18 months and was estimated using the average QoL of 
both groups at 12 months (0.79). The QoL values of patients experiencing a clinical event were 
based on several sources150,151,163,164. QoL values of patients without experiencing events were 
estimated by combining population-based QoL with procedure-related QoL. Similarly, the QoL 
values of patients who have experienced an event were estimated by combining population-
based QoL, procedure-related quality of life and event specific QoL.
Analysis
The costs and effectiveness expressed in LY and QALYs were estimated separately for both 
procedures. Dividing the incremental costs by the incremental effects leads to a deterministic 
estimate of the incremental cost-effectiveness ratio (ICER) of EVAR versus OSR. This point 
estimate was estimated when the mean values of the parameters are used (base case). When 
a strategy is considered more effective and less expensive than the alternative, this strategy is 
considered dominant and no ICER is estimated. 
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Table 7.3 | Quality of life      
intervention related quality of life EVAR osr Distribution EVAr Distribution osr source
1 months 0.67 0.61 Beta (52,26) Beta (46,29) 144
2 months 0.73 0.74 Beta (57,21) Beta (55,20) 144
3 months 0.75 0.78 Beta (58,20) Beta (59,16) 144
6 months 0.75 0.79 Beta (58,20) Beta (59,16) 144
12 months 0.77 0.81 Beta (60,18) Beta (61,14) 144
18 months 0.79 0.79  Assumption147
Quality of life complications Mean  Distribution  
First year after event  
Major amputation above knee 0.20 Normal (0.2,0.22)  151
Major amputation below knee 0.61 Normal (0.61,0.2)  151
MI 0.68 Beta (152,70)  150
DVT or PE 0.75 Beta (54,18)  162
Acute renal failure 0.44 Beta (184,232)  164
Renal failure requiring dialysis 0.44 Beta (184,232)  164
Pneumonia – community 0.90 Beta (180,20)  Assumption147
Pneumonia – hospital 0.85 Beta (170,30)  Assumption147
Stroke – disabling 0.38 Beta (56,91)  150
Stroke – non-disabling 0.74 Beta (109,38)  150
Subsequent years  
Major amputation above knee 0.20 Normal (0.2,0.22)  151
Major amputation below knee 0.61 Normal (0.61,0.2)  151
MI 0.72 Beta (159,62)  150
DVT or PE 0.75 Beta (54,18)  162
Acute renal failure 1.00 Beta (200,0)  Assumption147
Renal failure requiring dialysis 0.44 Beta (184,232)  164
Pneumonia – community 1.00 Beta (200,0)  Assumption147
Pneumonia – hospital 1.00 Beta (200,0)  Assumption147
Stroke – disabling 0.38 Beta (56,91)  150
Stroke – non-disabling 0.74 Beta (109,38)  150
Population norms UK Mean  Distribution  
Age 65–74 0.78 Beta (361,107)  71
Age 75+ 0.73 Beta (229,85)  71
DVT: deep venous thrombosis; EVAR: endovascular aneurysm repair; MI: myocardial infarction; PE: pulmonary embolism; 
OSR: open surgical repair  
Univariate analyses and scenario analyses were performed to estimate the impact of varying 
input parameters and assumptions. A scenario analysis was performed to estimate the impact of 
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the procedure related QoL estimates. The time until the EVAR-treated and OSR-treated patients 
have the same QoL was varied from 18 months to 24 months and 36 months. Furthermore, an 
analysis using QoL estimates from the EVAR-1 trial was also performed. An alternative scenario 
was analysed to estimate the impact of survival modelling methods on the cost-effectiveness of 
EVAR. Instead of using survival based on Schermerhorn et al.142, all-cause mortality (4 year) was 
based on the EVAR-1 trial143. Mortality rates for OSR and EVAR beyond 4-year follow-up were 
modelled as in the base-case analysis using adjusted Dutch national age-and gender-specific 
mortality statistics28. In addition, the cost-effectiveness of EVAR is estimated for a 65 year old 
patient and an 80 year old patient.
Furthermore, probabilistic sensitivity analyses (PSA) were performed by running a Monte Carlo 
simulation of 10,000 simulations of the model. In the PSA, parameters were varied simultaneously 
using a priori defined distribution (Tables 7.1 and 7.3). Gamma distributions were used for costs, 
log-normal distributions for relative risks, beta distributions were used for utility values and 
probabilities. In addition, a cost-effectiveness acceptability curve (CEAC) was created to present 
the probability of EVAR being cost-effective at varying willingness-to-pay thresholds167.
rEsULTs
Base-case analysis
Over a lifetime period, EVAR resulted in more life-years (8.674 LYs versus 8.648 LYs) and QALYs 
than OSR (4.704 QALYs versus 4.669 QALYs) (Table 7.4). These differences primarily occurred 
because EVAR patients (99.2%) had a higher 30-day survival compared with OSR patients (96.7%). 
After that period, the difference in survival diminished (‘survival catch-up’) and patients had a 
survival of 88% after 23 months, independent of the treatment they received. Consequently, 
EVAR patients do not gain any additional life-years after 23 months. 
In the DREAM trial, used as the source of QoL values in the base-case analysis, EVAR patients 
had a higher QoL in the first 2 months than OSR patients, but a lower QoL from 2 months to 18 
months follow-up. After that, no difference in procedure-related QoL was seen between the two 
treatment groups. However, OSR patients have a higher chance of having clinical events (e.g. MI, 
stroke) which leads to a reduced QoL and fewer QALYs compared to EVAR patients. When QoL 
values are combined with survival, there is a small QALY gain of 0.017 after one year, which first 
decreases to 0.013 after two years and then increases slightly to 0.035 over a lifetime.
Over a lifetime period, EVAR resulted in lower costs than OSR (€24,483 versus €25,595) mainly 
due to the lower initial hospital admission (including procedure) costs. Patients treated with 
EVAR were admitted to the hospital for 3.97 days, including 0.27 days on an intensive care unit 
126 | Chapter 7
(ICU), compared with OSR patients who were admitted for 11.5 days, including 2.7 ICU days. 
The device used in an EVAR procedure (€8,000) is more expensive than the device used in an 
OSR procedure (€627) but this difference was offset by the reduction in hospital days. Over the 
years, EVAR became less cost-saving since EVAR patients require more intensive follow-up than 
OSR patients, leading to an increase in average follow-up costs (EVAR €1,656; OSR €499). Follow-
up costs includes only the costs of diagnostic procedures (CT or duplex) and outpatient visits 
of surviving patients; the costs of complications and reinterventions were excluded in these 
calculations but included in the total costs.
In summary, EVAR and OSR can be considered equally effective (0.035), while EVAR is cost-saving 
(€-1,112) compared with OSR.
sensitivity and scenario analyses
Table 7.4 and Figures 7.3 and 7.4 present the results of the uncertainty analyses. The tornado 
diagram (Figure 7.3) presents the impact of the uncertainty per parameter (one-way sensitivity 
analyses) or scenario on either the incremental costs, incremental QALYs and the ICER.
Univariate sensitivity analyses
The price of an EVAR device and the number of ICU days after EVAR and OSR showed the greatest 
influence on the incremental costs (Figure 7.3). Increases in the number of ICU days after EVAR 
meant that EVAR was no longer cost-saving compared with OSR (incremental costs €5,361). The 
most influential parameter on the ICER was the hazard ratio of cardiovascular events.
Scenario analyses
In the base-case analysis, we assumed that there was no difference in QoL between the treatment 
groups after 18 months. When we increased this period to 24 months and 36 months, we found 
a reduction in QALY gain (0.02 and 0.017, respectively). When the QoL results from the EVAR-1 
trial was used, this led to a QALY increase (0.060) since that study found that QoL was equal after 
36 months and the QoL gain of EVAR versus OSR at 1 month follow-up was larger than that was 
used in the base-case analysis. An alternative approach to model survival based on the EVAR-1 
trial resulted in an increase in QALY gain (0.116) since the survival benefit continued during the 
remaining life-years; consequently, EVAR became even more cost-effective compared with OSR. 
A scenario analysis showed that EVAR was more effective (0.068 QALYs) in 80 year old patients 
since the initial gain in survival increases by age, as presented by Schermerhorn et al.142. 
Furthermore, the duration of survival benefit increases by age; 80-year-old EVAR and OSR 
patients showed an equal survival rate of 68% after 4 years, much longer than the duration 
seen with younger patients. For 65 year old patients, EVAR led to a QALY increase of 0.0375 and 
incremental costs of €-723.
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figure 7.3 | Tornado diagrams
EVAR: endovascular aneurysm repair; HR: hazard rate; ICER: incremental cost-effectiveness ratio; ICU: intensive care unit; 
OSR: open surgical repair; QoL: quality of life
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figure 7.4 | ICER plane and CEAC
EVAR: endovascular aneurysm repair; OSR: open surgical repair; PSA: probabilistic sensitivity analysis; QALY: quality adjusted 
life years
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Probabilistic sensitivity analysis
The results of the probabilistic sensitivity analysis (Figure 7.4) showed that in 81% of the 
simulations EVAR was more effective and cost-saving compared with OSR, while in 17.9% of the 
simulations EVAR was less effective but cost-saving. In only 1.1% of the simulations the ICER was 
located in the north-west (0.3%) or north-east (0.8%) quadrant, meaning that EVAR was very 
unlikely to be more expensive than OSR. As can be seen from the ICER plane, the incremental 
costs and effects are negatively correlated. If the chance of experiencing an event after EVAR 
decreases, the total costs of EVAR will decrease and the total QALYs after EVAR will increase. 
The CEAC (Figure 4) presents the chance that EVAR is cost-effective at a particular willingness-
to-pay threshold and shows that EVAR remains the most cost-effective strategy regardless of the 
threshold. If a willingness to pay threshold of €20,000 or €80,000 per QALY gained168 are used, 
EVAR has a high probability (95% and 87.5%, respectively) of being cost-effective compared with 
OSR. 
DisCUssion
This cost-utility analysis estimated the lifetime cost-effectiveness of elective EVAR compared with 
elective OSR in patients with AAA for a Dutch setting. In the base-case analysis, EVAR was more 
effective than OSR (difference of 0.035 QALYs) over a lifetime time horizon, due to the initial 
survival gain in the first 2 years and the reduction in events. EVAR and OSR can be considered 
equally effective since the gain in QALYs is minimal and the uncertainty analyses (PSA) showed 
a large variation in effectiveness (range: -0.129, 0.228 QALY). However, EVAR can be cost-saving 
(€-1,218) compared with OSR (range: €-3,397, €655) due to a shorter hospitalization. Scenario 
analyses showed that EVAR becomes more effective versus OSR when used in older patients, 
when QoL is based on the EVAR-1 trial137 or when mortality is based on the EVAR-1 trial143. 
In line with our results, many of the previous economic evaluations comparing elective EVAR 
with elective OSR concluded that EVAR was more effective than OSR95,140,161,162,169-171, with 
health gain ranging from 0.0012 to 0.42 QALYs. However, four studies estimated a QALY loss 
for EVAR143,144,156,161 (range: -0.01,-0.042). The QALY loss estimated by Brown et al.143, Epstein et 
al.161 and Epstein et al.156 was the result of assuming that the all-cause survival at 2 years or 
8 years follow-up were equal for EVAR and OSR, and assuming a greater hazard of late AAA 
deaths after EVAR. Prinssen et al.144 also found that the initial survival gain was offset by a later 
increase in mortality, which resulted in a negligible survival advantage. In our study, we used 
age-specific data from Schermerhorn et al.142, who found that mortality converged at 23 months, 
48 months and 51 months for patients with a baseline age of 67–74 years, 75–84 years and 85+ 
years, respectively. Thereafter, survival was equal between the EVAR and OSR patient groups. 
Use of this data improves the effectiveness of EVAR compared with the methods used by the 
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previously mentioned studies143,156,161. However, other studies172 have also assumed an equal 
survival after a specific time period or assumed that the initial benefit of EVAR continued without 
any convergence (catch-up) in survival. 
Most previous economic evaluations have reported that the total costs of EVAR were higher 
than those of OSR95,140,144,161,162,169,170,172,173, mainly due to the higher device costs. However, in four 
studies161,171,173,174 EVAR was considered cost-saving since the initial admission costs of EVAR were 
lower than those of OSR due to a reduction in hospital days. In our study, the higher costs of 
the device were offset by the reduction in hospitalization days and an EVAR procedure was less 
expensive than OSR. Consequently, EVAR was cost-saving over a lifetime time horizon compared 
with OSR. 
Most studies140,143,144,156,161,170,172,173 concluded that EVAR is not cost-effective compared with OSR 
due to the high costs of an EVAR procedure; some studies also found that EVAR was associated 
with a slight QALY loss. In contrast, we concluded that EVAR and OSR were equally effective and 
EVAR was cost-saving compared with OSR which was the result of the lower procedure costs. 
The number of hospital days after EVAR used in our study is somewhat lower than in other 
cost-effectiveness studies since those studies used resource use data from older clinical studies. 
The length of hospitalization has declined remarkably since the first generation of EVAR devices. 
Physicians are more experienced with an EVAR and the newer generations lead to fewer peri-
operative and post-operative complications. 
strengths & limitations
This study used long-term results from a large registry from the US142,148, which were considered 
applicable to the Dutch setting for a number of reasons: 1) the results were based on a very 
large population (n=45,660) with six-year follow-up, 2) the large number of clinical events, and 
3) mortality results were presented for different age categories. This registry provides good 
insights into the events that can occur during the first 30 days after the procedures as well as 
the reinterventions that may take place up to six years follow-up. Consequently, our study was 
able to incorporate many clinical events that were significantly different between procedures 
and thereby estimate a more realistic incremental cost-effectiveness ratio. However, the earlier 
cohort of the US registry142,148 also included patients who underwent EVAR using early generation 
devices which may have led to an overestimate of the reintervention rate in the EVAR group and 
an underestimate of the QALY gain of EVAR compared to OSR. 
The procedure costs estimated alongside the clinical trials were not considered applicable for the 
following reasons: 1) resource use and unit costs were considered outdated (e.g. length of stay) 
or 2) resource use and unit costs were based on another country. Therefore, the resource use 
was based on a Dutch registry, reporting outcomes from 2013165 from daily practice and not from 
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a randomized study. Resource use of the registry was combined with the Dutch costing manual153 
to estimate the costs that reflect current treatment practice.
It is important to recognize that the use of data from the older studies like EVAR-1137 could lead 
to different results (and therefore conclusions). However, the results of older studies may say 
very little about the current cost-effectiveness of EVAR versus OSR since newer devices have a 
better technical performance and physicians are more experienced with EVAR. One factor that 
affects the cost difference is the length of hospital stay following EVAR, which has decreased 
considerably over the years. Cost-effectiveness analyses based on older studies may present 
results that may not reflect the ‘real’ cost-effectiveness of EVAR nowadays.
Brown et al.143 included the chance of death while waiting for the procedure since they believed 
that excluding it could lead to bias. However, we did not include the chance of events before the 
procedure since the clinical experts were of the opinion that there was no difference between the 
procedures in mortality, waiting time and QoL. Consequently, the incremental survival between 
OSR and EVAR are correct but it may be possible that survival per strategy is somewhat lower.
The short-term (30 days) clinical events were based on Schermerhorn et al.142. One could argue 
that this study reported (non-)fatal events, which may lead to an overestimation of the clinical 
events for both treatment groups. However, the impact of this assumption will be minimal since 
short term clinical events are only included for patients who have survived the first 30 days. 
OSR has been associated with sexual dysfunction175 which may reduce QoL. Although sexual 
functioning was not explicitly incorporated in our analysis, it may have been included in the 
analysis because of our use of prospectively collected QoL (EQ-5D) data from the DREAM trial136, 
although the EQ-5D may not be sufficiently sensitive to changes in sexual functioning. Any steps 
to include sexual functioning more adequately would likely result in more favourable results for 
EVAR. 
This study assessed the cost-effectiveness of EVAR versus OSR in patients fit and anatomically 
suitable for both procedures. Some of the input values used in our analyses were based on the 
EVAR-1 trial143, which involved the selection of a small subgroup of the AAA population since 
patients needed to be fit for both procedures. Consequently, the effectiveness of EVAR and OSR 
can vary across the AAA patient population. EVAR will be more effective if it was compared to 
surveillance in patients who were not fit for OSR due to comorbidities. 
Furthermore, input data was based on published literature and the proportion men included 
in these studies is approximately 85%–95% since AAA is more common in men than in women. 
This study has estimated in the base case the cost-effectiveness of EVAR for a cohort of patients 
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with an average age of 72 years and 87% was men based on the DSAA registration165. The 
cost-effectiveness of women with AAA electively treated with EVAR or OSR should have been 
investigated separately but no information specific for women is available.
The Dutch guidelines for pharmacoeconomic research recommend the use of a societal 
perspective when assessing the cost-effectiveness of an intervention146. In this study we did not 
include productivity costs, travel costs and informal caregiver burden since we assumed that 
this is comparable between the two strategies. Prinssen et al.144 have included productivity costs 
and concluded that the OSR group (€363) had higher productivity costs than the EVAR group 
(€243). Tarride et al.173 estimated a difference of $16 between the patients groups. However, 
the proportion of patients with paid employment is relatively low since these patients are 
generally older than 65 years. Therefore, the difference in productivity costs will be minimal 
as estimated by Tarride et al.173 and Prinssen et al.144. Travel costs, indirect medical costs, and 
informal caregiver burden were not included in these two studies but it is reasonable to assume 
that indirect costs and outcomes will not influence the cost-effectiveness of EVAR. However, 
further research is required to estimate the impact of EVAR versus OSR on informal caregiver 
burden and indirect medical costs.
This study used several sources and assumptions to estimate the cost-effectiveness of EVAR 
versus OSR. The combination of data from multiple sources could be viewed as a limitation 
because it could lead to a biased estimate of EVAR’s cost-effectiveness. We therefore conducted 
various sensitivity analyses to assess the robustness of our results and to quantify the degree 
of uncertainty. However, we do believe that EVAR and OSR can be considered equally effective. 
Furthermore, due to reductions in hospital days and complications EVAR was cost-saving. 
implications
In 2013, 72%145 of the Dutch patients with AAA treated electively are undergoing EVAR. Various 
factors influence the procedure that a patient receives; the costs of a procedure and the 30-day 
mortality are just two of them. Clinicians are more likely to choose EVAR for patients suitable 
for both procedures because it is less invasive. Based on expert opinion, patients only undergo 
OSR when they are anatomically unsuitable for EVAR, very young or if a patient prefers OSR over 
EVAR. 
Patient are more likely to prefer EVAR over OSR since people are often risk-averse meaning that 
they would avoid the short term higher 30-day mortality of OSR even when they know that 
mortality converges after some years. 
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Conclusions
This study showed that EVAR and OSR can be considered equally effective and that EVAR can be 
cost-saving compared with OSR. Therefore, EVAR can be considered as a cost-effective solution 
for patients with AAA. However, the cost-effectiveness of EVAR is highly dependent on the price 
of the EVAR device and the reduction in hospital days, complications and 30-day mortality.
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ABsTrACT
Background: Patients with juxta-renal (JRAAA) or thoraco-adbominal aortic (TAAA) aneurysms 
requiring treatment may undergo open surgical repair (OSR) or a complex endovascular aneurysm 
repair (EVAR) such as a fenestrated (fEVAR) or branched EVAR (bEVAR). This article describes and 
discusses potential methods of evaluating the cost-effectiveness of fEVAR/bEVAR in JRAAA and 
TAAA and the challenges in that assessment.
methods: This study has four steps: literature review of (cost-)effectiveness, design of 
mathematical model, populating the model, and analysis.
results: The framing phase showed that fEVAR/bEVAR in JRAAA/TAAA should be evaluated for 
two populations: 1) fEVAR/bEVAR versus OSR in patients fit for OSR, and 2) fEVAR/bEVAR versus 
no surgery in patients unfit for OSR. The literature reviews in the assessment phase yielded no 
relevant studies. We constructed two related models: a short-term (30-day) model of costs and 
effectiveness and a long-term model estimating lifetime costs and effectiveness beyond 30 days. 
Both models include complications, reinterventions and mortality. In the end, we concluded 
that a cost-effectiveness analysis would not be meaningful because of insufficient effectiveness 
evidence, large variation in technical features regarding fEVAR/bEVAR stent-grafts, and rapid 
changes in fEVAR/bEVAR technology. 
Conclusion: It is currently impossible to estimate the cost-effectiveness of fEVAR or bEVAR. Their 
cost-effectiveness and the related uncertainty can only be evaluated if there is some evidence 
on the effectiveness and costs of fEVAR/bEVAR. The model developed in this study can be used 
to determine which data should be collected to ensure a proper assessment of fEVAR/bEVAR. 
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inTroDUCTion
Standard endovascular aneurysm repair (EVAR) is an established choice of treatment for 
abdominal aortic aneurysm (AAA) in anatomically suitable patients, with certain advantages over 
open surgical repair (OSR). However, standard EVAR is not feasible in complex aneurysms such 
as juxta-renal (JRAAA), para-renal and thoraco-abdominal aortic aneurysms (TAAA). Advanced 
endovascular technologies such as fenestrated and branched EVAR (fEVAR/bEVAR) have been 
developed over the last decade for such patients. Although fEVAR/bEVAR was originally used 
predominantly in patients considered physiologically unfit for OSR, fEVAR/bEVAR are now a 
frequently chosen option for most patients. 
Many observational studies176-178 and case series have observed a reduction in mortality and 
morbidity after fEVAR/bEVAR compared with OSR, despite fEVAR/bEVAR patients being older and 
having more co-morbidities. However, a thorough investigation of its comparative effectiveness 
[e.g. a randomized controlled trial (RCT)] versus open repair has never been conducted. In 
addition, it is not appropriate to extrapolate the results of randomized controlled trials of EVAR 
for infrarenal aneurysms since performing an OSR in patients with JRAAA or TAAA is associated 
with a higher perioperative mortality risk and increased use of critical care compared with OSR 
in infrarenal AAA patients. 
The use of fEVAR/bEVAR techniques has increased rapidly over the last decade and continues 
to increase, despite uncertainties in their comparative effectiveness13. Therefore there is a 
need to examine the value of fEVAR/bEVAR in a comprehensive manner. With this in mind, the 
National Institute for Health Research (NIHR) Health Technology Assessment programme began 
a ‘short report’ in 2013 on the cost-effectiveness of fEVAR/bEVAR in JRAAA and TAAA. This article 
describes and discusses our attempt to assess the cost-effectiveness of fEVAR/bEVAR in that 
study13 and the challenges that arose during the assessment.
mETHoDs
The estimation of the cost-effectiveness of fEVAR and bEVAR from an UK NHS perspective was 
performed in two phases: framing phase and assessment phase. These phases can be compared 
with the first two phases that are used in a NICE technology appraisal process; scoping and 
assessment. Since this study was a short report performed for NIHR, it was based on the same 
methodology.
In the first “framing” phase, the boundaries of the study were set and justified179. Key points that 
are considered in the framework are: 1) objective of the analysis, 2) audience for the evaluation, 
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3) viewpoint of the analysis, 4) analytic time horizon, 5) target population, 6) intervention, and 
7) alternative interventions for comparison179. These key points can be compared with the issues 
that need to be addressed in the scoping phase of a NICE appraisal180.
 
The second “assessment” phase, was divided into four separate steps: 1) systematic review of 
current evidence on the effectiveness and cost-effectiveness, 2) development of the structure of 
the model, 3) populate the model, and 4) analyses. Although a systematic review is a mandatory 
component of a full technology assessment report, it is not required in an economic evaluation180. 
We nevertheless conducted a systematic review to avoid any possibility of ‘cherry picking’ of 
values for input parameters, in line with the ISPOR Taskforce Reports on ‘modeling good research 
practices’132. 
Both the clinical and cost-effectiveness reviews are conducted according to NICE guidelines180. 
The effectiveness review focused primarily on studies reporting on RCT data comparing fEVAR/
bEVAR with OSR or no surgery since these studies provided the most valid evidence of relative 
efficacy. If no RCTs were identified, the review was to be extended to include (non-randomized) 
comparative studies. Potential bias arising from the study design of these studies was explored. 
The synthesis of outcome data was performed using a meta-analysis when sufficient relevant 
and valid data is available. The cost-effectiveness review focuses on studies evaluating the cost-
effectiveness of fEVAR/bEVAR. Furthermore, studies reporting on useful outcomes [e.g. quality 
of life (QoL), costs, resource use or transition probabilities (e.g. reinterventions)] to inform the 
decision model are also potentially relevant. 
The cost-effectiveness analysis (CEA), the last three steps of the assessment phase, was conducted 
according to the NICE guide to the methods of technology appraisal180. Specific requirements 
(e.g. discount rate, time horizon and perspective) are recommended in this guideline.
rEsULTs
1 | framing phase
Objective and audience
The objective of this study is to inform the NHS on the cost-effectiveness of fEVAR/bEVAR in 
patients diagnosed with JRAAA or TAAA. 
Disease and population
Patients with an enlarged AAA (diameter >5 cm) located close to the origin of the renal arteries, 
juxta-renal or in both the thoracic and abdomen are diagnosed with JRAAA or TAAA, respectively. 
Those patients can be divided in two main groups, those fit for OSR and those unfit for OSR. 
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Without the existence of the interventions fEVAR or bEVAR, patients would be treated with 
an OSR if considered to be fit enough. Patients who are not fit for OSR would be treated with 
no surgery, i.e. best medical therapy. Fitness of patients for an OSR can be determined based 
on the fitness criteria that were used for the EVAR trials143, which evaluated EVAR with either 
OSR (EVAR-1 trial181) or medication (EVAR-2 trial182) for the treatment of AAA depending on the 
fitness of the patient. Patients were considered unfit for OSR if a patient had 1) an American 
Society of Anaesthesiology (ASA) grade of IV, 2) cardiac symptoms, 3) renal symptoms, or 4) 
respiratory symptoms. However, these guidelines to determine the fitness for OSR were subject 
to treatment variation143. Aneurysm size was also important for determining the fitness of a 
patient since patients who were earlier described as ‘unfit for open repair’ and later developed 
a larger aneurysm were suddenly deemed ‘fit for the procedure’143.
Potentially, subgroups can be determined by age, gender, whether dialysis dependent, aneurysm 
size, fitness, number of target vessels, whether elective or emergency and symptomatic 
versus non-symptomatic since these characteristics may have a substantial impact on the 
cost-effectiveness. Furthermore, the type of OSR can also lead to differences in perioperative 
mortality176 and consequently in the cost-effectiveness of fEVAR/bEVAR.
Interventions and comparators
Based on the fitness for OSR two treatment comparisons for this population were evaluated: 1) 
fEVAR/bEVAR versus OSR and 2) fEVAR/bEVAR versus no surgery. 
fEVAR and bEVAR are specially manufactured stent-grafts with openings to allow blood to reach 
branches of the aorta13. This procedure is performed endovascular and is therefore less invasive 
than OSR since during an OSR an aortic clamp must be placed leading to cardiovascular instability 
and stress. Also, open surgery for TAAA frequently requires cardiopulmonary bypass and on 
occasion circulatory arrest. The no surgery strategy can be defined as optimal conservative 
care, i.e. patients should receive statins, beta-blockers, antihypertensives, antiplatelets, and/or 
lifestyle advice. Full descriptions of the interventions are reported in the full report13. Ideally, the 
cost-effectiveness of fEVAR and bEVAR should be evaluated separately since the morbidity and 
mortality may differ between procedures, however this was not possible.
Complications due to a fEVAR/bEVAR procedure that can occur peri-operatively or post-
operatively are 1) aneurysm or laparotomy related reinterventions (e.g. conversion from 
endovascular repair to open repair, bowel resection, amputation of the lower leg) and 2) medical 
complications (e.g. myocardial infarction (MI), stroke, deep venous thrombosis (DVT), pulmonary 
embolism, pneumonia, renal failure). Patients undergoing OSR are associated with higher short-
term mortality and medical complications; however aneurysm-related reinterventions are more 
frequently performed in patients undergoing endovascular repair142. 
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Viewpoint, health outcome measures and costs
The CEA, steps three and four of the assessment phase, estimates the costs from a NHS and 
personal and social services perspective; i.e. including all direct costs. It is required to draw 
data for the costs from routine NHS sources (e.g. NHS reference costs, Personal Social Services 
Research Unit (PSSRU), British National Formulary (BNF)), and expert opinion where necessary. 
Adopting the NHS perspective implies that all direct health effects (quality adjusted life years), 
whether for patients or other people, of all treatment strategies need to be estimated. According 
to the NICE guidelines, costs and outcomes need to be discounted at 3.5% per year180.
Analytic horizon
The costs and outcomes in the CEA are preferably estimated for a time horizon that is long 
enough to reflect all important differences in costs and outcomes between the technologies 
being compared. FEVAR/bEVAR, OSR and no surgery do lead to differences in survival or benefits 
that persist for the remainder of a person’s life and thus a lifetime time horizon is required. 
2 | Assessment phase
2.1 | Systematic review of currently available evidence
As part of the assessment phase, two systematic reviews were performed on the clinical 
effectiveness and cost-effectiveness of fEVAR/bEVAR. The systematic review on clinical 
effectiveness showed that there were no prospective comparative studies of fEVAR/bEVAR 
in either those fit or unfit for OSR13. Treatment allocation was based on physician or patient 
preferences and not randomized (based on chance) and therefore patient groups were not 
comparable (i.e. age and comorbidities) leading to bias. Thus, no source of information on efficacy 
of fEVAR/bEVAR in preventing mortality and serious complications in direct comparison to OSR 
was available. The cost-effectiveness review resulted also in zero included studies focussing on 
the costs, effectiveness or cost-effectiveness of fEVAR/bEVAR, OSR or no surgery in JRAAA or 
TAAA patients. The full report contains the full searches and results of both reviews13. 
2.2 | Structure of the model
A decision model was created since no existing studies evaluating the cost-effectiveness of 
fEVAR/bEVAR were found. The model consists of two separate models for both short-term and 
long-term outcomes. The short-term model, a decision tree, estimates costs and effects pre-
operatively (including the effect of waiting time), intraoperative, and post-operative up to 30 
days. A long-term model estimates the lifetime costs and effects of the individuals who have 
survived the initial procedure and the 30 day post-operative period. The long-term model 
structure is adopted from previously published HTA reports for the evaluation of EVAR by Brown 
et al.143 and Chambers et al.183 since it is likely that the treatment and disease pathways of EVAR 
and fEVAR/bEVAR are comparable, even if the input parameters are not. See Appendix 2 of the 
full report13 for the quality of these studies based on the Drummond et al. checklist184. 
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Model structure | short-term model (fit for OSR)
Figure 8.1 shows the structure for a short-term decision model for this comparison. It is likely 
that patients have to wait until the actual surgery (OSR or fEVAR/bEVAR) can be performed. In 
particular, patients who will be treated with fEVAR or bEVAR have to wait since a large proportion 
of the patients will have to wait for custom-made devices while the inventory of off-the-shelf 
devices is expanding. The inclusion of waiting time in the model was deemed to be important 
since a difference in waiting time could lead to differences in mortality. 
Patients who actually receive fEVAR or bEVAR may later switch to an OSR due to problems such as 
an endoleak or stent-graft migration, therefore it was important to incorporate these conversions 
into the model. Based on a study evaluating the cost-effectiveness of EVAR183, it was assumed 
that the conversion took place during the time-span of the short term model and that it was not 
possible that patients undergoing OSR are converted to EVAR. 
Furthermore, mortality (all-cause and aneurysm related) and complications during the first 30 
days are incorporated in the short-term model. Medical complications can be categorised into 
four types: cardiac complications (e.g. myocardial infarction, DVT), pulmonary complications (e.g. 
pneumonia), renal complications (e.g. renal failure), and neurological complications (e.g. stroke). 
Furthermore, aneurysm-related and laparotomy related reinterventions are also incorporated in 
the model structure. A reintervention for patients who underwent fEVAR or bEVAR could either 
be an OSR or again an endovascular procedure. Reinterventions are included as complications. 
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Model structure | short-term model (unfit for OSR)
The same assumptions described above for those fit for OSR apply for patients unfit for OSR. 
Waiting time is not an issue for patients treated with medication only and in some cases 
conversion from fEVAR or bEVAR to OSR might not be possible since patients are considered not 
fit for OSR. Figure 8.2 shows a structure for a short-term decision model for this comparison. 
Model structure | long term model 
The long-term model estimates lifetime costs and effects of patients who have survived the 
waiting time before the procedure and the 30-day post-operative period. For such a long-term 
model, a Markov model seems most appropriate (Figure 8.3). This model consists of two chronic 
health states: 1) event-free and 2) (non-)aneurysm related death and this structure is similar 
to the economic evaluation of EVAR versus OSR presented by Chambers et al.183. Patients start 
out in the event-free state and have a risk of a non-fatal event leading to readmission. Patients 
may be readmitted to the hospital if, for example, a reintervention is required. Note that the 
readmission state is a temporary health state: after the readmission patients move back to the 
event-free state. Eventually, all patients will die from aneurysm-related causes or other causes. 
As in the economic evaluation by Chambers et al.183 it was assumed that patients who convert 
from EVAR to OSR during the primary admission have the same long-term prognosis as patients 
initially undergoing OSR.
The cycle length needs to be short enough to ensure that no more than one event occurs during 
one cycle. A cycle length of 6 months was considered appropriate according to the timing of the 
events used by Brown et al.143. A half-cycle correction was incorporated and thus it was assumed 
that transitions occur half-way through the cycle. 
Non-fatal 
readmission 
Non-
Aneurysm 
related death 
Aneurysm 
related death 
Event-free 
figure 8.3 | Long term model
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2.3 | input parameters
The third step in the assessment phase is to populate the previously proposed model. Estimates 
for the input parameters need to be provided by the systematic reviews on clinical effectiveness 
and cost-effectiveness, literature or expert opinion. Two experts were consulted; however these 
experts were of the opinion that it was not feasible to provide valid estimates for the input 
parameters since there exists vast variation in stent-grafts used between patients and between 
centres. Since no studies were included in the systematic reviews and we were unable to receive 
estimates from clinical experts we were not able to complete this third step. Nevertheless, 
suggestions on parameters that need to be included are provided below.
Transition probabilities
For the short-term model (Figures 8.1 and 8.2) it is important to collect data in the period before the 
treatment during waiting time and up to 30 days after the procedure. Data concerning mortality, 
conversions, reinterventions, and complications are important for this model. The structure of 
the long-term model (Figure 8.3) requires three time-dependent transition probabilities: 1) non-
aneurysm related mortality, 2) aneurysm related mortality, and 3) non-fatal readmissions. These 
transition probabilities need to be based on general population mortality estimates185 (non-
aneurysm related mortality) and on clinical effectiveness data from comparative studies. 
Patients could be readmitted due to a clinical event but also to undergo a reintervention. Brown 
et al.143 did not incorporate clinical events such as MI or stroke in the model since there was no 
significant difference between the treatment strategies (OSR versus EVAR) in the EVAR-1 trial. 
While this assumption might be valid for the evaluation of EVAR, the results of clinical studies 
will show if this assumption also holds for an evaluation of fEVAR or bEVAR. Moreover, an RCT is 
likely to be underpowered to detect significant effects for these events. Generally, when events 
like MI or stroke are considered clinically relevant, they should be included in the long-term 
model since such clinical events have a substantial impact on the quality of life of patients and 
healthcare costs. Furthermore, the impact of radiation of the CT scans used during follow-up and 
of the fluoroscopy used during the interventions could be incorporated in the model if this is 
deemed important. However, the mean age of the EVAR patients included in the EVAR-1 trial143 
is relatively high (74.1±6.1) and thus the impact of radiation on the incremental costs and effects 
will probably be negligible. 
Since a lifetime time horizon is proposed, short term clinical data from clinical studies need 
to be extrapolated to capture all differences in costs and effects between treatments. Crucial 
assumptions concerning survival have to be made when data is lacking. Brown et al.143 estimated 
the cost-effectiveness of EVAR compared with OSR and assumed in the base-case analysis that 
there is no difference in the rate of AAA deaths between treatments after eight years since the 
risk of AAA death diminishes over time. Chambers et al.183 used a constant hazard ratio (1.072) for 
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non-aneurysm related death for EVAR versus OSR until the non-aneurysm related survival curves 
converged. The impact of these assumptions on the cost-effectiveness needs to be explored 
through sensitivity analyses. 
Table 8.1 | Cost data required for the cost-effectiveness analysis
Category resource use Unit costs
Procedurea
Preoperative embolization p/procedure
Cardiopulmonary bypass and reperfusion p/procedure
Theatre time min p/min
Preoperative stay days p/day
Intensive care unit stay days p/day
High dependency unit stay / coronary care unit days p/day
Ward stay days p/day
Red blood cell units p/unit
Platelets units p/unit
Fresh frozen plasma units p/unit
Fluoroscopic time min p/min
Contrast ml p/ml
Device & consumables actual & list prices
medication use
Statins mg p/mg
Antiplatelet mg p/mg
Anticoagulant mg p/mg
Betablocker mg p/mg
Antihypertensive mg p/mg
follow-upb
Outpatient visits number of visits p/visit
CT-scan number of scans p/scan
Complications c
Intensive care unit stay days p/day
High dependency unit stay days p/day
Ward stay days p/day
Outpatient visit visits p/visit
Emergency room visit visits p/visit
Proceduresd p/procedure
a Primary intervention, conversions to OSR and reinterventions. Including complications during primary admission; b 1 
year and subsequent years; c Cardiovascular complications, renal complications, pulmonary complications, neurological 
complications. The resource use should be measured of each complication separately; d This will depend on the complication
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Costs
For the short-term model is it important that valid resource use estimates (e.g. theatre time or 
blood products) of the procedures are used. Table 8.1 shows the resource use and unit costs that 
at least need to be collected.
Tables 8.2 and 8.3 present estimates of some of the key parameters identified in Table 8.1. 
This overview is based on five clinical studies that were identified in the clinical effectiveness 
review but were excluded based on study design due to selective treatment assignment13. Thus, 
it is crucial to realize that these values should not be used for the economic model without 
adjustments; instead, they should be seen as indicative for which parameters might differ 
between treatments.
Table 8.2 | Estimates of key parameters to estimate the costs of OSR
Parameter min max mean source
Mean theatre time (min) 89 150 120 178,186
Median theatre time (min)   235 176
Mean blood loss (mL)   3436 177
Median blood loss (mL) 1550 2000 1775 176,186
Mean stay (days) 7.2 21.7 14.0 177,178,186
Median stay (days)   12 176 
Mean ICU stay (days) 7.4 29.3 18.3 176,177
Median ICU stay (days)   28 176,178
ICU: intensive care unit
Outcomes
The outcomes of interest for the model are life years (LY) and quality adjusted life years 
(QALY). LYs are directly estimated with the model using the number of years that patients live 
after each intervention. Then LYs should be combined with quality of life (QoL) estimates to 
obtain the number of QALYs for each intervention. It is important to obtain QoL estimates of 
patients treated with fEVAR/bEVAR, OSR or with no surgery in order to assess differences in 
QALYs between a minimal invasive procedure (fEVAR/bEVAR) versus an invasive procedure (OSR) 
and also to compare fEVAR/bEVAR with no procedure. Quality of life was measured with the 
EQ-5D alongside the EVAR-1 and 2 trials181,182 (Tables 8.4 and 8.5). These values might also be 
appropriate for patients with JRAAA or TAAA since it is likely that these patients have the same 
quality of life as patients with AAA. 
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2.4 | Analyses
The last step is to actually perform the analyses when the model is populated. Since populating 
the model for all parameters was not possible, it was not possible to conduct this last step of the 
assessment phase.
The base-case analysis should report the (incremental) cost-effectiveness of fEVAR/bEVAR versus 
OSR and fEVAR/bEVAR versus no surgery in both disaggregated and aggregated forms.
In addition, subgroup and sensitivity analyses should be performed. The impact of parameters 
such as the costs of the endovascular procedures and 30-day mortality on the cost-effectiveness 
of fEVAR or bEVAR should be evaluated in univariate sensitivity analyses. Scenario analyses 
estimating the influence of late non-aneurysm mortality, late aneurysm mortality, and 
complication estimates on the cost-effectiveness should be performed. Furthermore, it could be 
useful to conduct best-case and worse-case scenario analyses and to produce tornado diagrams. 
Probabilistic sensitivity analysis should be performed to estimate the influence of parameter 
uncertainty on the ICER. Cost-effectiveness acceptability curves could be very informative. Lastly, 
structural uncertainty should be addressed by varying structural assumptions (e.g. disease 
progression of patients who are converted from fEVAR/bEVAR to OSR).
Table 8.3 | Estimates of key parameters to estimate the costs of fEVAR/bEVAR 
Parameter min max mean source
Mean theatre time (min) 266 290 278 178,186
Median theatre time (min)   300 176
Mean blood loss (mL)   370 177
Median blood loss (mL) 500 1250 875 176,186
Mean fluroscopy time (min) 54 88 71 178,186
Mean contrast (ml) 156 288 222 178,186
Mean stay (days) 3.5 10.5 7.2 177,178,186
Median stay (days)   7 176
Mean ICU stay (days) 0.9 6.2 3.6 176,177
Median ICU stay (days)   4 176
ICU: intensive care unit
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Table 8.4 | Quality of life estimates (EQ-5D) EVAR-1 trial181
Timepoint EVAR (N=543) OSR (N=539)
  mean sD n mean sD n
Baseline 0.75 0.22 541 0.74 0.23 531
0–3 months* 0.73 0.21 238 0.67 0.25 245
3–12 months* 0.71 0.25 476 0.73 0.23 414
12–24 months* 0.74 0.24 398 0.75 0.25 371
* Post-operative
Table 8.5 | Quality of life estimates (EQ-5D) EVAR-2 trial182
Timepoint EVAR (N=166) No surgery (N=172)
 mean sD n mean sD n
Baseline 0.58 0.31 164 0.63 0.28 171
0–3 months* 0.57 0.28 48 0.56 0.29 92
3–12 months* 0.64 0.28 122 0.60 0.26 120
12–24 months* 0.65 0.24 88 0.60 0.30 68
* Post-operative
DisCUssion
This study presented the first two phases of the appraisal of fEVAR/bEVAR; framing and 
assessment. The framework of the study, framing phase, is described in this study. Patients 
diagnosed with JRAAA or TAAA could be treated with fEVAR/bEVAR, OSR or no surgery 
depending whether they are fit for OSR or not. All interventional treatments are associated with 
complications such as reinterventions, MI or stroke. Of the four steps of the assessment phase 
we were able to conduct only the first two steps: 1) performing systematic reviews of the clinical 
effectiveness and the cost-effectiveness of fEVAR/bEVAR and 2) producing the structure for a 
decision model. Both reviews resulted in zero included studies. A model structure was proposed 
based on a previously published report on the cost-effectiveness of EVAR183. The last two steps, 
populating the model and performing the analyses, could not be completed for several reasons: 
1) evidence on clinical effectiveness of the interventions is lacking, 2) large variation in technical 
features of the fEVAR/bEVAR stent grafts and consequent variation in the effectiveness and costs 
across the stent grafts and patients, making expert solicitation problematic, and 3) fEVAR/bEVAR 
intervention is an evolving area and consequently the results will not be valid for the near future. 
However, recommendations on populating the model and on the analyses that can be performed 
are provided in this study. Furthermore, the type of data that need to be collected are described.
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The cost-effectiveness of fEVAR/bEVAR could not be estimated since no evidence on efficacy and 
costs were available and therefore it remains uncertain whether the extra cost of fEVAR/bEVAR 
compared with the alternatives is justified by the advantages for patients. Some health economist 
would argue that it is always possible to model the cost-effectiveness of an intervention since 
uncertainty analyses can be performed. Univariate and multivariate sensitivity analyses or 
threshold analyses are appropriate methods to estimate the impact of parameter uncertainty 
on the cost-effectiveness; however in this specific case, in our opinion, too many parameters 
were uncertain making these types of analyses less worthwhile. Value of information analyses, 
estimating the expected value of perfect information for a model, specific parameters or sets 
of parameters187, could have been performed although it is very clear that more evidence on 
efficacy and costs is required. Despite the fact that it is important to perform a CEA, we are of the 
opinion that no meaningful conclusions can be drawn from such a model other than that more 
research is required to collect data to inform the model which is already clear without filling the 
model with arbitrary input values.
research priorities
Given that there is clearly crucial uncertainty in many input parameters, including probability 
of technical success (target vessel perfusion), risk of death, durability (risk of relapse), risk 
of adverse events and quality of life, there is a need for an RCT, or at least a well-conducted 
prospective cohort study with proper comparability at baseline and statistical techniques 
to adjust for potential confounding. Also, we recommend that this should be at least in the 
population of younger, fitter patients, i.e. those for whom OSR is suitable, in order to answer the 
question whether fEVAR or bEVAR is clinically effective or cost-effective in comparison with OSR. 
Ideally, there should also be one RCT for each of fEVAR and bEVAR and consideration should also 
be given to separate trials in the non-OSR eligible population. Preferably, such a trial should be 
long enough to identify patients who develop longer-term problems such as renal failure. 
When considering an RCT evaluating fEVAR/bEVAR, Canavati et al.176 have identified that it 
can be a challenge to include a sufficient number of patients so that subgroup analyses with 
enough statistical power can be performed. Subgroup analyses are important as there will be 
large variation in both procedures but especially in open procedures for this indication leading 
to variation in operative risk. Greenberg et al.188 have also raised the challenge of including 
sufficient patients. We therefore recommend a multicentre study. However, Greenberg et al.188 
also recognised the challenge of disseminating endovascular skills and the rapid technology 
improvements that occur for branched devices. It is important to keep in mind that a learning 
effect can exist and this can negatively influence the perioperative mortality of these procedures. 
Verhoeven et al.189 have recognised this problem and suggested that a learning curve has to 
be taken into account because half of the occlusions in non-stented fenestrations or scallops 
occurred in fEVAR interventions that were performed in the early stage. Therefore, we 
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recommend strict criteria in terms of surgeon experience, centre experience (e.g. 50 fEVAR and/
or 25 bEVAR procedures in the last 3 years), type of stent graft and OSR technique. Also, a ‘tracker 
trial’, i.e. one where the intervention is allowed to change with improvements in technology, 
might be considered190. Ideally, subgroup analyses could also be undertaken to investigate the 
effect of risks such as aneurysm size and presence of comorbidities.
In addition, we recommend that the CEA should be conducted alongside the RCT or other 
prospective cohort study. Ideally, in order to take into account both the short- and long-term 
economic consequences, this ought to be constructed as a model as described in the result 
section. Furthermore, in designing the prospective study, there is the opportunity to collect 
primary data to inform such a model, such as resource use and utilities, as specified in detail 
in the result section. When such a trial is conducted the presented structure can be used to 
estimate the cost-effectiveness of fEVAR/bEVAR.
Conclusion
Given that not all steps of the assessment phase could be conducted, it remains uncertain 
whether fEVAR or bEVAR are cost-effective. However, this study gives a clear model structure 
that can be used to inform decisions about which data should be collected, and can be a first step 
in the development of a final model once data collection has taken place. 
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ABsTrACT
objectives: Decision analytic modelling is essential in performing cost-effectiveness analyses 
(CEAs) of interventions in cardiovascular disease (CVD). However, modelling inherently poses 
challenges that need to be dealt with since models always represent a simplification of reality. 
The aim of this study was to identify and explore the challenges in modelling CVD interventions.
methods: A document analysis was performed of 40 model-based CEAs of CVD interventions 
published in high-impact journals. We analysed the systematically selected papers to identify 
challenges per type of intervention (test, non-drug, drug, disease management programme, and 
public health intervention), and a questionnaire was sent to the corresponding authors to obtain 
a more thorough overview. Ideas for possible solutions for the challenges were based on the 
papers, responses, modelling guidelines, and other sources.
results: The systematic literature search identified 1,720 potentially relevant articles. Forty 
authors were identified after screening the most recent 294 papers. Besides the challenge of 
lack of data, the challenges encountered in the review suggest that it was difficult to obtain 
a sufficiently valid and accurate cost-effectiveness estimate, mainly due to lack of data or 
extrapolating from intermediate outcomes. Despite the low response rate of the questionnaire, 
it confirmed our results.
Conclusions: This combination of a review and a survey showed examples of CVD modelling 
challenges found in studies published in high-impact journals. Modelling guidelines do not 
provide sufficient guidance in resolving all challenges. Some of the reported challenges are 
specific to the type of intervention and disease, while some are independent of intervention 
and disease.
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inTroDUCTion
Decision analytic modelling when performing economic evaluations of interventions in 
cardiovascular disease (CVD) is challenging. For example, modelling is necessary if extrapolation 
of short-term or intermediate results to long-term outcomes is required and numerous strategies 
need to be evaluated without direct evidence. Thus, modelling inherently poses challenges that 
need to be dealt with since models always represent a simplification of reality. The presence of 
challenges could be dependent on the type of intervention or the phase of disease in which the 
intervention would be used. 
There are several ways to deal with the challenges in obtaining an accurate, precise and valid 
estimate of the cost-effectiveness. The International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM) have recently 
published a series of recommendations for best practice in performing cost-effectiveness 
analyses based on a model132,187,191-195. These recommendations suggest some practical solutions 
to present challenges in modelling. However, these recommendations are not specific for any 
type of disease or intervention and therefore this review aims to identify and analyse challenges 
(e.g. multiple indications) in modelling the cost-effectiveness of CVD-interventions that currently 
exist in the field. Furthermore, we present ways to address the challenges based on current 
economic modelling guidelines and the opinions of experts from the field.
mETHoDs
In order to identify current challenges in the field of CVD, a document analysis was performed of 
model-based cost-effectiveness analyses (CEA) of CVD-interventions that were recently published 
(ever since January 2009) in disease specific, health economical and general medical journals. In 
addition, a questionnaire was sent to the corresponding authors of the selected papers to obtain 
a more thorough overview of current CVD-modelling challenges.
selection
To select systematically relevant papers, we used a search string that contained both cost-
effectiveness terms, based on the validated NHS-EED cost-effectiveness filter196, and a disease 
specific MeSH term (‘cardiovascular disease’).The search was performed on May 8, 2013. We 
assumed that the papers published in journals with a relatively high impact factor are more 
susceptible to complicated challenges. Therefore, we limited the search results to twelve relatively 
high impact factor journals in 3 categories: cardiovascular medicine, general medicine and health 
economics/health technology assessment (HTA) journal. To select these twelve journals we 
sorted all possible journals per category on impact factor, based on journal citation reports®197 
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and included the four highest ranked journals that also published sufficient cardiovascular 
CEAs. The following journals were selected in the cardiovascular medicine category: Circulation, 
European Heart Journal, Journal of the American College of Cardiology, and International 
Journal of Cardiology; in the general medicine category: The Lancet, New England Journal of 
Medicine, The Journal of the American Medical Association, and Annals of Internal Medicine; 
and in the health economical category: Value in Health, PharmacoEconomics, Health Technology 
Assessment, and Medical Decision Making.
We sorted the search results (via Ovid MEDLINE®) of the twelve journals on entry date and 
selected the most recent CEAs or methodological papers presenting results, both based on 
modelling methods and evaluating a CVD-related intervention, until we reached a convenience 
sample of 40 unique corresponding authors. Authors were selected if they met the following 
inclusion criteria: they should have evaluated a CVD intervention using modelling methods and 
could only be included once as a corresponding author. The most recent publication of authors 
that met inclusion criteria was included. 
Document analysis
Using the 40 publications, we extracted CVD modelling challenges explicitly mentioned in the 
methods and discussion sections of the papers and determined the frequency of these challenges 
over all papers. Before data extraction, a list with challenges was created to identify possible 
challenges that were present in the studies. These challenges were based on our own experience 
and that of five other researchers with sufficient experience (3–15 years) in performing model-
based CEAs. A challenge was added to the list when it was described in the paper but not included 
in the existing list. For each paper, two reviewers (LB and WR or JS) identified the challenges 
described in the methods and discussion sections. To be complete, we included the identified 
challenges of both reviewers after we carefully considered both sets of results. Challenges were 
initially analysed by type of intervention, although it is likely that challenges are not specific 
for one type of intervention and therefore present in several interventions. Interventions were 
categorised into tests (e.g. screening, diagnostic), non-drug interventions (e.g. surgically or non-
diagnostic devices), drug interventions, disease management programs (DMPs) and public health 
interventions.
Questionnaire
To supplement our literature review, we sent a questionnaire by e-mail to the corresponding 
authors of the 40 papers to identify challenges that were not described in the papers and to 
estimate the importance of the challenges. The same five modelling experts tested a pilot version 
of the questionnaire and indicated new challenges that were not previously identified. The first 
part of the questionnaire focussed on the solved and unsolved challenges that authors faced 
while creating and using the model used to perform their analyses. Authors were asked to provide 
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data requirement and modelling challenges and also asked to provide their source of inspiration 
if they managed to solve the specific challenge. The second part of the questionnaire focussed 
on the challenges that the respondent may have experienced during any CEA modelling of a CVD 
intervention. The list used for the document analysis was also the basis for the questionnaire. 
Respondents were asked to indicate how often the challenge had occurred in model based CVD 
intervention CEAs conducted by the respondent and how much impact it could have had on the 
ICER. 
Analysis
The challenges brought forward by the corresponding authors and identified in the literature 
review were analysed. We then examined ways to address them based on the current modelling 
guidelines132,187,191-195, other literature and the solutions provided by the authors. 
rEsULTs
selection
The systematic literature search identified 1720 potentially relevant publications. In order to 
reach the target of 40 relevant papers with unique corresponding authors, we read title, abstract 
and full paper in case title and abstract were non-conclusive, of 294 publications (Figure 9.1). 
Table 9.1 provides an overview of the publications written by these authors. Most (49%) of 
the publications involved CEAs of tests and drugs; analyses of non-drug interventions, disease 
management programs and public health interventions were less common. Health economics 
journals accounted for approximately half of the publications included in this study.
Challenges
Table 9.2 presents the presence and frequency of each challenge in each type of intervention and 
provides ways to address them. Furthermore, papers that have presented a solution for a specific 
challenge are also identified in Table 9.2.
Data requirements challenges 
Challenges such as lack of data (e.g. effectiveness, costs, adverse events or parameter distributions) 
and difficulties in evidence synthesis are usually addressed by performing sensitivity analyses 
which show the impact on the outcomes. Univariate or multivariate sensitivity analyses, scenario 
analyses or probabilistic sensitivity analyses are often used in addressing data requirements 
challenges. Furthermore, it is important to recognize the problem of publication bias when a 
meta-analysis is performed to estimate the effectiveness of an intervention. Trial registries (e.g. 
ClinicalTrials.gov) can be searched to identify clinical trials that have not published their results 
to reduce the risk of bias from selective publication. Furthermore, funnel plots can be used to 
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identify if publication bias exists198. When publication bias is an issue then it could be useful to 
adjust for this in the meta-analysis199. 
Drug
intervenons
13*
40
papers selected
1720
potenally relevant studies
294
most recent papers screened
254 papers excluded:
– No model-based CEA
– No CVD intervenon
– Author already included
Test
intervenons
11
Non-drug
intervenon
9*
DMP
1
Public health
intervenons
7
figure 9.1 | Flowchart of selected papers
* One study investigated two types of interventions (drug and non-drug interventions)
Structural uncertainty
Besides parameter uncertainty our document analysis showed that modelling studies often 
encountered structural uncertainties. This means that it was difficult to include or consider: i) all 
relevant comparators, ii) all relevant disease states or events, and iii) a sufficient time horizon to 
capture all relevant differences in costs and consequences. Often not all relevant comparators 
are included in the model due to data requirements as could be seen in the study performed 
by Magnusson et al.200 which estimated the cost-effectiveness of drug-eluting stents compared 
with coronary artery bypass based on the FREEDOM trial. The trial did not include the second 
generation of drug-eluting stents, which meant that the authors were unable to evaluate stents 
that were available during the trial. When direct evidence between comparators is lacking then 
mixed treatment comparison or network meta-analysis could be a solution. Recently, seven 
tutorial papers were published on evidence synthesis methods for decision making including 
network meta-analysis201-207. Stettler et al.208 compared the safety and effectiveness of bare metal 
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stents and drug-eluting stents by means of a network meta-analysis. Bojke et al.209 discussed 
ways (modelling averaging, model selection and parameterizing structural uncertainty) to 
address structural uncertainty. Frederix et al.210 have explored the influence of model structures 
in breast cancer treatment on the estimated cost-effectiveness of an intervention.  
Table 9.1 | Characteristics of the studies included in the literature review 
 frequency intervention strategya
 Test Drug non-drug DmP Public health 
intervention
  n % n % n % n % n % Total
Generic journals 1 17% 1 17% 0 0% 0 0% 4 67% 6
The Lancet 1 50%    1 50% 2
New England Journal of 
Medicine      1 100% 1
Annals of internal medicine   1 33%   2 67% 3
 Journal of the American 
Medical Association
          0
Cardiovascular disease journals 5 33% 4 27% 4 27% 0 0% 2 13% 15
European Heart Journal    1 100%   1
Circulation 3 43% 2 29% 1 14%  1 14% 7
Journal of the American 
College of Cardiology 2 50%  1 25%  1 25% 4
 International Journal of Cardiology   2 67% 1 33%     3
Economic evaluation journals 5 25% 8 40% 5 25% 1 5% 1 5% 20
Health Technology Assessment 1 33%  1 33%  1 33% 3
Medical Decision Making   1 100%    1
Value in Health 3 21% 6 43% 4 29% 1 7%  14
 PharmacoEconomics 1 50% 1 50%       2
Total 11 27% 13 32% 9 22% 1 2% 7 17% 41
DMP: disease management programme
a One study investigated two types of interventions (drug and non-drug interventions)
 
162 | Chapter 9
Ta
bl
e 
9.
2 
| 
Fr
eq
ue
nc
ie
s 
of
 c
ha
lle
ng
es
 p
er
 t
yp
e 
of
 in
te
rv
en
ti
on
s
 
 
 
Te
st
 
in
te
rv
en
ti
on
 
(n
=1
1)
n
on
-d
ru
g 
in
te
rv
en
ti
on
 
(n
=9
)
D
ru
g 
in
te
rv
en
ti
on
 
(n
=1
3)
D
m
P 
 
 
(n
=1
)
Pu
bl
ic
 h
ea
lt
h 
in
te
rv
en
ti
on
 
(n
=7
)
To
ta
l  
(n
=4
1†
)
M
et
ho
do
lo
gi
ca
l 
pa
pe
r
Ex
am
pl
e 
pa
pe
r
D
at
a 
re
qu
ir
em
en
t 
ch
al
le
ng
es
#
%
#
%
#
%
#
%
#
%
#
%
re
fe
re
nc
e
re
fe
re
nc
e
1
Tr
ea
tm
en
t 
eff
ec
ti
ve
ne
ss
8
73
%
8
89
%
10
77
%
1
10
0%
5
71
%
32
80
%
19
1,
19
9,
21
1
2
Pr
ev
al
en
ce
2
18
%
N
A
N
A
N
A
N
A
N
A
N
A
3
43
%
5
31
%
19
1,
21
1
3
Ac
cu
ra
cy
 d
at
a
5
45
%
N
A
N
A
N
A
N
A
N
A
N
A
4
57
%
9
56
%
19
1,
21
12
12
4
Co
m
pl
ia
nc
e*
3
27
%
1
11
%
5
38
%
1
10
0%
1
14
%
11
37
%
19
1,
21
1
21
3
5
Q
ua
lit
y 
of
 li
fe
7
64
%
8
89
%
7
54
%
0
0%
3
43
%
24
71
%
19
1,
21
1
6
Re
so
ur
ce
 u
se
6
55
%
7
78
%
7
54
%
1
10
0%
3
43
%
24
60
%
19
1,
21
1
7
U
ni
t 
co
st
s
6
55
%
5
56
%
9
69
%
0
0%
4
57
%
23
56
%
19
1,
21
1
8
In
di
re
ct
 c
os
ts
1
9%
1
11
%
0
0%
0
0%
0
0%
2
5%
21
4
9
M
iss
in
g 
va
lu
es
1
9%
4
44
%
0
0%
0
0%
0
0%
5
13
%
21
5
10
Pa
ra
m
et
er
 d
is
tr
ib
uti
on
s
4
36
%
4
44
%
3
23
%
1
10
0%
2
29
%
14
35
%
19
1,
21
1,
21
6
11
Ad
ve
rs
e 
ev
en
ts
5
45
%
6
67
%
6
46
%
0
0%
1
14
%
18
45
%
12
Su
bp
op
ul
ati
on
 d
at
a
4
36
%
1
11
%
2
15
%
0
0%
2
29
%
8
20
%
21
7
13
Ev
id
en
ce
 sy
nt
he
sis
1
9%
3
33
%
5
38
%
0
0%
1
14
%
10
25
%
13
2,
18
7,
19
2,
20
1
21
8
M
od
el
lin
g 
ch
al
le
ng
es
#
%
#
%
#
%
#
%
#
%
#
%
re
fe
re
nc
e
re
fe
re
nc
e
1
St
ru
ct
ur
e
3
27
%
4
44
%
3
23
%
0
0%
4
57
%
13
32
%
20
9,
21
0
1a
Co
m
pa
ra
to
rs
3
27
%
3
33
%
0
0%
0
0%
0
0%
6
15
%
19
1,
20
1
20
8,
21
9
1b
D
is
ea
se
 p
at
hw
ay
2
18
%
2
22
%
0
0%
0
0%
2
29
%
6
15
%
13
2,
22
0
15
0
1c
Ti
m
e 
ho
ri
zo
n
0
0%
1
11
%
1
8%
0
0%
0
0%
2
5%
19
1,
19
2,
22
1
90
2
He
te
ro
ge
ne
ity
2
18
%
0
0%
2
15
%
0
0%
0
0%
4
10
%
21
1,
21
7
3
Hi
st
or
y
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
19
1
163Challenges in modelling the cost-effectiveness of cardiovascular disease interventions | 
Chapter
9
Ta
bl
e 
9.
2 
| 
(C
on
ti
nu
ed
)
 
 
 
Te
st
 
in
te
rv
en
ti
on
 
(n
=1
1)
n
on
-d
ru
g 
in
te
rv
en
ti
on
 
(n
=9
)
D
ru
g 
in
te
rv
en
ti
on
 
(n
=1
3)
D
m
P 
 
 
(n
=1
)
Pu
bl
ic
 h
ea
lt
h 
in
te
rv
en
ti
on
 
(n
=7
)
To
ta
l  
(n
=4
1†
)
M
et
ho
do
lo
gi
ca
l 
pa
pe
r
Ex
am
pl
e 
pa
pe
r
4
Ex
tr
ap
ol
ati
ng
 s
ho
rt
/i
nt
er
m
ed
ia
te
 r
es
ul
ts
7
64
%
7
78
%
7
54
%
1
10
0%
4
57
%
26
65
%
19
1
22
2
5
Co
m
pe
ti
ng
 r
is
ks
2
18
%
0
0%
1
8%
0
0%
0
0%
3
8%
22
3
22
4
6
M
ul
ti
pl
e 
te
sti
ng
3
27
%
0
0%
N
A
0%
N
A
0%
2
29
%
5
31
%
22
5,
22
6
7
M
ul
ti
pl
e 
in
te
rv
en
ti
on
s 
eff
ec
ts
0
0%
1
11
%
0
0%
0
0%
2
29
%
3
8%
22
7
8
Le
ar
ni
ng
 c
ur
ve
2
18
%
0
0%
N
A
N
A
N
A
N
A
0
0%
2
8%
22
8
22
9
9
W
ai
t 
ti
m
e 
(e
.g
. c
ap
ac
it
y 
co
ns
tr
ai
nt
s)
0
0%
2
22
%
N
A
N
A
N
A
N
A
0
0%
2
8%
23
0
12
5
10
M
ul
ti
pl
e 
in
di
ca
ti
on
s
0
0%
0
0%
0
0%
0
0%
1
14
%
1
3%
23
1
11
Le
ad
 ti
m
e
0
0%
N
A
N
A
0
0%
0
0%
0
0%
0
0%
23
2
12
Re
us
ab
ili
ty
N
A
N
A
0
0%
N
A
N
A
N
A
N
A
N
A
N
A
0
0%
23
3
13
Pr
oc
es
s 
uti
liti
es
N
A
N
A
0
0%
N
A
N
A
N
A
N
A
N
A
N
A
0
0%
23
3
14
Sc
en
ar
io
 a
na
ly
se
s
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
* 
Co
m
pl
ia
nc
e 
in
 s
tu
di
es
 t
ha
t 
ev
al
ua
te
 t
es
t 
in
te
rv
en
ti
on
s 
ap
pl
ie
s 
to
 t
he
 d
ru
g 
tr
ea
tm
en
t,
 w
hi
ch
 is
 p
ar
t 
of
 t
he
 s
tr
at
eg
y
† 
O
ne
 s
tu
dy
 in
ve
sti
ga
te
d 
tw
o 
ty
pe
s 
of
 in
te
rv
en
ti
on
s 
(d
ru
g 
an
d 
no
n-
dr
ug
 in
te
rv
en
ti
on
s)
. N
A
 =
 n
ot
 a
pp
lic
ab
le
. 
Th
e 
pr
op
or
ti
on
s 
w
er
e 
ca
lc
ul
at
ed
 b
as
ed
 o
n 
th
e 
nu
m
be
r 
of
 s
tu
di
es
 t
ha
t 
co
ul
d 
ha
ve
 b
ee
n 
ex
po
se
d 
to
 t
he
 c
ha
lle
ng
es
. 
164 | Chapter 9
Patient heterogeneity
The difficulty of incorporating patient heterogeneity is reported in some of the papers. Sufficient 
incorporation of heterogeneity in a model requires a great deal of data that is often not available. 
Recently, a review by Grutters et al.217 provided a comprehensive overview of the current 
knowledge regarding patient heterogeneity within economic evaluations of healthcare programs 
and provided guidance for researchers to address heterogeneity.
Extrapolation of short term or intermediate results 
Modelling guidelines recommend that models should include long term or final outcomes191. 
One common problem in modelling is that the length of follow-up of a clinical study used in 
the model is shorter than the time horizon of the model. Another problem is the fact that only 
intermediate outcomes (e.g. sensitivity and specificity of coronary angiography) or surrogate 
outcomes (e.g. the effect of statins on LDL cholesterol) are presented. Methods to extrapolate 
intermediate and surrogate outcomes are: i) using population level data (e.g. national mortality 
statistics), ii) long-term epidemiological (observational) studies or registries that reflect the 
natural history of disease, iii) extrapolating survival curves, and iv) assuming different scenarios 
for extrapolation (based on e.g. expert opinion). A common approach in CVD is to use trial-based 
results (short term) and extrapolate them by using literature or assuming different scenarios for 
extrapolation. Furthermore, final outcomes (lifetime costs or survival) of previously published 
models that focus on a later stage in disease progression can be used. For example, Lieu et 
al.222 used published results from a modelling study to estimate the cost-effectiveness of primary 
angioplasty. In addition, a CEA evaluating new generation CT scanners for the diagnosis of 
coronary artery disease combined five existing models to extrapolate test outcomes62. However, 
combining existing models introduces additional uncertainty since these are often designed for 
different populations/interventions234. 
Competing risks
Some studies (8%) recognized the challenge of competing risks (events that preclude or alter the 
likelihood of another event occurring193. The paper of Putter et al.223 reviewed statistical methods 
for the analysis of competing risks and how to model them. Wolbers et al.224 has considered three 
models to account for competing risks in risk prediction models for coronary heart disease. 
Multiple intervention effects
Some treatment strategies consist of multiple interventions and some single interventions have 
an effect on more than one clinical outcome. Estimating the effectiveness of such interventions 
could be a challenge. It is more likely that CEAs evaluating public health interventions or DMPs 
have more difficulty in estimating the effectiveness since they often exist of multiple interventions. 
This challenge can also arise when estimating the cost-effectiveness of lifestyle interventions or 
drug interventions such as the ‘poly pill’ that combines several pills (e.g. statins, aspirin, blood 
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pressure lowering drugs, folic acid)235. It is important to recognize the problem of interrelating 
outcomes and overestimation of the ‘real’ treatment effect. Interrelating outcomes are present if 
an intervention (e.g. cardiovascular DMP) has an effect on multiple outcomes (e.g. blood pressure 
and smoking) which interact in some way to improve health. When it comes to primary CVD 
prevention, the Framingham risk score9 or the SCORE risk function7 are often used to overcome 
the problem of interrelating outcomes. Both risk functions estimate the risk of developing a 
(non-) fatal event in the coming ten years based on several risk factors (e.g. smoking, cholesterol 
or age). While none of the included studies consisted of multiple interventions, some of them 
recognized that their single intervention could have an effect on more than one clinical outcome. 
When treatment effectiveness of such a strategy is lacking it is possible to use a synergy factor. 
Van Kempen et al. multiplied the individual relative risks of the single interventions (aspirin and 
statins) and multiplied this with a synergy factor 52. This factor can be varied through sensitivity 
analyses and incorporates the interaction between drugs (synergy or dyssynergy). 
Learning curve
Obtaining effectiveness evidence of new tests and other non-drug interventions (e.g. endovascular 
aneurysm repair vs. open aneurysm repair) is often difficult due to the presence of a learning 
curve231. It is important to include the consequences of learning effects for new (invasive) 
procedures. Learning effects could influence operating time of a procedure, diagnostic accuracy, 
and the frequency of adverse events. Ramsay et al. presents statistical techniques to incorporate 
learning effects of tests and procedures but concluded that new statistical techniques should be 
developed228. The impact of incorporating a learning curve on the cost-effectiveness of strategies 
will vary depending on various factors. Woods et al. has investigated the impact of the learning 
curve of heart transplantation on the operative and post-operative hospital costs229 . 
Waiting time 
In real life it is likely that tests and procedures are not performed immediately after each other, 
sometimes because of capacity issues. However, CEAs usually do not incorporate capacity 
constraints and the time delay between tests and procedures. Two papers identified waiting 
time as a challenge125,143 and one of them examined this issue in detail125. Neglecting waiting time 
may lead to an overestimate of the effectiveness and cost-effectiveness of an intervention, since 
a delay in assessment may prolong suffering or increase risk of cardiovascular events (e.g. MI or 
cardiac arrest). If waiting time is deemed important, a disutility for the quality of life loss due to 
postponed treatment can be added. When the delay in treatment is due to capacity constraints 
then modelling guidelines suggest using an agent-based simulation model or a discrete-event 
simulation (DESM) to incorporate competition for resources191, as performed by Jahn et al.125 
who evaluated the cost-effectiveness of drug-eluting stents versus bare metal stents. A tree that 
precedes a Markov model can also be used to include waiting time from capacity constraints by 
modelling a proportion of the cohort that suffers from these constraints. 
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Multiple indications
Performing an economic evaluation of an intervention that can be used for several indications is 
also considered as a challenge (3%). Usually interventions are evaluated for a specific indication, 
however many tests and drugs can be used for several indications. Drugs are divisible and can 
be evaluated for each indication separately and thus are not per se a challenge. However, for 
example the cost-effectiveness of a CT scanner in diagnosing CAD can be evaluated but this 
intervention can also be used in various ways such as brain CT scans. The weighted average of its 
use in multiple applications can be used to estimate the overall value of both costs and effects 
of the intervention231 in order to decide whether or not to purchase the scanner. In order to 
estimate a weighted average of its use for all applicants we need to know the relative frequency 
of each application and have a sufficient understanding of the alternative strategy, including the 
health and economic consequences of correct and incorrect diagnoses. Furthermore, all effects 
would preferably be expressed using the same unit of health gain (i.e. life years or QALYs).
Diagnostic performance 
Several authors (56%) have indicated that it is a challenge to obtain values for the diagnostic 
accuracy (sensitivity and specificity) of a test. These input parameters to a model usually have 
an important impact on the cost-effectiveness of the test since these parameters are key in 
extrapolating an initial disease status assessment, either being correct or incorrect (false positive 
or false negative diagnosis). It is even more a challenge when tests are performed in combination 
or sequence and previous test results need to be incorporated in the model, as recognized by 
Denchev et al.236. It is a challenge to estimate the sensitivity and specificity of each individual 
test and of the whole strategy. It is very common to assume that tests are independent, however 
this does not allow for already known test results leading to misinterpretation of the test results 
(posterior probability). Since the interpretation depends on the prior probability (known test 
results and prevalence of outcome) and the accuracy of the test. Hunink et al. has explored the 
influence of assuming independence for multiple test strategies225. Weintraub et al. examined 
the application of Bayes theorem in non-invasive diagnosis of CAD226 and showed that it is 
not always appropriate to assume independency. This challenge is mainly due to lack of data, 
since it is almost impossible to perform an observational diagnostic evaluation study in order 
to derive reliable estimates of diagnostic, therapeutic and health status outcomes for multiple 
test strategies237. Furthermore, estimates of the sensitivity and specificity of a test (e.g. CT 
angiography) could also be invalid since they are often derived by comparing the result with 
a “gold standard” (e.g. invasive coronary angiography) which may not necessarily be 100% 
accurate62. When data is not available, the best strategy is to vary the accuracy estimates in 
sensitivity analyses to estimate the impact on the cost-effectiveness. However, the sensitivity 
and specificity of a test might be linked, so that improvements in one parameter may be achieved 
at the expense of reductions in the other212. Berry et al.212 has incorporated the link in a decision 
tree evaluating magnetic resonance angiography. In addition, the ISPOR-SMDM modelling 
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guidelines recommend incorporating test results that are prognostic in the states or as tracker 
variables in state-transition models192.
Compliance and persistence
Compliance and persistence of interventions (e.g. drug intervention or lifestyle interventions) 
is usually higher in clinical trials than in daily practice due to close monitoring. Non-compliance 
can have an impact on medicine acquisition costs and subsequent overall health care resource 
utilization and costs238. However, non-compliance may not always result in clinically meaningful 
differences between efficacy and effectiveness due to long duration of action in relation to its 
dosing interval (e.g. statins)238. Sokol et al. has investigated the impact of medication adherence 
on hospitalization risk and healthcare costs for four conditions: hypertension, diabetes, chronic 
heart failure and hypercholesterolemia213. Drummond et al. proposes some suggestions for 
trials to become more generalizable to a real-world situation239. Guidelines on compliance 
measurements are provided by Peterson et al.240. While compliance could also be based on what 
is seen during observational studies, these must be adjusted for confounding through multivariate 
regression techniques or propensity scoring192. If no ‘real’ estimates of the compliance are 
available, it could be useful to perform several scenario analyses with different assumptions to 
estimate the impact of compliance on the cost-effectiveness241. Ideally, these scenarios should 
be based on expert opinion, partly to determine how any observed short term compliance rates 
could be extrapolated. Modelling guidelines recommends considering dynamic characteristics 
like compliance in the states or as tracker variables187. Hughes et al.238 also recognized the 
challenge of incorporating compliance into models and provided some techniques to implement 
compliance in decision models, DES models and Markov models.
Other challenges
Other challenges not identified in the document analysis but included in our survey are: i) 
reusability, ii) lead time bias, iii) incorporating history, iv) process utilities, and v) defining 
appropriate scenario analyses. Some interventions such as telemonitoring devices for heart 
failure can be reused in several patients and this element of reusability might be incorporated in 
economic evaluations233. Lead time bias could be present in test interventions in the CVD field232 
and should be considered in CEAs. Incorporating history in a model may be a challenge and could 
be solved by increasing the number of states in state-transition models or modelling the cost-
effectiveness with a DESM model191. Process utilities (ease, comfort of use or the unpleasantness 
of a device) could be a potential challenge, although this was not identified in any of the studies 
included in the document analysis.
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Questionnaire
In total, six (15%) corresponding authors completed and returned the questionnaire after sending 
one reminder to all corresponding authors and an additional reminder to the authors who were 
initially willing to complete the questionnaire. Of the six papers they had authored, two focused 
on drugs, two on tests, one on a population based strategy, and one on a device. These authors 
had previously conducted an average of four CEAs of CVD interventions using an economic 
model. The challenges found in the document analysis were confirmed by the respondents, in 
particular lack of data and extrapolating short term results. However, the questionnaire also 
led to the identification of challenges that were not described in the paper. For example, one 
respondent indicated that extrapolation of initial surrogate outcomes to later clinical events was 
a challenge, even though this issue was not prominently documented in the paper written by 
that author. This was very likely because it was a methodological paper which focused on the 
impact of utilities on the incremental effects242. 
DisCUssion
Model-based cost-effectiveness analyses of CVD interventions are always accompanied by 
challenges in modelling methods and data requirements. This review identified and analysed the 
challenges that currently exist in the CVD area. Furthermore, some ways to address the identified 
challenges based on the literature and on expert opinion are mentioned.
Lack of effectiveness data and quality of life data, determining a model structure, and extrapolating 
short term or intermediate results are very frequently reported or implied challenges in the 
document analysis. However, frequency is not necessarily an indicator of importance (i.e. degree 
of impact on the ICER). Less frequently reported challenges are difficulties in incorporating 
patient heterogeneity and including waiting time for an intervention in the model. The document 
analysis also showed that more complex interventions are associated with more and more 
complex challenges. Public health interventions, DMPs and tests are interventions being more 
difficult to evaluate since it combines several interventions (e.g. companion diagnostic) instead 
of one single therapy. CVD interventions have become more complex (including DMP, targeted 
treatments and devices) over the years, meaning that more parameters and relationships 
between parameters have to be included in the analysis. Consequently, the complexity of models 
has also increased over the years243; for example, a simple decision tree is now used much less 
often than before. Despite the increased complexity of models, authors of the included studies 
did not report any challenges that were impossible to be solved. One solution that is often used 
to overcome challenges is the use of sensitivity analysis. The influence of structural uncertainty 
and patient heterogeneity on the outcomes is less often assessed in model-based economic 
evaluations than uncertainty regarding parameters and methodology.
169Challenges in modelling the cost-effectiveness of cardiovascular disease interventions | 
Chapter
9
Limitations
Since we limited our review by including only 40 papers in a limited number of journals, the papers 
do not represent all model-based CEAs of CVD interventions. However, we do not expect that 
the challenges identified using the document analysis differ substantially from those reported in 
other papers since we have used the most recent papers and those who were published in the 
most relevant and highest impact journals.
The identification of challenges from papers is a subjective process which may result in 
inconsistencies when estimating their frequencies. However, we tried to eliminate this 
subjectivity by having two reviewers score all studies. Furthermore, the identification of 
challenges was dependent on whether authors reported all of the challenges they encountered 
in their study. Consequently, some of the challenges actually encountered might not have been 
identified by the reviewers and this might have led to an underestimation of the frequencies. To 
identify challenges that were not reported in the articles we have sent the questionnaire to the 
corresponding authors. However, the response rate was 15% and therefore the usefulness of 
the questionnaire results may be limited. For the responders, the questionnaire did confirm the 
results of our own document analysis. 
recommendations
This review identified challenges that were present in recently published model-based CEAs in 
the field of CVD. However, most of these challenges and the ways to address them could also 
be applied to interventions in other disease areas. Challenges are often the result of data that 
is not available, particularly relating to CEAs of test and non-drug interventions. To our opinion 
there are two main reasons for this. First, the current regulatory framework in the US and 
Europe for tests and non-drug interventions is less stringent than for pharmaceuticals; i.e. the 
European Medicines Agency does not requires a randomized study design for market approval, 
while the US Food and Drug Administration requires only a single RCT demonstrating safety and 
effectiveness for high-risk tests or non-drug interventions233. We recommend the regulations 
concerning pharmaceuticals should be applied to these type of interventions as well since these 
interventions are also subject to the same budget constraints and should therefore meet the 
same requirements for appraisal233,244. Second, tests and non-drug interventions are generally 
also associated with clinical research limiting factors such as the impossibility of double blinding. 
We recommend that primary studies on tests and non-drug interventions pursue using rigid 
research methods as in drug efficacy studies. 
We found that the validity of economic models concerning the challenges and assumptions are 
often not described in papers. However, if validity of models is described, this generally concerns 
the face validity and technical validity (debugging) only, instead of disclosing how challenges 
are addressed. We recommend authors were to report their findings according to the CHEERS 
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statement 245 making it easier to investigate the validity of the model. While modellers are generally 
very resourceful when it comes to overcoming challenges, one could question whether those 
challenges are adequately addressed since there are often many ways to do so. For instance, Van 
Kempen et al. showed that the use of different methods to model the treatment effectiveness 
of statins (through lipid level modification, fixed risk reduction of CVD events or risk reduction 
of CVD events proportional to individual change in low-density lipoprotein cholesterol) led to 
different results227. Consequently, they also addressed the importance of carefully considering 
the assumptions underlying a simulation model and performing extensive model validation. As 
in the case of breast cancer modelling246, we recommend standardization of and better guidance 
for disease-specific modelling in economic evaluations 
Conclusions
Modelling is unavoidable when performing comprehensive economic evaluations and always 
comes with challenges. This study provides examples of CVD modelling challenges encountered 
during studies published in high-impact journals. Some of the reported challenges are specific 
for CVD, but most challenges are present in all types of diseases. Modelling guidelines do not 
provide sufficient assistance in resolving all challenges but it is probably unrealistic to expect 
this. Besides identifying where more research is needed, this review provides some directions 
for researchers about how to deal with modelling challenges when performing cost-effectiveness 
analyses in the area of cardiovascular disease. 
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Since healthcare expenditures are expected to rise in the future due to aging and the 
development of new medical technologies, it is necessary to spend the healthcare budget wisely. 
Cost-effectiveness analyses can improve the quality of choices in allocating limited health care 
resources. Cardiovascular disease (CVD) accounts for 9.2% of the total health care expenditure 
in the Netherlands 2. In this area many non-pharmaceutical technologies (e.g. stents, prostheses 
and diagnostic tests) are used to diagnose and treat patients with CVD. In the previous years, 
many new or improved non-pharmaceutical technologies came to the market and therefore 
it is important to estimate if these interventions are cost-effective compared to existing 
interventions. However, it is often challenging to accurately estimate the cost-effectiveness of 
these interventions due to a number of reasons.
In this thesis, the aim was to assess the cost-effectiveness of various technologies in CVD 
and to identify and deal with challenges in the cost-effectiveness analysis methods. The cost-
effectiveness of a hypothetical test for primary prevention of CVD was estimated. We evaluated 
the cost-effectiveness of diagnostic tests for primary and secondary prevention of coronary 
artery disease (CAD) and the cost-effectiveness of drug-eluting stents (DES) versus bare metal 
stents (BMS) was summarized in a systematic review. Treatment variation (stent choice) in 
patients diagnosed with CAD and the health related quality of life (HRQoL) of patients with CAD 
were explored. Subsequently, the cost-effectiveness of fenestrated endovascular repair (fEVAR), 
branched endovascular repair (bEVAR) and endovascular repair (EVAR) versus open surgical 
repair (OSR) or medication was estimated. Finally, we described the challenges that arise in 
modelling the cost-effectiveness of CVD interventions in a review paper. 
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oVErViEw of CAsE sTUDiEs
In Chapter 2 we estimated the potential cost-effectiveness of a biomarker test that could be used 
to decide which individuals with an intermediate CVD risk would benefit from statin treatment. 
Prognosis of different age- and gender-specific cohorts was simulated with a Markov model to 
estimate the potential costs and quality-adjusted life-years for four strategies: treat all with 
statins, treat none with statins, treat according to the European guidelines, or use a test to select 
individuals for statin treatment. We concluded that a perfect hypothetical test would dominate 
the other strategies if the test did not cost more than €237, consequently a less-than-perfect test 
would have to cost less than €237.
New generation dual-source coronary CT (NGCCT) scanners were evaluated in Chapter 3 for 
patients with known or suspected CAD who are difficult to image. The cost-effectiveness was 
assessed for three strategies: use of invasive angiography (ICA) only, ii) use of NGCCT only, and 
iii) use of a combination of NGCCT and (in the event of positive NGCCT) ICA. Extensive modelling, 
combining several models, was performed to estimate the cost-effectiveness of NGCCT for both 
CAD populations, separately. We concluded that the use of NGCCT might be considered as cost-
effective in both populations since it is cost-saving compared to ICA and it generates similar 
health effects. 
In Chapter 4 we explored what factors are associated with variation in stent choice in patients 
undergoing a percutaneous coronary intervention (PCI), based on a prospective cohort of 
Dutch patients with (un)stable CAD treated with BMS or DES. Using multiple logistic regression 
analyses we showed that besides clinical factors, which may be considered as legitimate reasons 
for variation, the treating hospital was also associated with type of stent. This association with 
stent choice could arise because of financial arrangements with stent manufacturers, budget 
constraints or operators preferences (believers versus non-believers of DES) which may lead to 
differences in long-term outcomes. 
In Chapter 5 we performed multiple linear regressions to identify variables that are significantly 
associated with HRQoL and SF-36 component scores in Dutch patients with stable and unstable 
CAD. We observed significant associations with gender, systolic blood pressure, body mass index, 
previous PCI, New York Heart Association class, previous cerebrovascular accident or transient 
ischaemic attack, peripheral vascular disease, pack-years (tobacco) and pulmonary disease in the 
stable CAD group. Unstable CAD patients had higher average physical component score, mental 
component score and SF-36 dimension scores than stable CAD patients. The mental health 
dimension was the least affected dimension of the SF-36 but CAD had a negative impact on the 
physical dimensions. Knowledge of these associations can help to identify ways to improve care 
(e.g. increase physical activity) and thereby improve HRQoL. 
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In Chapter 6 we presented a case study, a systematic review on the cost-effectiveness of DES 
versus BMS using meta-regression analyses exploring the usefulness of such methods compared 
with conventional review methods. Sixteen eligible studies were identified, with a combined 
total of 508 analyses, and the incremental cost-effectiveness ratios found in these studies ranged 
from DES being dominated by BMS to DES being dominant. The meta-regressions showed 
associations (e.g. type of lesion) that were expected (based on individual studies), however we 
also revealed unpredicted associations: e.g. model quality was negatively associated with the 
number of repeat revascularizations avoided. Consequently, meta-regressions can be of added 
value, identifying significant associations that could not be identified using conventional review 
methods or sensitivity analyses of individual studies.
Patients with a large unruptured abdominal aortic aneurysm (AAA) can be treated electively with 
EVAR or OSR. An existing model estimating the lifetime cost-effectiveness of EVAR for the UK was 
adopted for the Netherlands in Chapter 7. EVAR and OSR can be considered equally effective and 
in addition EVAR was cost-saving compared with OSR for a cohort of individuals (87% men) with 
an age of 72 years old. Thus EVAR can be considered as a cost-effective solution for patients with 
AAA, however this is highly dependent on the price of an EVAR device and the degree to which 
EVAR reduces hospital days, complications and 30-day mortality. 
Besides estimating the cost-effectiveness of EVAR versus OSR we described the cost-effectiveness 
of fEVAR and bEVAR in Chapter 8. This study was performed as a short report for National Institute 
for Health Research Health Technology Assessment programme and followed two phases (framing 
and assessment). The assessment phase was performed according to the NICE guidelines on 
technology appraisal methods and has four steps: literature reviews of (cost-) effectiveness, 
design of mathematical model, inclusion of data in model, and analysis. We showed that the 
framing phase and the first two steps of the assessment phase could be performed. However, we 
were unable to populate the model and estimate the cost-effectiveness of fEVAR/bEVAR since no 
evidence on efficacy and costs were available. It therefore remains uncertain whether the extra 
cost of fEVAR/bEVAR is justified by the advantages for patients. 
CHALLEnGEs EnCoUnTErED AnD DEALT wiTH in THE CAsE 
sTUDiEs
Modelling methods to estimate the cost-effectiveness of cardiovascular interventions 
require some simplification of reality. It is impossible to develop a model that estimates the 
(incremental) cost, (incremental) effects and disease progression both accurately and validly 
without making assumptions. As a consequence, we also encountered many challenges in the 
case studies described in chapters 2–8; some of these could be dealt with, while some could not. 
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The main challenge of almost all economic evaluations is lack of data, although the degree of 
missing data varies between studies. The type of lack of data is dependent on the timing of the 
economic evaluation (Figure 10.1). When an economic evaluation is performed while research is 
still focusing on basic research of the mechanisms there is often no data about the technology 
being developed that can be used in an economic evaluation. For example, in Chapter 2 the aim 
was to estimate the cost-effectiveness of a hypothetical test to support decisions about statin 
treatment and, like many other early HTA studies, there was no accuracy and cost data about 
the test. Therefore, we were required to perform sensitivity analyses and scenario analyses to 
estimate the potential cost-effectiveness of the test. Although it could be argued that this cost-
effectiveness analysis was performed too early, sensitivity analyses enable us to determine the 
parameters of the test that were required in order for it to be cost-effective. The second type 
of lack of data exists before a product enters the market but has been investigated in several 
studies (e.g. RCT) which are needed for market approval. When data from these studies is used 
in a cost-effectiveness analysis of that product, the generalizability to the real world is limited 
due to the strict inclusion and exclusion criteria used in creating the study population. This type 
is often present for pharmaceutical interventions, since non-pharmaceutical interventions may 
not be required to estimate the effectiveness of the intervention in a randomized clinical study. 
The last type of lack of data was present in Chapter 7 where we estimated the cost-effectiveness 
of EVAR. EVAR was already used in daily practice and thus clinical data was available since the 
EVAR-1137, OPEN138 and ACE139 trials were published. However the data presented in the clinical 
trials were ‘outdated’ meaning that daily practice cannot be compared with the care that was 
provided at the time that the trials were conducted. Nowadays, the frequency of complications 
and length of stay after EVAR have decreased over time as a result of technological advances and 
the increasing experience (learning curve) with the procedure. These types of temporal changes 
in effectiveness, safety and efficiency are often seen in non-pharmaceutical technologies due to 
their short product lifecycle. Consequently, other sources of clinical data (DSAA registry) were 
required to obtain a valid and relevant cost-effectiveness estimate since it is unlikely that a new 
RCT will be conducted due to ethical reasons. 
Estimating the cost-effectiveness of a test (e.g. diagnostic) requires more complex modelling 
than that of pharmaceuticals since test strategies have an effect on the treatment pathway 
and not directly on the effectiveness247. Furthermore, besides the improvements in treatment 
decisions also the consequences of incorrect diagnosis need to be incorporated in a model. In 
Chapter 3 several existing models were combined to translate and extrapolate the accuracy data 
into long term health outcomes (lifetime cost-effectiveness) incorporating the whole range from 
diagnostics to clinical pathway to complications and radiation in the model which can be seen as 
a challenge. Needless to say, the optimal combination of models was a challenge in and of itself.
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UnsoLVED CHALLEnGEs EnCoUnTErED in THE CAsE sTUDiEs
Other challenges that were encountered in the case studies estimating the cost-effectiveness 
of a diagnostic test were multiple testing and the gold standard assumption. In Chapter 2, we 
assumed that the hypothetical test was performed only once at baseline and that it could predict 
events for the coming ten years. However, it is possible that a test would be repeated more often. 
Incorporating multiple testing means that the posterior probability depends on the accuracy of 
the test and the prior probability (previous test result and the prevalence). We were unable to 
include a multiple testing scenario but we would recommend collecting data on the test results 
taking into account the dependency between test results, as performed in the CEMARC trial59. 
Furthermore, the optimal timing of the test should be determined; i.e. how often should the test 
be performed in order to have a good predictive value and acceptable cost-effectiveness.
In Chapter 3, it was assumed that ICA was the ‘gold standard’ when assessing the diagnostic 
accuracy of NGCCT. However pathological research248-251 has shown that ICA underestimates the 
extent and severity of stenosis, resulting in false-negative results and an imperfect sensitivity. 
Consequently, when a study shows that NGCCT leads to more positive test outcomes than ICA, it 
would imply that some of these patients have a false positive test (NGCCT positive & ICA negative) 
which would lead to a lower estimate of the specificity of NGCCT [proportion true negatives 
(both NGCCT and ICA negative) of all patients with a negative ICA outcome]. To overcome this 
challenge we would recommend: 1) to perform sensitivity analyses varying accuracy estimates 
to estimate the impact on the cost-effectiveness, 2) to collect new data on NGCCT using 
(pathological) research, or 3) to adjust for the gold standard challenge using correlation between 
the test results. 
Besides determining which patient should receive statin therapy (Chapter 2) a test potentially 
could also have an additional effect (e.g. through life style modification) as a result of patients 
being aware of having a high risk. We were unable to incorporate this additional effect in the 
model and would recommend in further research that a literature-based model should use a 
multiplier effect to incorporate the two separate effects of the test into the model. However, the 
ideal way to deal with the multiple intervention effects challenge is to collect new data focussing 
on both effects of the test and if necessary to incorporate the additional effects in the analyses. 
Multiple indications is a challenge that may only exist in non-pharmaceutical interventions. 
The cost-effectiveness of pharmaceuticals for different indications can easily be obtained since 
these interventions are divisible. However, pharmaceuticals are also often used for an off-label 
indication which should also be evaluated in a cost-effectiveness analysis. In Chapter 2, we had a 
specific decision problem and therefore did not incorporate the cost-effectiveness of NGCCT for 
other indications. However, such a CT scanner will be used for many other indications and thus a 
weighted average of its use in multiple applications can be used to estimate the overall value of 
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both costs and effects in order to decide whether or not to purchase an intervention. In order to 
estimate a weighted average of its use for all applicants we need to know the relative frequency 
of each application. Thereafter, the relative frequencies should be combined with the results of 
the separately performed cost-effectiveness analyses of every application. However, this solution 
is only possible when the comparators are identical for every indication. 
Most (literature-based) models do not incorporate patient heterogeneity. For example, in many 
models one utility estimate is used for patients without events and several (dis-)utility estimates 
when events have occurred. As we can see in Chapter 5 it seems that HRQoL is associated with 
many clinical characteristics and thus it may be too simple to use one generic utility for all 
patients assuming a homogenous cohort of patients. Especially, when these characteristics are 
also associated with the occurrence of clinical events. Consequently, to incorporate all individual 
differences that may lead to differences in incremental costs and effects there are three options: 
1) individual patient level modelling, 2) using aggregate/cohort models subdividing Markov 
states in separate states to account for all characteristics that are considered important, and 3) 
performing subgroup analyses. If individual patient data is available, individual patient modelling 
can be considered as the most sophisticated method. 
Determining a structure that adequately includes all significant and clinically relevant events for 
each individual patient is often challenging. As we could see in Chapter 6, where we explored 
the added value of performing meta-regression analyses, model-based economic evaluations 
varied considerably in the modelling methods used (e.g. assumptions concerning restenosis, 
thrombosis or waiting time). In our studies in Chapters 2, 3 and 7 we also made assumptions 
to simplify the model. For example, we did not include waiting time in the model but made 
assumptions concerning the timing of the conversions. Furthermore, we have shown in Chapter 
4 that treatment variation not only exists across countries but also between hospitals; this 
variation may have an important impact on the structure of the model and may lead to the 
need to create multiple models. Consequently, the cost-effectiveness of an intervention may 
differ between studies due to structural uncertainty, since individual studies may have used 
different assumptions. In Chapter 9 we have recommended some ways to incorporate structural 
uncertainty. To improve the comparability of the studies but also to improve the structures of 
models (i.e. good representation of current disease and treatment pathway), it would be useful 
if modelling methods (e.g. structural assumptions or time horizon) are standardized for specific 
decision problems210 based on expert opinion, clinical guidelines and clinical studies. In addition, 
researchers should provide sufficient documentation of the methods, including structural 
assumptions, that were used to estimate the cost-effectiveness of an intervention. This would 
enable decision makers to determine if the results are transferable or applicable to their own 
setting (e.g. clinical practice, time horizon, perspective, discount rates, costs). 
Lack of data is a challenge that will continue to be present in every economic evaluation, in any 
form whatsoever (Figure 10.1). In Chapter 8, when estimating the cost-effectiveness of fEVAR/
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bEVAR, it was decided that it was really too early to populate the model and to perform the 
analyses since no clinically relevant data was available. The timing of this challenge is often 
present in non-pharmaceuticals; interventions are used in clinical practice but no comparative 
data is available to perform a formal assessment. Manufactures of devices do not always have to 
show effectiveness using RCT data to receive market access approval233. 
oTHEr CHALLEnGEs 
In Chapter 9 we identified and analysed the challenges that currently exist in the field of CVD, 
based on expert opinion. Some of the reported challenges in this chapter are specific for CVD, 
but most challenges are present in all types of diseases. Modelling guidelines do not provide 
sufficient assistance in resolving all challenges but it is probably unrealistic to expect this. Besides 
identifying where more research is needed, this study provided some directions for researchers 
about how to deal with modelling challenges when performing CEAs in the area of CVD. Many 
challenges that were identified in this chapter were recognized in the case studies, these 
include multiple testing and multiple indications (Table 10.1). Beside the challenges presented 
in the case studies, we also recognized challenges like compliance and persistence, and process 
utilities. However, in our case studies we did not have to deal with those challenges and thus only 
recommendations based on other studies can be provided. In chapter 9, we provided suggestions 
to deal with those challenges.
TiminG of CHALLEnGEs
Estimating the cost-effectiveness of an intervention that is accurate, recent and generalizable to 
the whole population always implies overcoming challenges. The frequency and the importance 
of the challenge are often dependent on the timing of the CEA and the stage of research that 
is performed at the time of the study (Figure 10.1). Three stages of research were defined; 1) 
research before clinical use, 2) research before market access and 3) research after market 
access, which are dependent on the medical product development process and the clinical 
use of the intervention. Depending on the type of research that has been performed and the 
objective of the study we can distinguish two types of health technology assessment (HTA): 
(very) early HTA and classic HTA. (Very) early HTA estimates the potential cost-effectiveness of a 
technology for manufacturers and investors of the technology using evidence from early bench 
and animal testing, early clinical experience, previous generations of the technology252 and 
assumptions (research before clinical use). Classic HTA estimates the current cost-effectiveness 
of a technology for regulators, payers and patients using clinical studies performed with the 
technology252 (research before and after market access). 
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Many challenges are present across all stages of research. Therefore, when challenges are 
present in more than one stage of research, we specified what exactly can be a challenge 
for HTA based on research stage and clinical uptake. For example, the challenge regarding a 
learning curve is present when HTA is based on research that is performed before or after market 
access. Before market access, the experience with the technology by clinical pioneers is still 
increasing. Therefore, estimating the cost-effectiveness of the technology at that specific time 
would imply that it will not reflect the real cost-effectiveness since it is likely that complications 
are more frequent than when a physician have reached the plateau of the learning curve. This 
phenomenon was also seen in the trials evaluating EVAR; physicians were still improving and 
devices were improved and consequently reinterventions were reduced in the years after the 
trials. Consequently, the cost-effectiveness of EVAR versus OSR based on the trials was less 
favourable than it currently is. After market access, the technology will diffused to peripheral 
hospitals and physicians there will need to learn the procedure. Subsequently, the initial 
frequency of complications may be relatively high but also decrease over time. Ideally, to obtain 
a valid and accurate cost-effectiveness estimate, the technology should be fully adopted by 
the physicians and the quality of the procedure should met an acceptable standard. However, 
evaluating the cost-effectiveness of a fully adopted intervention might also be considered too 
late since it takes years to reach the plateau of the learning curve253, especially in procedures 
like fEVAR/bEVAR that are not performed very frequently. Furthermore, newer versions which 
are easier to use come to the market. However, it could be argued that complications during the 
learning process should also be incorporated in the assessment since this is part of what actually 
happens in daily practice. One could examine the cost-effectiveness with the first patients 
separately from the cost-effectiveness with patients treated later and estimate a weighted 
average of the cost-effectiveness results. In any case, it is clear that accounting for a learning 
curve in a cost-effectiveness analysis is a complicated challenge.
fUrTHEr rEsEArCH
Further research is required to deal with the challenges (e.g. multiple testing) that were unsolved 
in the case studies and the additional challenges (e.g. compliance and persistence) that were 
identified in chapter 9. In addition, to have a more thorough overview of the challenges that may 
be encountered in assessing the cost-effectiveness of CVD interventions we would recommend 
case studies in other cardiovascular disease areas like peripheral vascular disease or congenital 
heart disease since these diseases are not covered in this thesis. However, the reported 
challenges in this thesis may also apply to these other types of CVD since the types of treatment 
that are used in those types are fairly comparable to those discussed in this thesis. This thesis 
provided a first attempt to provide an overview of the timing of the challenges which could be 
improved if more case studies are performed. 
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Table 10.1 | Overview of challenges identified in chapters
Challenges solved case Unsolved case Other
Data requirement challenges
1 Lack of relevant data 2,7 8
1a Treatment effectiveness 7 8
1b Prevalence/prior 9
1c Accuracy data 2 3
1d Compliance & persistence 9
1e Quality of life 8
1f Resource use 7 8
1g Unit costs 2,7 8
1l Indirect costs 9
1h Missing values 9
1i Parameter distributions 8
1j Adverse events 8
1k Subpopulation data 9
2 Combining sources 3
Challenges solved case Unsolved case Other
Modelling challenges
1 Structure 4,6
1a Comparators 9
1b Disease pathway 2,3,4,6,7
1c Time horizon 9
2 Heterogeneity 5
3 History 9
4 Extrapolating short/intermediate results 3
5 Competing risks 9
6 Multiple testing 2
7 Multiple interventions effects 2
8 Learning curve 7
9 Wait time (e.g. capacity constraints) 7
10 Multiple indications 3
11 Lead time 9
12 Reusability 9
13 Process utilities 9
14 Scenario analyses 9
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GEnErAL ConCLUsions
Based on the studies presented in this thesis we can conclude that assessing the cost-effectiveness 
of cardiovascular disease interventions always requires overcoming many challenges. Some can 
be ‘solved’ by gathering additional data and using sensitivity analyses while others require more 
sophisticated methods such as individual patients simulations. In some cases, it may not be 
possible to obtain a valid estimate of the cost-effectiveness of an intervention. Many challenges 
arise as the result of lack of data and thus it is necessary to obtain reliable and sufficient data to 
assess a valid, accurate and relevant cost-effectiveness estimate for a CVD intervention. 
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figure 10.1 | Timing of challenges
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inTroDUCTion
Since healthcare expenditures are expected to rise in the future due to aging and the 
development of new medical technologies, it is necessary to spend the healthcare budget wisely. 
Cost-effectiveness analyses (CEA) can feed into making choices in allocating limited health care 
resources. Cardiovascular diseases (CVD) accounts for 9.2% of the total health care expenditure 
in the Netherlands. In this area many non-pharmaceutical technologies (e.g. stents, prostheses 
or diagnostic tests) are used to diagnose and treat patients with CVD. In the previous years, 
many new or improved non-pharmaceutical technologies came to the market and therefore 
it is important to estimate if these interventions are cost-effective compared to existing 
interventions. However, it is often challenging to accurately estimate the cost-effectiveness of 
these interventions due to a number of reasons.
In this thesis, the aim was to assess the cost-effectiveness of various technologies in CVD and to 
identify and deal with challenges in the cost-effectiveness analysis methods. Several case studies 
were performed to identify the challenges and a review was performed to provide an overview 
of the challenges that arise in modelling the cost-effectiveness of cardiovascular interventions. 
The case studies focussed on the cost-effectiveness of diagnostic tests for primary and secondary 
prevention of CVD and coronary artery disease (CAD) and treatment strategies for CAD and 
aortic aneurysms. In addition, analyses of treatment variation and health related quality of life of 
patients diagnosed with CAD are performed. 
CAsE sTUDiEs
In Chapter 2 we estimated the potential cost-effectiveness of a biomarker test that could be used 
to decide which individuals with an intermediate CVD risk would benefit from statin treatment. 
Prognosis of different age- and gender-specific cohorts was simulated with a Markov model to 
estimate the potential costs and quality-adjusted life-years for four strategies: treat all with 
statins, treat none with statins, treat according to the European guidelines, or use a test to select 
individuals for statin treatment. We concluded that a perfect hypothetical test would dominate 
the other strategies if the test did not cost more than €237, consequently a less-than-perfect test 
would have to cost less than €237.
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New generation dual-source coronary CT (NGCCT) scanners were evaluated in Chapter 3 for 
patients with known or suspected CAD who are difficult to image. The cost-effectiveness was 
assessed for three strategies: use of invasive coronary angiography (ICA) only, ii) use of NGCCT 
only, and iii) use of a combination of NGCCT and (in the event of positive NGCCT) ICA. Extensive 
modelling, combining several models, was performed to estimate the cost-effectiveness of 
NGCCT for both CAD populations, separately. We concluded that the use of NGCCT might be 
considered as cost-effective in both populations since it is cost-saving compared to ICA and it 
generates similar health effects. 
In Chapter 4 we explored what factors are associated with variation in stent choice in patients 
undergoing a percutaneous coronary intervention (PCI), based on a prospective cohort of Dutch 
patients with unstable or stable CAD treated with bare-metal stents (BMS) or drug-eluting 
stents (DES). Using multiple logistic regression analyses we showed that besides clinical factors, 
which may be considered as legitimate reasons for variation, the treating hospital was also 
associated with type of stent. This association with stent choice could arise because of financial 
arrangements with stent manufacturers, budget constraints or operators preferences (believers 
versus non-believers of DES) which may lead to differences in long-term outcomes. 
In Chapter 5 we performed multiple linear regressions to identify variables that are significantly 
associated with health related quality of life (HRQoL) and short form (SF)-36 component scores in 
Dutch patients with stable and unstable CAD. We observed significant associations with gender, 
systolic blood pressure, body-mass index, previous PCI, NYHA class, previous cerebrovascular 
accident or transient ischaemic attack, peripheral vascular disease, pack-years (tobacco) and 
pulmonary disease in the stable CAD group. Unstable CAD patients had higher average physical 
component score, mental component score and SF-36 dimension scores than stable CAD 
patients. The mental health dimension was the least affected dimension of the SF-36 but CAD 
had a negative impact on the physical dimensions. Knowledge of these associations can help to 
identify ways to improve care (e.g. increase physical activity) and thereby improve HRQoL. 
In Chapter 6 we presented a case study, a systematic review on the cost-effectiveness of DES 
versus BMS using meta-regression analyses exploring the usefulness of such methods compared 
with conventional review methods. The meta-regressions showed associations (e.g. type of 
lesion) that were expected (based on individual studies), however we also revealed unpredicted 
associations: e.g. model quality was negatively associated with the number of repeat 
revascularizations avoided. Consequently, meta-regressions can be of added value, identifying 
significant associations that could not be identified using conventional review methods or 
sensitivity analyses of individual studies.
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Patients with a large unruptured AAA can be treated electively with endovascular aneurysm 
repair (EVAR) or open surgical repair (OSR). An existing model estimating the lifetime cost-
effectiveness of EVAR for the UK was adopted for the Netherlands in Chapter 7. EVAR and OSR 
can be considered equally effective and in addition EVAR was cost-saving compared with OSR. 
Thus EVAR can be considered as a cost-effective solution for patients with AAA, however this is 
highly dependent on the price of an EVAR device and the degree to which EVAR reduces hospital 
days, complications and 30-day mortality. 
Besides estimating the cost-effectiveness of EVAR versus OSR we have described how the cost-
effectiveness of fenestrated and branched EVAR (fEVAR/bEVAR) should be estimated in Chapter 
8 using the NICE guidelines on technology appraisal methods. We showed that the framing phase 
and the first two steps of the assessment phase could be performed. However, we were unable 
to populate the model and estimate the cost-effectiveness of fEVAR/bEVAR since no evidence on 
efficacy and costs were available. It therefore remains uncertain whether the extra cost of fEVAR/
bEVAR is justified by the advantages for patients. 
oVErViEw CHALLEnGEs
In Chapter 9 we identified and analysed the challenges that currently exist in the field of CVD, 
using review methods. Lack of effectiveness data and quality-of-life data, determining a model 
structure, and extrapolating short- or intermediate-term results, are very frequently reported 
or implied challenges. Modelling guidelines do not provide sufficient assistance in resolving all 
challenges but it is probably unrealistic to expect this. Besides identifying where more research 
is needed, this study provided some directions for researchers about how to deal with modelling 
challenges when performing CEAs in the area of CVD.
DisCUssion
Chapter 10 discusses the main findings of the case studies and describes the challenges that were 
encountered in the case studies. Beside the challenges that were (un)solved in the case studies 
we described also the challenges that were identified in the review performed in chapter 9 but 
were not encountered in the case studies. Furthermore, suggestions to solve the challenges are 
provided. Moreover, we linked the timing of the study (early HTA versus classical HTA) and the 
type of clinical research with the type of challenges that may encounter during a study evaluating 
the cost-effectiveness of a cardiovascular intervention. 
202 | Summary
Based on this thesis we could conclude that assessing the cost-effectiveness of cardiovascular 
disease interventions requires always overcoming many challenges. Some can be ‘solved’ using 
gathering additional data, using sensitivity analyses others require more sophisticated methods 
such as individual patients simulations. In some cases, it is even not possible to estimate the cost-
effectiveness of an intervention validly, it was too early. Many challenges are the result of lack of 
data and thus it is necessary to obtain reliable and sufficient data to assess a valid, accurate and 
relevant cost-effectiveness estimate for a CVD intervention. 
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Een verantwoorde verdeling van het gezondheidszorgbudget is belangrijk gegeven de verwachte 
verdere stijging in gezondheidszorguitgaven vanwege de vergrijzing van de samenleving en de 
ontwikkeling van nieuwe medische technologieën. Kosteneffectiviteitsanalyses in combinatie 
met budgetimpact analyses kunnen helpen in het bepalen van de efficiëntie van een technologie 
en hoe het gezondheidszorgbudget zinnig verdeeld kan worden. In Nederland wordt 9,2% van 
de totale uitgaven aan de gezondheidszorg besteed aan hart- en vaatziekten (HVZ). Bij HVZ 
worden veel niet-farmacologische technologieën [bijv. stents, prothesen of (beeldvormende) 
diagnostiek] gebruikt voor de diagnostisering en behandeling van patiënten met HVZ. Het is 
belangrijk om de kosteneffectiviteit van deze interventies in kaart te brengen, met name omdat 
er in de afgelopen jaren veel nieuwe of verbeterde niet-farmacologische interventies op de 
markt zijn verschenen. Om verschillende redenen is het een uitdaging om een valide schatting te 
maken van de kosteneffectiviteit van dit type interventies.
Het doel van dit proefschrift was het berekenen van de kosteneffectiviteit van verschillende 
cardiovasculaire interventies en het in kaart brengen van de daarmee gepaard gaande onderzoeks-
methodologische uitdagingen. Verschillende casestudies zijn uitgevoerd om deze uitdagingen te 
identificeren en een review is uitgevoerd om een overzicht te geven van de uitdagingen die 
ontstaan wanneer men de kosteneffectiviteit van een cardiovasculaire interventie modelleert. De 
casestudies richtten zich op de kosteneffectiviteit van diagnostische interventies voor primaire 
en secundaire preventie van HVZ maar ook op de kosteneffectiviteit van behandelstrategieën 
voor coronaire hartziekte en aneurysmata van de aorta. Verder is behandelvariatie en kwaliteit 
van leven van patiënten met coronaire hartziekte onderzocht. 
CAsEsTUDiEs
In hoofdstuk 2 is de potentiele kosteneffectiviteit berekend van een hypothetische biomarker test 
die gebruikt kan worden om te bepalen of individuen met een intermediair HVZ risico behandeld 
zouden moeten worden met statines. Ziektebeloop van verschillende leeftijd en geslacht 
specifieke cohorten is gemodelleerd met behulp van een Markov model. De kosteneffectiviteit 
is berekend voor vier verschillende behandelstrategieën: 1) iedereen behandelen met statines, 
2) niemand behandelen met statines, 3) behandelen volgens de huidige Europese richtlijn of 
4) het gebruik van een test om te bepalen welke patiënten statines zouden moeten krijgen. Uit 
deze studie bleek dat een perfecte hypothetische test de andere strategieën zou domineren 
wanneer de test niet meer dan €237 kost. 
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In hoofdstuk 3 is de kosteneffectiviteit berekend van de nieuwe generatie dual-source CT-
scanners (NGCCT) voor patiënten met coronaire hartziekten of die verdacht worden van 
coronaire hartziekten waarbij de oudere generatie CT-scanners niet afdoende zijn (bijv. obesitas, 
aritmie). De kosteneffectiviteit van drie diagnostische strategieën is bepaald: 1) invasieve 
coronaire angiografie (ICA), 2) NGCCT of 3) een combinatie van NGCCT en ICA (wanneer 
NGCCT positief is). Verschillende beslismodellen zijn gecombineerd om de kosteneffectiviteit 
van NGCCT te berekenen waarbij in ogenschouw werd genomen: korte termijn accuraatheid, 
gevolgen van stralingsbelasting en lange termijn kosten en gezondheidsuitkomsten (overleving, 
kwaliteit van leven, klinische events). Uit deze studie bleek dat de NGCCT kosteneffectief kan 
zijn voor patienten met coronaire hartziekten en voor patienten die verdacht worden van 
coronaire hartziekten, omdat NGCCT leidt tot kostenbesparingen en resulteert in gelijkwaardige 
effectiviteit ten opzichte van ICA.
In hoofdstuk 4 is onderzocht welke factoren geassocieerd zijn met de stent keuze voor patiënten 
die een percutane coronaire interventie (PCI) ondergaan. Deze studie is gebaseerd op een 
cohort van Nederlandse patiënten (Circulating Cells studie) met instabiele of stabiele coronaire 
hartziekten die behandeld worden met een bare-metal stent (BMS) of een drug-eluting stent 
(DES). Op basis van verschillende logistische regressies kunnen we concluderen dat naast klinische 
aspecten ook het behandelend ziekenhuis geassocieerd was met de stent keuze. Deze associatie 
kan het gevolg zijn van prijsafspraken met stent fabrikanten, budget afspraken of voorkeuren van 
artsen. De variatie in stent keuze kan leiden tot verschillen in langer termijn klinische uitkomsten 
zoals trombose of restenose. 
Hoofdstuk 5 is net als hoofdstuk 4 gebaseerd op de Circulating Cells cohort studie. In dit 
hoofdstuk is met behulp van verschillende lineaire regressies, getracht te onderzoeken welke 
factoren significant geassocieerd zijn met gezondheidsgerelateerde kwaliteit van leven en SF-36 
component scores bij patiënten met stabiele of instabiele coronaire hartziekten. Significante 
associaties met kwaliteit van leven zijn gevonden met geslacht, systolische bloeddruk, body 
mass index (BMI), eerdere PCI, New York Heart Association (NYHA) klasse, eerdere transient 
ischemic attack (TIA) of beroerte, aanwezigheid van perifeer vaatlijden, aantal pakjaren (roken) 
en aanwezigheid van longaandoeningen in de stabiele angina groep. Gemiddeld hebben de 
instabiele patiënten een hogere fysieke component score, mentale component score en SF36 
domein scores dan de stabiele angina patiënten. De mentale component score is het minste 
aangedaan door coronaire hartziekte, de fysieke component score is het meeste negatief 
beïnvloed door coronaire hartziekte. Kennis van deze associaties kan helpen om manieren te 
vinden om de zorg voor patiënten met coronaire hartziekten te verbeteren zoals het aanmoedigen 
van fysieke inspanning. 
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De resultaten van een systematische review van de kosteneffectiviteit van drug-eluting stents 
versus bare-metal stents zijn gepresenteerd in hoofdstuk 6. De bruikbaarheid van meta-
regressie analyses bovenop de conventionele systematische review methode is bekeken in deze 
casestudie. Naast de verwachte associaties zijn met behulp van de meta-regressie analyses ook 
associaties gevonden die met een conventionele systematische review niet naar voren zouden 
komen: de kwaliteit van de studies is negatief geassocieerd met het aantal vermeden opnieuw 
uitgevoerde PCIs. Deze casestudie laat zien dat meta-regressies waardevol kunnen zijn in het 
verklaren van verschillen in uitkomsten tussen kosteneffectiviteitsanalyses ten opzichte van 
conventionele review methoden of onzekerheidsanalyses van individuele studies.
Patiënten met een groot ongeruptureerd abdominaal aorta aneurysma (AAA) kunnen electief 
behandeld worden met een endovasculaire (EVAR) of open (OSR) behandeling van het 
aneurysma. Een bestaand model dat de levenslange kosteneffectiviteit van EVAR versus OSR 
heeft berekend voor Groot-Britannië is aangepast naar de Nederlandse setting. Hoofdstuk 7 laat 
zien dat de effectiviteit van EVAR en OSR gelijkwaardig is aan elkaar maar dat EVAR leidt tot een 
kostenbesparing. Hieruit kan geconcludeerd worden dat EVAR een kosteneffectieve oplossing is 
voor patiënten met AAA. De mate van kosteneffectiviteit is sterk afhankelijk van de kosten van 
het EVAR device en de reductie in opnamedagen, complicaties en 30-dagen mortaliteit als gevolg 
van EVAR. 
Naast het schatten van de kosteneffectiviteit van EVAR versus OSR is in hoofdstuk 8 beschreven 
hoe de kosteneffectiviteit van gefenestreerde (fEVAR) en branched (bEVAR) EVAR berekend moet 
worden aan de hand van de NICE richtlijnen. Deze studie laat zien dat het mogelijk was om de 
framing fase en de eerste twee stappen van de assessment fase uit te voeren. Het was dus niet 
mogelijk om voldoende betrouwbare data te vinden om de kosteneffectiviteit van fEVAR/bEVAR 
te berekenen. Het is onduidelijk of de extra kosten van een fEVAR/bEVAR procedure (met name 
de prothese) opwegen tegen de klinische voordelen voor de patiënt. 
oVErziCHT UiTDAGinGEn
In hoofdstuk 9 hebben is met behulp van een review geïdentificeerd en geanalyseerd welke 
uitdagingen er op dit moment zijn op het gebied van het modelleren van cardiovasculaire 
interventies. De meest gerapporteerde en geïmpliceerde uitdagingen zijn: gebrek aan data over 
effectiviteit en kwaliteit van leven, het bepalen van de meest geschikte model structuur en het 
extrapoleren van korte termijn en intermediaire uitkomsten. Modelleringsrichtlijnen zijn niet in 
staat om voor alle uitdagingen aanbevelingen te doen. Naast het identificeren van de uitdagingen 
waar nog onderzoek naar gedaan moet worden, biedt deze studie handvatten voor onderzoekers 
om uitdagingen op het gebied van cardiovasculaire interventies op te lossen. 
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In hoofdstuk 10 worden de conclusies van de gepresenteerde casestudies bediscussieerd en 
worden de uitdagingen van deze casestudies beschreven. Naast deze uitdagingen worden ook de 
uitdagingen die uit de review uit hoofdstuk 9 naar voren kwamen aangehaald. Bovendien worden 
ook nog suggesties gedaan om een aantal van deze uitdagingen op te lossen. Verder hebben we 
de timing van de studie (vroege HTA versus klassieke HTA) en het type klinische onderzoek gelinkt 
aan het type uitdaging die voor kan komen tijdens het berekenen van de kosteneffectiviteit van 
een cardiovasculaire interventie. 
Op basis van dit proefschrift kunnen we concluderen dat het berekenen van de kosten-
effectiviteit van een cardiovasculaire interventie altijd gepaard gaat met het overwinnen van 
onderzoeksmethodologische uitdagingen. Sommige van deze uitdagingen kunnen opgelost 
worden door meer data te verzamelen of onzekerheid analyses uit te voeren terwijl andere 
uitdagingen meer geavanceerde methoden vereisen zoals individuele patiëntsimulatietechnieken. 
In sommige gevallen is het zelfs onmogelijk om een valide en accurate schatting van de 
kosteneffectiviteit van een interventie te maken omdat het te vroeg in het proces was. De meeste 
uitdagingen zijn het gevolg van niet beschikbare data en daarom is het belangrijk om voldoende 
betrouwbare data te verzamelen. Met deze data kan een valide, accurate en relevante schatting 
gemaakt worden van de kosteneffectiviteit van een cardiovasculaire interventie. 
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Wat heerlijk om na vele jaren hard aan mijn proefschrift te hebben gewerkt, eindelijk het 
dankwoord te kunnen schrijven. Waarschijnlijk ook het meest gelezen deel van mijn proefschrift. 
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veel plezier terug op mijn promotie-tijd. Hopelijk kunnen we in de toekomst nog samenwerken, 
duizend maal dank voor alles!
Ik wil de promotiecommissie bedanken voor het beoordelen van mijn proefschrift en voor het 
opponeren bij de verdediging. 
De hoofdstukken van dit proefschrift zijn ontstaan uit de samenwerking met gedreven 
collegaonderzoekers, in het bijzonder Maiwenn. Bedankt voor de kennis en inzichten, zonder 
jullie waren deze papers niet geworden zoals ze nu zijn. Ook de fijne werksfeer bij het iBMG is 
een goede basis geweest voor de totstandkoming van dit proefschrift, waarvoor mijn dank. Cobi 
en Liza, dank voor jullie ondersteuning tijdens de laatste loodjes. 
Lieve vrienden en vriendinnetjes, dankzij jullie was het leven buiten het promoveren een 
feestje. De mannen van het collectief wil ik graag bedanken voor alle gezellige momenten die 
we de afgelopen jaren meegemaakt hebben op het werk maar ook (ver) daarbuiten. Ik zal deze 
momenten niet missen.... nee hoor grapje ;-) Igna, Hedwig en Saskia zonder jullie waren de jaren 
bij iBMG niet hetzelfde geweest. Naast collega’s zijn we ook goede vriendinnen en hadden we 
zelfs ons eigen schrijfclubje. We hebben ontzettend veel leuke dingen beleefd de afgelopen jaren, 
zoals etentjes, congressen, party avonden (de ene avond nog onvergetelijker dan de ander) en de 
Roparun. Ik had het niet zonder jullie willen doen! Hed, bedankt voor al je steun en gezelligheid 
de afgelopen jaren, en heel erg bedankt voor de kleine attenties die je regelde (zoals de beschuit 
met muisjes op Juliette’s Birthday). Op naar jouw promotie! Ig, ik ben je naast al het andere 
hierboven genoemde ook heel erg dankbaar voor de koffie ‘challenge’. Zonder jou was ik nooit 
koffie gaan drinken en was ik nog steeds in slaap gevallen na de lunch. Helaas had je zelf al 
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Mijn lieve familie ben ik ook dankbaar voor het verwezenlijken van mijn proefschrift. Pap, Mam, 
Rutger, Tamara, Stijn en Eva bedankt voor jullie getoonde interesse en de gezelligheid op de 
zondagavonden tijdens de family dinners. In het bijzonder wil ik graag Stijn en mijn ouders 
bedanken. Lieve Stijn, tijdens mijn opleidingen speelde jij altijd een grote rol aan het einde: de 
opmaak van mijn scripties, die er altijd fantastisch uitzagen! Ook nu heb je weer urenlang met 
mij samen aan de opmaak van mijn proefschrift gezeten maar nog veel belangrijker tijdens de 
plechtigheid ben je mijn paranimf! Heel erg bedankt voor alles. Papa en mama, heel erg bedankt 
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Since healthcare expenditures are expected to rise in the future due to aging 
and the development of new medical technologies, it is necessary to spend the 
healthcare budget wisely. Cost-effectiveness analyses can feed into making choices 
in allocating limited health care resources. Cardiovascular diseases account for a 
large proportion of the total health care expenditure in the Netherlands. In this 
area many non-pharmaceutical technologies (e.g. stents, prostheses or diagnostic 
tests) are used to diagnose and treat patients with cardiovascular diseases. In the 
previous years, many new or improved non-pharmaceutical technologies came to 
the market and therefore it is important to estimate if these interventions are cost-
effective compared to existing interventions. However, it is often challenging to 
accurately estimate the cost-effectiveness of these interventions due to a number 
of reasons. In this dissertation, the aim was to assess the cost-effectiveness of 
various technologies in cardiovascular diseases and to identify and deal with 
challenges in the cost-effectiveness analysis methods.
